CLINICAL STUDY PROTOCOL  
U1111 -[ADDRESS_1008133] of Soliqua™ 100/33 on the Percentage of Time 
in Range (TIR) from Continuous Glucose Monitoring (CGM) in 
Insulin -Naïve Patients With Very Uncontrolled Type 2 Diabetes Mellitus 
LPS16990 
Short Title  Soli- CGM  
Sponsor:  [COMPANY_011] US Services Inc.  
[ADDRESS_1008134]:  
Medical Monitor:  
Version of
 Protocol: 
Date of Protocol:  18 Aug 2021  
CONFIDENT
IAL 
Any and all information presented in this document shall be treated as confidential and 
shall remain the exclusive property of [COMPANY_011] (or any of its affiliated companies). The use of such confidential information must be restricted to the recipi[INVESTIGATOR_737861], published or otherwise communicated to any unauthorized 
persons, for any reason, in any form whatsoever, without the prior written consent of [COMPANY_011] (or the concerned affiliated company); ‘affiliated company’ means any corporation, partnership or other entity which at the date of communication or afterwards (i) controls 
directly or indirectly [COMPANY_011], (ii) is directly or indirectly controlled by [CONTACT_13225], with ‘control’ 
meaning direct or indirect ownership of more than 50% of the capi[INVESTIGATOR_13040], partnership or other entity. 
The study will be conducted according to the International Council for Harmonisation 
harmonised tripartite guideline E6(R1): Good Clinical Practice.  
[STUDY_ID_REMOVED]
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  [ADDRESS_1008135] read and understood all sections of the protocol titled “ A [ADDRESS_1008136] of 
Soliqua™ 100/33 on the Percentage of Time in Range (TIR) from Continuous Glucose 
Monitoring (CGM) in Insulin-N aïve Patients With Very Uncontrolled Type 2 Diabetes 
Mellitus ” and the accompanying prescribing information, dated February 2019. 
I agree to supervise all aspects of the protocol and to conduct the clinical investigation in 
accordance with the Final Protocol Version 1.0, dated 18 Aug  2021; the International Council 
for Harmonisation harmonised tripartite guideline E6(R1): Good Clinical Practice ; and all 
applicable government regulations. I will not make changes to the protocol before consulting with [COMPANY_011] US Services Inc. or implement protocol changes without institutional review 
board approval except to eliminate an immediate risk to participants. I agree to administer 
study drug only to participants under my personal supervision or the supervision of a sub-investigator. 
I will not supply the investigational drug to any person not authorized to receive it. 
Confidentiality will be protected. Participant identity will not be disclosed to third parties or appear in any study reports or publications. 
I will not disclose information regarding this clinical investigation or publish results of the 
investigation without authorization from [COMPANY_011] US Services Inc. 
   
Signature [CONTACT_789]   [INVESTIGATOR_737862]™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  [ADDRESS_1008137] of Abbreviations ................................................................................................................40  
1. Introduction ......................................................................................................................43  
1.1 Background Information .........................................................................................43  
1.2 Rationale  .................................................................................................................44  
1.3 Benefit -Risk Assessment  ........................................................................................46  
Study Objectives, Estimands, and Endpoints ...................................................................48  
2.1 Primary Efficacy Objective, Estimands, and Endpoints  .........................................48  
2.2 Key Secondary Efficacy Objectives and Endpoints ...............................................49  
2.3 Secondary, Other Efficacy, and Safety Objectives and Endpoints .........................49  
Investigational Plan  ..........................................................................................................52  
3.1 Study Design  ...........................................................................................................52  
3.1.1  Rationale of Study Design .......................................................................56  
3.1.2  Duration of Study Participation for Each Participant ..............................56  
3.1.3  End of Study Definition ...........................................................................58  
Selection of Study Population and Discontinuation/Withdrawal .....................................59  
4.1 Inclusion Criteria  ....................................................................................................59  
4.2 Exclusion Criteria  ...................................................................................................60  
4.3 Screen  Failure  .........................................................................................................62  
4.4 Discontinuation From Study Treatment and/or Withdrawal From the Study .........63  
4.4.1  Discontinuation From Study Treatment ...................................................63  
[IP_ADDRESS]  Permanent Discontinuation ......................................................................63  
[IP_ADDRESS]  Temporary Discontinuation .....................................................................[ADDRESS_1008138] to Follow-up.....................................................................................63  
4.4.3  Handling of Withdrawals  .........................................................................64  
4.4.4  Replacements  ...........................................................................................66  
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  [ADDRESS_1008139] ..................................................................67  
5.2.1  Background OADs Related to Glycemic Management  ...........................67  
5.2.2  Appropriate Corrective Action/Rescue Therapy  ......................................[ADDRESS_1008140]..........................................................................71  
5.7 Management of Clinical Supplies ...........................................................................72  
5.7.1  Study Drug Packaging and Storage .........................................................72  
5.7.2  Study Drug Accountability ......................................................................72  
5.7.3  Other Supplies..........................................................................................73  
[IP_ADDRESS]  Blood Glucose Meter Kit .........................................................................73  
[IP_ADDRESS]  CGM Device (FreeStyle Libre Pro Flash Glucose Monitoring System) .74  
5.8 Overdose Management  ...........................................................................................74  
5.8.1  Treatment of Overdose ............................................................................75  
5.9 Blinding...................................................................................................................75  
5.10  Treatment Accountability and Adherence  ...............................................................75  
5.11  Concomitant Therapy  ..............................................................................................76  
 Study Assessments and Procedures ..................................................................................77  
6.1 Study Visits  .............................................................................................................77  
6.2 Efficacy Assessments  ..............................................................................................80  
6.2.1  CGM Measures  ........................................................................................80  
6.2.2  MMTT -Derived β-Cell Function and PPG Measures ..............................82  
6.2.3  Fasting SMPG  ..........................................................................................83  
[IP_ADDRESS]  SMPG During Symptomatic Hypoglycemia ...........................................83  
6.2.4  FPG Measurements  ..................................................................................84  
6.2.5  HbA1c Measurements ..............................................................................84  
6.2.6  Assessment of Patient -Reported Outcome ..............................................84  
6.3 Safety Assessments  .................................................................................................85  
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 6 of 156 6.3.1  Physical Examination  ..............................................................................85  
6.3.2  Hypoglycemia Events ..............................................................................85  
6.3.3  Clinical Safety Laboratory Assessments ..................................................87  
6.3.4  Vital Signs  ................................................................................................89  
6.3.5  Adverse Events  ........................................................................................89  
[IP_ADDRESS]  Suspected Unexpected Adverse Events  ...................................................90  
[IP_ADDRESS]  Adverse Events of Special Interest  ..........................................................91  
[IP_ADDRESS]  Pregnancy .................................................................................................92  
[IP_ADDRESS]  Eliciting and Documenting AEs ..............................................................92  
[IP_ADDRESS]  Reporting AEs  ..........................................................................................93  
[IP_ADDRESS]  Assessment of Severity  ............................................................................93  
[IP_ADDRESS]  Assessment of Causality  ..........................................................................93  
[IP_ADDRESS]  Follow-up of Participants Reporting AEs ................................................[ADDRESS_1008141] Complaints.........................................94  
6.4 Outcomes Research Assessments  ...........................................................................95  
6.5 Sample Collections  .................................................................................................95  
6.6 Use of Biological Samples And Data For Future Research  ....................................95  
6.6.1  Assessment of β-Cell Function Indices ...................................................96  
 Study- Specific Committees  ..............................................................................................97  
 Statistical Considerations  .................................................................................................98  
8.1 Estimands and Intercurrent Events .........................................................................98  
8.2 Statistical Hypothesis  ..............................................................................................99  
8.3 Sample Size Determination .....................................................................................99  
8.4 Analysis Sets  .........................................................................................................100  
8.5 Description of Subgroups to Be Analyzed ............................................................100  
8.6 Accountability, Demographics, and Baseline Characteristics  ..............................100  
8.6.1  Adherence  ..............................................................................................101  
8.7 Statistical Analysis Methodology  .........................................................................101  
8.7.1  Overview of Statistical Methods: Estimation of Estimands and 
Sensitivity Analyses  ...............................................................................103  
8.7.2  Analysis of Primary Endpoint ...............................................................104  
[IP_ADDRESS]  Main Estimation of Primary Estimand  ..................................................104  
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 7 of 156 [IP_ADDRESS]  Sensitivity Analysis of Primary Endpoint ..............................................104  
[IP_ADDRESS]  Supplementary Analysis of Primary Endpoint.......................................105  
8.7.3  Analysis of Key Secondary Efficacy Endpoints ....................................105  
[IP_ADDRESS]  Main Estimation of Key Secondary Estimand .......................................105  
[IP_ADDRESS]  Sensitivity Analysis of Key Secondary Endpoints ................................105  
[IP_ADDRESS]  Handling of Missing Data ......................................................................105  
8.7.4  Analyses of Secondary Endpoints .........................................................106  
8.7.5  Analyses of Other Efficacy Endpoints ...................................................107  
8.7.6  Assessment of β-Cell Function Indices .................................................107  
8.7.7  Analysis of PRO Endpoint .....................................................................107  
8.7.8  Safety Analyses  ......................................................................................107  
[IP_ADDRESS]  Adverse Events  ......................................................................................108  
[IP_ADDRESS]  Hypoglycemia Events ............................................................................[ADDRESS_1008142] of the Study ................................................................................ 111 
9.3 Participant Information and Consent .................................................................... 111 
 Investigator’s Obligations .............................................................................................. [ADDRESS_1008143] ....................................................................................................... 117 
10.6  Adverse E vents and Study Report Requirements ................................................. 117 
10.7  Investigator’s Final Report ................................................................................... 117 
 Study Management ......................................................................................................... 118 
11.1  Monitoring ............................................................................................................ 118 
11.1.1  External Data Monitoring Committee  ................................................... 118 
11.1.2  Monitoring of the Study ......................................................................... 118 
11.1.3  Inspection of Records ............................................................................ 118 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  [ADDRESS_1008144] .................................................................................................................123  
 Appendices .....................................................................................................................126  
13.1  Appendix: Schedule of Events ..............................................................................126  
13.2  Appendix: Diabetes Medication Satisfaction Tool ...............................................132  
13.3  Appendix: Participant eDiary Information ...........................................................136  
13.4  Appendix: Clinical Laboratory Tests ....................................................................137  
13.5  Appendix: Adverse Events: Definitions and Procedures for Recording, Evaluating, 
Follow-up, and Reporting .............................................................................139  
13.5.1  Definition of AEs  ...................................................................................139  
13.5.2  Definition of SAEs.................................................................................140  
13.5.3  Recording and Follow-up of AEs and/or SAEs .....................................142  
13.5.4  Reporting of SAEs .................................................................................144  
13.6  Appendix: Liver Safety .........................................................................................146  
13.7  Appendix: Contraceptive and Barrier Guidance ...................................................148  
13.8  Appendix: Source Documents ..............................................................................153  
13.9  Appendix: Eligibility and Analysis Criteria for CGM Measurements  ..................155  
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  [ADDRESS_1008145] of Tables  
Table  2-1  Primary Efficacy Objective, Estimand, and Endpoint .................................... 48  
Table  2-2  Key Secondary Efficacy Objectives and Endpoints ....................................... 49  
Table  2-3  Secondary, Other Efficacy, and Safety Objectives and Endpoints  ................. 49  
Table  5-1  Recommended Dose Adjustment Algorithm for Soliqua 100/[ADDRESS_1008146] of Figures  
Figure 3–1  Study Diagram ................................................................................................ 54  
Figure 6–1  Criteria for CGM Device Reinsertion  ............................................................. 81  
Figure 13–1  Criteria for CGM Device Reinsertion  ........................................................... 156  
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 10 of 156 Protocol Synopsis  
Protocol Number:  LPS16990 
Universal Trial 
Number:  U1111 -1261-7399 
Title:  A [ADDRESS_1008147] of Soliqua™ 100/33 on the 
Percentage of Time in Range (TIR) from Continuous Glucose 
Monitoring (CGM) in Insulin-N aïve Patients With Very 
Uncontrolled Type  2 Diabetes Mellitus  
Short Title  Soli-CGM  
Sponsor:  [COMPANY_011] US Services Inc.  
[ADDRESS_1008148] Bridgewater, NJ [ZIP_CODE] [LOCATION_003] 
Study Phase:  Phase  4 
Study Sites:  US only: Multicenter (Approximate number of sites: 15) 
Indication:  Type 2 diabetes mellitus  
Rationale: Soliqua™ 100/33 is a fixed-ratio combination of insulin glargine U100 (100 units/mL) plus lixisenatide (33  μg/mL), a glucagon- like 
peptide [ADDRESS_1008149] ( GLP -1 RA ; Soliqua 2019). The 
combination of a basal insulin and a GLP-1 RA addresses both fasting and postprandial hyperglycemia, thus ensuring more comprehensive glycemic control than basal insulin alone. The efficacy and safety of Soliqua 100/33 has been clearly established in randomized controlled clinical studies. In the LixiLan-O study, the 
glycated hemoglobin ( HbA1c ) of patients uncontrolled on oral 
antidiabetic drugs (OADs) who  were treated with Soliqua  100/33 
decreased from 8.1% (baseline) to 6.5% (end of study) with the majority (74%) achieving the HbA1c target of <7% ( Rosenstock 
et al 2016). The efficacy of Soli qua 100/33 was also demonstrated 
by a 2.9% HbA1c reduction from baseline, with 74% of patients achieving an HbA1c of <7%, in a subgroup of patients with type 2 diabetes mellitus ( T2DM ) with baseline HbA1c ≥9% uncontrolled 
on OADs from the LixiLan-O study ( Davies et al 2019 ). Similarly, 
patients uncontrolled on basal insulin in the LixiLan -L study 
demonstrated an HbA1c reduction from 8.1% to 6.9%, and most (55%) reached their target HbA1c of <7% ( Aroda et al 2016
). These 
results were achieved without weight gain and with fewer 
gastrointestinal (GI) side effects than with  lixisenatide alone, likely 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 11 of 156 due to a more gradual titration of the GLP -1 RA dose ( Rosenstock 
et al 2016 ; Davies et al 2019 ). 
Continuous glucose monitoring (CGM) provides a more complete 
pi[INVESTIGATOR_737863]-monitored blood glucose or HbA1c ( Danne et al 2017). In the US, use of CGM 
is becoming mainstream, driven by [CONTACT_737892], convenience, ease of use, cost- effectiveness,  and increased 
reimbursement. Continuous glucose monitoring facilitates improved glycemic control while reducing hypoglycemia risk ( Danne et al 
2017; Ba ttelino et al 2019 ) and is rapi[INVESTIGATOR_737864] (HCPs) for management of patients with type  1 diabetes mellitus (T1DM) and insulin- treated 
T2DM . 
Time in range (TIR) is one of the metrics derived from CGM and is 
increasingly utilized to assess glycemic control. It can correlate with HbA1c values as well as the risk of diabetes -related complications 
(both microvascular and macrovascular). The International Consensus Report on “clinical targets for CGM interpretation” has identified “TIR” as a metric providing more actionable information than HbA1c and has defined targets for clinical use( Battel ino et al 
2019). For example, in patients with uncomplicated T2DM  whose 
HbA1c targets are <7%, the recommended TIR (for a target range of 70-180 mg/dL) is >70% of the readings. 
Soliqua 100/[ADDRESS_1008150] to diet and exercise to 
improve glyce mic control in adults with T2DM ( Soliqua 2019). The 
2021 Standards of Medical Care in Diabetes from the American 
Diabetes Association ( ADA ; ADA 2021a ; ADA 2021b) recommends 
the use of fixed-ratio combinations when the combination of individual components is indicated, such as when a GLP- 1 RA is 
added to basal insulin or vice versa.  The ADA 2021 Standards also 
recommend dual combination therapy in individuals with HbA1c values ≥1.5% from their glycemic target. Correlations of HbA1c and TIR indicate that CGM glucose readings of patients with an HbA1c ≥9% are in range 40% of the time or less, compared with the 70% 
TIR associated with an HbA1c of 7% ( Battelino et al 2019
). 
Although there are currently no studies using CGM measurements to capture glycemic excursions and variabil ity related to Soliqua 
100/33, a post hoc analysis demonstrated  improvement in all 
measures of glycemic variability compared with its individual 
components (eg, lixisenatide or insulin glargine U100), assessed by 7-point blood glucose profiles. These findings were  attributable to 
Soliqua 100/33’s  complementary  mechanisms  of action , which 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 12 of 156 demonstrat e reductions in both fasting and postprandial 
hyperglycemia ( Aronson et al 2019).  
The current study is intended to replicate these results using CGM 
to measure TIR and glycemic variability in a patient population with very uncontrolled T2DM  (HbA1c ≥9%- 13%),  who are most likely 
to benefit from a fixed-ratio combination approach, such as Soliqua 100/33. 
The primary objective of this study is to demonstrate an 
improvement in the percentage of TIR from  baseline to the end of 
the study (16  weeks) in insulin-naïve patients with very 
uncontrolled (HbA1c ≥9%- 13%) T2DM on 2+ OADs with or 
without GLP -1 RA s. 
Benefit -Risk 
Assessment  Soliqua 100/33 has demonstrated superior glycemic efficacy in 
patients with T2DM uncontrolled on oral therapi[INVESTIGATOR_014], basal insulin, or GLP -1 RA (including weekly GLP-1 RA) with durable efficacy 
(52 weeks) compared with its individual components (insulin 
glargine U100 and  lixisenatide) , and recently premixed insulin 
analog (BIAsp 30) in those uncontrolled on basal insulin and oral therapi[INVESTIGATOR_014]  (
Rosenstock et al 2021). Additionally, compared with 
insulin glargine U100 alone, patients on Soliqua 100/33 had weight neutrality with no increase in hypoglycemia events ; compared with 
lixisenatide  alone, they experienced fewer GI adverse events (AEs)  
(Aroda et al 2016;  Rosenstock et al 2016;  Blonde et al 2019).  
Soliqua 100/33 has also shown greater HbA1c reduction, less weight gain, and less hypoglycemia compared to a premixed insulin analog (BiAsp 70/30) in individuals not controlled on basal insulin therapy ( Rosenstock et al 2021).  No new risks have been identified 
for the population to be included in Study LPS16990. In this study, treatment with Soliqua  100/33 will be consistent with the current US 
Food and Drug Administration (FDA )-approved label indications 
(Soliqua 2019
). During the titration period, the dose of Soliqua 
100/33 will be adjusted upwards or downwards by 2 to 4 units every week, or at the investigator’s discretion, based on the participant’s blood glucose monitoring results, with the objective of safely 
attaining a fasting self -measured plasma glucose (SMPG) value of 
80 to 100 mg/dL, as well as other glycemic goals , while minimizing 
the risk of hypoglycemia and hyperglycemia. The duration of the titration period and number of phone contacts to safely meet the study goals will also be at the discretion of the investigator. 
Therefore, the risk for patients participating in this study and using daily doses of Soliqua 100/33 up to a maximum of 60 units of 
insulin glargine and 20  μg of lixisenatide is considered accep table. 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 13 of 156 All patients enrolled in this study will benefit from medical care and 
continuous monitoring of their glucose levels. 
The important identified risks for Soliqua 100/33 are hypoglycemia 
or hyperglycemia associated with alterations in the insulin dosing regimen, hypersensitivity reactions, overdose due to medication errors, injection site reactions, and GI AEs, 
including nausea, 
diarrhea, and vomiting . This study proposes a titration algorithm with 
titration targets that will closely follo w the US label for 
Soliqua 100/33( Soliqua 2019), except in instances of hyper- or 
hypoglycemia, which require specific attention. All study 
participants will benefit from the safety monitoring planned during 
site visits as well as during the additional titration phone contacts. 
Given the expected improvement of glycemic control and the additional measures to improve diabetes management, the benefits are considered to outweigh any potential risks associ ated with 
Soliqua 100/33. Therefore, the benefit- risk ratio for patients 
participating in Study LPS16990 is considered favorable. 
 
Objectives and Endpoints:  Objectives  Endpoints  
To determine the effect of 
Soliqua 100/33 on indices of 
glycemic control and variability , 
as measured via CGM, from 
baseline to Week  16, in 
insulin -naïve patients with v ery 
uncontrolled ( HbA1c ≥9%-13%) 
T2DM    
Efficacy O bjectives   
Primary Objective  Primary Endpoint  
• To demonstrate that in patients with T2DM failing to achieve glycemic control 
(HbA1c ≥9 %-13%) on their 
current regimen of 2+ OADs with or without GLP -1 RA s, 
introduction of Soliqua 100/33 exhibits superiority in 
terms of time spent in range 
(70-180 mg/dL) at Week  16 
compared with baseline , as 
measured by [CONTACT_28047]  
 • Change in the percentage of TIR 
(70-180 mg/dL) from baseline to 
Week  16 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 14 of 156 Key S econdary Objectives  Key S econdary Endpoints  
• To evaluate  the impact of 
Soliqua 100/33 on measures 
of glycemic control and 
variability  in patients with 
T2DM • Change (%) from baseline to 
Week  16 in coefficient of 
variation (CV)  
• Change (mg/dL) from baseline 
to Week  16 in mean daily blood 
glucose 
• Change (mg/dL ) from baseline 
to Week  16 in the maximum 
postprandial glucose (PPG) exposure in the [ADDRESS_1008151] meal  
• Change (%) from baseline to 
Week  16 in time above range 
(TAR ; >180  mg/dL)  
Secondary Objectives  Secondary Endpoints  
• To evaluate the impact of Soliqua 100/33 on other measures of glycemic control 
and variability in patients with T2DM • Proportion (%) of patients achieving  CV <36%  
• Change (%)  from baseline to 
Week  16 in TIR (70-180 mg/d L) 
for specific time  blocks 
(6 am-12 pm, 12 pm -6 pm, 
6 pm-12 am , and 12 am-6 am)  
• Proportion (%) of patients 
achieving Glucose Management 
Indicator (GMI ) <7% and <9% 
at Week 16 
• Change from baseline to 
Week  16 in the 4-hour PPG area 
under the concentration versus time curve from 0 to 4 hours 
(AUC
0-4h) after start of  the 
breakfast meal, including time to 
reach maximum concentration (T
max) 
• Proportion (%) of patients at  
Week  16 who spend 
<15 minutes/day at a glucose level <54  mg/dL  
 
 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 15 of 156 Other Efficacy Objectives  
• To evaluate the impact of 
Soliqua 100/33 on additional measures of glycemic control 
and variability in patients with T2DM Other Efficacy Endpoints  and 
Analyses 
• Change (mg/dL) from baseline 
to Week  16 in mean of daily 
difference (MODD) of glucose 
levels  
• Change (%) from baseline to Week  16 in TAR (>250 mg/dL)  
• Change (%) from baseline to 
Week  16 in time below range 
(TBR; <70 mg/dL)  
• Correlation of change in the percentage of TIR 
(70-180 mg/dL) and least square (LS) mean ch ange in 
patient -reported outcome (PRO) 
from baseline to Week  16 
• Correlation of percentage of TIR 
(70-180 mg/dL) and HbA1c 
percentage achieved at Week  16 
• Correlation of patients reaching 
60 units/day insulin glargine 
U100 and TIR >70%  
• Change in HbA1c percen tage 
from baseline to Week  16 
PRO Objective  
• To assess patient -perceived 
treatment impact on 
health -related quality of life 
(HRQoL) and treatment 
satisfaction  PRO Endpoint  
• Change from baseline to 
Week  16 in diabetes medication 
treatment satisfaction scores 
(total score and by [CONTACT_737893] ), 
using the  Diabetes Medication 
Satisfaction Tool ( DM-SAT ) 
questionnaire  
Safety O bjective  Safety E ndpoints  
• To assess the safety and 
tolerability of Soliqua 100/33 Safety evaluations will include evaluation of the following (for 
16 weeks) : 
• Overall hypoglycemia 
• Confirmed hypoglycemia  
o ADA Level  1: Measurable 
glucose concentration 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 16 of 156 <70 mg/dL (3.9  mmol/L) 
but ≥54 mg/dL (3.0 mmol/L)  
o ADA Level  2: Measurable 
glucose concentration 
<54 mg/dL (3.0 mmol/L) 
that needs immediate action  
o ADA Level  3: Severe event 
characterized by [CONTACT_317797]/or physical 
functioning that requires 
assistance * from another 
person for recovery  
• AEs, serious adverse events (SAEs), and advers e events of 
special interest (AESI s) 
 
 *Note that “requires assistance” means that the person could not help themselves. 
Assisting a person out of kindness, when assistance is not required, should not be 
considered a “requires assistance” incident.  
Study Population:  Key Inclusion C riteria  
Each participant must meet all of the following criteria to be 
enrolled in this study: 
1. Is capable of understanding the written informed consent, 
provides signed written informed consent, is willing and able to 
complete the electronic diary (eDiary) , and agrees to comply 
with protocol requirements (confirmed by [CONTACT_737894] ). 
2. Is an adult ≥18 years of age. 
3. Has an HbA1c ≥9%-13% during the run -in period. 
4. Was d iagnosed with T2DM at least 6 months before  the baseline 
period. 
5. Has been treated with  2+ OADs  with or without GLP-1 RAs 
with stable doses ( for both) for 3 months before the screening 
period. 
6. Is willing and able to wear the CGM device continuously for 
14 days to capture CGM measures at baseline (from Visit  2 
[ie, the run-in period] until the next site visit at Visit 3.1) and 
again at  the end of the treatment period [ie, from Visit 6 until the 
next site visit at Visit 7; Section  13.1).  
7. Is willing and able to prick fingers a minimum of 2 to 4 times 
per week , using sterile lancets provided with a manual blood 
glucose meter kit.  
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 17 of 156 8. Is willing to discontinue daily  (oral or injectable)  or weekly 
GLP -1 RA or DPP -4i before  administration of Soliqua 100/33. 
9. Is willing and able to inject Soliqua 100/33 and increase dose as 
needed to achieve SMPG target.  
Key Exclusion C riteria  
Participants meeting any of the following criteria will be excluded 
from the study: 
1. Has T1DM or any other types of diabetes, except T2DM. 
2. Is being treated with meglitinides ( eg, nateglinide, repaglinide). 
3. Has a b ody mass index (BMI) >40  kg/m² during the screening 
period.* 
*Body weight and height will be recorded during the screening 
period for the calculation of BMI (metric: BMI  = weight (kg)/height 
[m2]). 
4. Provides less than equivalent of 8 days of evaluable CGM data (not necessarily consecutive) over a 14-day period (eg, days of 
CGM device wear × % time CGM device active  < 8; 
Section  6.2.1). 
5. Has any current or previous skin conditions, including (but not limited to) severe psoriasis, burns, eczema, scarring, and excessive tattoos, that would inhibit the proper wearing of the CGM  device.  
6. Has a h istory of severe nausea and vomiting that resulted in  
subsequent discontinuation of GLP- 1 RA.  
7. Has a k nown history or presence of clinically significant 
pancreatitis or gastroparesis. 
8. Has had  an epi[INVESTIGATOR_737865] (defined as the onset of neuroglycopenia before the appearance of autonomic warning symptoms [for example, blurred vision, difficulty speaking, feeling faint, difficulty thinking, and confusion] or as the failure to sense a significant fall in  blood glucose below normal levels) within the 6 months 
before  the screening period. 
9. Has any clinically significant abnormality identified from the  
physical examination, vital sign  measurements,  or laboratory 
tests (eg, amylase, lipase, alanine aminotransferase [ ALT] 
>3 × upper limit of normal [ULN], calcitonin ≥20 pg/mL, severe 
renal impairment [estimated glomerular filtration rate 
<30 ml/min/1.73m2] or end -stage renal disease) or visual 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  [ADDRESS_1008152] igator 
or any qualified designee, would make implementation of the 
protocol or interpretation of the study results difficult or would preclude safe participation in the study.  
10. Has personal or immediate family history of medullary thyroid 
cancer (MTC) or a genetic condition that predisposes the 
participant to MTC (eg, multiple endocrine neoplasia 
syndromes). 
11. Has current or known history of alcohol or drug abuse within 6 months before  the screening period. 
12. Has s ignificant current (within past 2 months) or expected use of 
medications known to affect glycemia (eg, ≥5 mg/day prednisone). 
13. Uses substances known to interfere with CGM readings, such as 
aspi[INVESTIGATOR_248] -containing products (>650 mg/day of salicylic acid ) or 
supplements containing vitamin  C (>1000 mg/day of ascorbic 
acid) taken during the 14-day periods of CGM measure at 
baseline ( ie, from Visit 2  to Visit 3.1) and end of the treatment 
period ( ie, from Visit 6  to Visit 7). 
14. Has undergone previous treatment with any insulin (except for short- term treatment due to intercurrent illness, including 
gestational diabetes, at the discretion of the investigator). 
15. Is enrolled in another clinical study or has taken other 
investigational drug(s) within 1 month or 5 half -lives from 
screening, whichever is longer. 
16. Has a h ypersensitivity to Soliqua 100/33, either of its  active 
components (insulin glargine or lixisenatide), or any of its excipi[INVESTIGATOR_11792], in the opi[INVESTIGATOR_871], contraindicates participation in the study. 
17. Has used  weight loss drugs (including over-the-counter and 
herbal medications) within 12 weeks before  the screening visit.  
Study Design:  This is a 16 -week, multicenter, interventional, open -label, 
single- arm, Phase 4 study using blinded CGM (FreeStyle Libre P ro) 
to demonstrate improvement in the percentage of TIR from baseline 
in patients adding Soliqua 100/33 and treated for 16 weeks. The 
study will be conducted in approximately 100 patients whose T2DM is very uncontrolled on 2+ OADs with or without GLP-1 RAs (with 
stable doses for 3 months), as evident from a screening HbA1c of 
≥9%-13%. The stu dy will attempt  to represent the diversity of the 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 19 of 156 US patient population  with T2DM  through site recruitment 
efforts . 
All eligible participants will undergo 14  days of blinded continuous 
CGM monitoring at baseline ( the run-in period) and a mixed -meal 
tolerance test (MMTT) while on baseline medications . Soliqua 
100/33 treatment will be initiated on Day 0 (Visit 3.2) , after  the 
MMTT  (which is scheduled at Visit 3.1). Sulfonylurea (SU) doses 
should be down-titrated by 50% when starting Soliqua 100/33, and  
the last doses of daily dipeptidyl peptidase-4 inhibitor (DPP-4i) and 
daily GLP -1 RA (oral or injectable)  should be administered  on the 
morning of Day –1, the day before the first dose of Soliqua 100/33 
(Section  13.1).  
At Visit 3.1, participants on OADs or an oral or injectable GLP -1 
RA will be required to take their dose after  blood sample for fasting 
plasma glucose ( FPG) and HbA1c is collected and  30 minutes  
before  administration of the meal during the MMTT  (during which 
measures for both β -cell function and PPG analyses will be 
captured) . Participants on a weekly GLP -[ADDRESS_1008153] their 
baseline MMTT conducted within 7 (± 3) days after their last dose 
and administer their last weekly GLP -1 RA dose 7 (± 2) days before  
the first dose of Soliqua 100/33.  
During the end of the treatment period (from Visit 6 to Visit 7), 
participants will again be required to undergo 14 days of blinded 
continuous CGM monitoring and a MMTT (only to derive PPG measures).  Soliqua 100/33 should be administered 30 minutes 
before administration of the meal during the MMTT at Visit 7 (during which only measures for PPG analyses will be captured). 
All participants will be allowed to continue their background OADs (except DPP -4i and SU, as previously described) at stable doses and 
regimens throughout the study period, unless they have to be stopped or modified for safety reasons.  
The study comprises the following periods: 
• A screening period of up to 2 week s. 
• A run -in period of 2 weeks , including the baseline period. 
o At Visit 2, the CGM device will be applied to the back of the 
upper arm of the participant and baseline CGM data will be collected continuously for 14 days ; the device will be 
removed at the subsequent site visit during the baseline period (ie, Visit 3.1), after the MMTT.  
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 20 of 156 o During the baseline period, on Day  –1 (Visit 3.1), 
participants  will return to the site for the MMTT  (for both 
β-cell function and PPG measures ) and CGM removal and 
data download (after the MMTT) . Dispensing of the 
Soliqua 100/33 pen and instruction on administration of 
Soliqua 100/[ADDRESS_1008154] during this visit. 
o Visit 3.2 ( ie, Day 0) during the baseline period is the first 
day of Soliqua 100/[ADDRESS_1008155] to ALL  participants to ensure that all administration  
procedures were successfully executed and to answ er any 
questions. ( Note: The first day of Soliqua 100/33 
administration  [ie, Visit 3.2 , Day  0] for participants on 
weekly GLP -1 RA will depend on their administration 
schedule and may not be the day immediately following 
Visit 3.1. Soliqua 100/33 administration  for these 
participants  should be 7 [± 2] days after  their last weekly 
GLP -1 RA dose.) 
 A phone contact [CONTACT_737895] -1 RA on the day before 
Soliqua 100/33 initiation , to remind  them of the next 
morning’s injection and  to provide instructions for  
SoloStar pen use. The participants will provide their concomitant medication  details  to the site personnel over 
the phone.  
• A 16 -week, open- label treatment period . 
o Visit 3.2 (ie, Day  0) is the first day of Soliqua 100/33 
administration and begins the open- label treatment period 
(with different initiation requirements based on weekly or daily GLP -1 RA use, as explained above). 
o The dose of Soliqua 100/33 will be adjusted during the titration period (ie, from Week s 1 through 12; Visits 4.0 to 
5.4), at the investigator’ s discretion , until the desired fasting 
SMPG value (80 -100 mg/dL) is achieved 
(Table:  Recommended Dose Adjustment Algorithm for 
Soliqua 100/33). 
o During Visits 4.0 to 4.6, weekly phone contacts for dose adjustments are to continue at the investigator ’s discretion 
until the desired fasting SMPG value is achieved.  
o If the desired fasting SMPG value is not achieved in the first 8 weeks of treatment, the investigator has the option to 
continue weekly dose titration phone contacts for a n 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 21 of 156 additional 4 weeks (until Week  12; ie, from Visits  5.1 to 5.4)  
with the purpose of achieving glycemic targets. 
o At Visit 6, a blinded CGM device will again be applied to 
the back of the upper arm of the participant and CGM data 
will be collected continuously for 14 days; the device will be removed at the subsequent site visit (ie, Visit 7), after the 
MMTT (only to derive PPG measures).  
o At the end of the study (ie, Visit  7), participants should 
discuss with the investigator, in collaboration with the ir 
HCP, whether to remain on the Soliqua 100/33 treatment regimen or transition to an alternate antihyperglycemic therapy.  
• A 2-week post- treatment safety follow -up period after the last 
dose of Soliqua 100/33 (eg, treatment completion ) or after 
premature/permanent treatment discontinuation from 
Soliqua 100/33. 
Estimated Study 
Duration: The total duration of the study will be approximately [ADDRESS_1008156] (IMP) shipment will need at least 72  hours’ 
notice from the investigator to arrange a home visit and direct- to-patient (DTP) IMP supply, if required. An unscheduled site 
or home visit can be planned during the treatment period for IMP Soliqua 100/33 resupply, if required. If DTP Soliqua 100/[ADDRESS_1008157] 72 hours’ notice to collect Soliqua 100/[ADDRESS_1008158] participant in the study. Although [COMPANY_011] has every intention of completing the study, [COMPANY_011] reserves the right to discontinue the study at any time for clinical or administrative 
reasons.  
Efficacy Assessments:  The schedule of events (SoE) is provided in Section  13.1. 
The efficacy assessments are as follows:  
 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 22 of 156 • CGM measures . 
• MMTT -derived  β-cell function and PPG  measures . 
o Biomarkers of β- cell function ( plasma glucose, insulin , and  
C-peptide) will be collected at baseline;  whereas only 
plasma glucose will be collected at  Visit 7. 
• Fasting SMPG. 
• FPG measurements . 
• HbA1c measurements ( during the screening and run-in periods 
and at Visits 3.1 and 7). 
CGM Measures  
Blinded CGM will be performed for 14 continuous days during 
baseline (ie, from Visit 2 to Visit 3.1) and again for 14 days at the 
end of the treatment period (ie, from Visit 6 to Visit 7; Section  13.1 ). 
The baseline CGM measure will be captured before discontinuing 
the daily  (oral  or injectable)  or weekly GLP -1 RA , DPP -4i, or 
down-titration of SU by 50%, and before  initiation of Soliqua 
100/33 treatment . The blinded CGM device (FreeStyle Libre Pro) 
will be applied to the back of the upper arm of the participant and activated at Visit 2 (ie, the run-in period). Participants will be 
required to wear the device continuously for 14 days for baseline CGM data collection, with device removal and data download on Day –1 at their next site visit during the baseline period (ie,  
Visit 3.1), after collection of C-peptide, insulin, and plasma glucose data from the MMTT. Downloaded CGM data will be reviewed by [CONTACT_737896]’ study eligibility. (Note: During the run-in period, CGM device reinsertion will be allowed for participants who do not meet the equivalent of at least 8  days of 
evaluable CGM data [not necessarily consecutive] over a 14- day 
period as a result of premature sensor failure [eg, days of CGM device wear × % time CGM device active < 8] ; 
Table  6-1 and 
Figure 13–1 .) Similarly, participants will be required to 
continuously wear the devi ce for 14  days at the end of the treatment 
period from Weeks  14 to 16 (ie, Visit 6 to Visit 7) to collect CGM 
data, with device removal and data download on the fifteenth day 
after CGM placement (ie, Visit 7), after collection of only plasma 
glucose data from the MMTT. Downloaded CGM data will be verified by [CONTACT_737897]’ 
study completion. During the end of the treatment period, CGM device reinsertion will also be allowed for participants who do not 
meet the equivalent of at least 8  days of evaluable CGM data (not 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 23 of 156 necessarily  consecutive ) over a 14 -day period as a result of  
premature sensor failure ( eg, days of CGM device wear × % time 
CGM device active < 8; Table  6-1 a nd Figure 13–1), if data can be 
captured during the 14-day end of treatment window. (Note: The 
minimum requirement for evaluable CG M data is if at least 10 out 
of 14 days [not necessarily consecutive] have at least  ≥80% of 
evaluable CGM data per 24 -hour period  during the run-in period as 
well as  the end of the treatment period [ie, from Weeks 14 to 16] ; 
Battelino et al 2020 .) 
Participants with less than  equivalent of 8 days of evaluable CGM 
data (not necessarily consecutive) of a 14-day period (eg, days of 
CGM device wear × % time CGM device active < 8) during the run-in period will be considered as screen failures . For participants  
who discontinue study treatment prematurely, the visit window can 
be extended by [ADDRESS_1008159] the CGM data  before they 
permanent ly discontinue the treatment . 
MMTT -Derived  β-Cell Function and PPG Measures  
Participants will undergo the MMTT  (while wearing the CG M 
device) to assess maximum PPG exposure in the [ADDRESS_1008160] meal (tested at a central laboratory) with biomarkers of 
β-cell function  (plasma glucose, insulin , and C-peptide) measured at 
Visit 3.1 (ie, site visit during the baseline period). The baseline 
MMTT will be conducted before discontinuing the daily (oral or 
injectable)  or weekly  GLP -1 RA, DPP -4i, or down- titration of SU  
by 50%. Participants on OADs or an oral or injectable GLP -1 RA 
will be required to take their dose after the blood sample for FPG 
and HbA1c is collected  and 30 minutes before  administration of the 
meal during the MMTT ( Visit 3.1). Participants who are on weekly 
GLP -[ADDRESS_1008161] their baseline MMTT conducted within 
7 (± 3) days after their last dose.  During baseline (Visit 3.1), blood 
samples will be collected at the following time  points: premeal 
(30 min)  and just before administration of OADs or GLP -1 RA (oral 
or injectable ) (baseline); time 0 (just before the meal), 10 min, 
20 min ; and 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, and 4.[ADDRESS_1008162]- meal  for 
plasma  glucose, C-peptide, and insulin levels.  
At the end of the treatment period (Visit 7), participants will again undergo the MMTT (while wearing the CGM device; only to derive PPG measures ). Soliqua 100/33 should be administered 30 minutes 
before administration of the meal during the MMTT at Visit 7. At the end of the treatment period (Visit 7), blood samples will be collected for plasma glucose levels , as follows: premeal  (30 min) 
and just be fore administration of  Soliqua  100/33;  and time 0 (just 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 24 of 156 before the meal),  0.5, 1.0, 1.5, 2.0, 2.5, 3.0, and 4.[ADDRESS_1008163] meal follow ing Soliqua 100/33 
administr ation for 16  weeks compared with baseline. During both 
baseline and end -of-treatment asses sments, removal of the CGM 
device and download of data will be done after completion of the MMTT ( Section  
13.1).  
The MMT T includes  a standardized m eal (ie, Boost Very High 
Calorie ) that contains approximately 530 kcal and is composed of 
19% carbohydrates, 44% protein, and 33% fat. The composition and the quant ity of the st andardized meal must be identical throughout 
the study period. 
During the baseline period (ie, Visit 3.1), on the day of the MMTT, 
the partic ipants must  not eat any food or drink, except water, for at 
least [ADDRESS_1008164] (to be completed in the 
morning) . At the end of the treatment  period ( ie, Visit 7), the MMTT 
will also  be performed in a fasted stat e (eg, no consumption of any 
food or drink for at least [ADDRESS_1008165]) , and partic ipants will receive their Soliqua 100/[ADDRESS_1008166] (i e, consumption of the 
meal  and just after th e first blo od draw ). 
For partic ipants who discontinue study treatment prematurely, the 
visit window can be extended by [ADDRESS_1008167] the CGM data, followed by [CONTACT_737898] , before t hey permanently discontinue 
the treatm ent. 
Fasting SMPG 
Participan ts will be supplied with a glucometer and an eDiary at the 
screening visit. Appropriate training will be provided to the 
participants related to proper use of the glucometer and eDiary completio n. Fasting SMPG values (lowest values in conjunction 
with measurements from the previous 3 days) will be used to titrate 
and adjust Soliqua 100/[ADDRESS_1008168] 3 to 4 times per week throughout the study period 
(to inform each dose adjustment) and record the results in the 
eDiary. During the titration period, fasting SMPG should be performed on each of the 3 to 4 days before each dose adjustment. (Note: Additional titration is at the discretion of the investigator 
with the goal of achieving glycemic targets while minimiz ing the 
risk of hypoglycemia and hyperglycemia.) 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 25 of 156 SMPG During Symptomatic Hypoglycemia  
Whenever participants experience hypoglycemia symptoms, they 
(or others, if applicable) should measure plasma glucose, if possible. 
Participants should be instructed to measure plasma glucose levels before  carbohydrate intake/administration of glucose whenever 
symptomatic hypoglycemia is suspected, unless safety considerations necessitate immediate carbohydrate/glucose rescue before  confirmation with the SMPG  values . Participants must 
contact [CONTACT_737899] a decisi on regarding  any necessary 
actions can  be made. Participants should be instructed to measure 
plasma glucose levels  again after  the event resolves.  
FPG Measurements  
Blood samples will be collected to determine FPG at the time points specified in the SoE ( Section  13.1) and will be measured at a central 
laboratory. For the scheduled site visits, participants are required to arrive fasting without administering the  Soliqua 100/33 injection. 
Fasting is defined as no food intake in the 8 hours before blood sampling, except water.  
HbA1c M easurements  
Blood samples will be collected to measure HbA1c during the 
screening  and run-in periods, and  at Visit 3.1 (before administ ration 
of the meal ) at the central laboratory, to determine study eligibility , 
and at the end of the 16- week treatment period  (Visit 7), to 
determine change in glycemic control. 
Assessment of PRO  
Diabetes Medication Satisfaction Tool 
The assessment of treatment -related impact on participants’ 
health -related quality of life and their satisfaction with diabetes 
therapy will be assessed using the DM-SAT questionnaire 
(Anderson et al 2009) at the baseline visit before stoppi[INVESTIGATOR_737866]- titration of baseline therapi[INVESTIGATOR_737867] ( Section  13.1). The DM -SAT questionnaire ( Section 13.2) is 
a 16-item measure with 4  subscales assessing wellbeing (3  items), 
medical control (3  items), lifestyle (5 items), and convenience 
(5 items).  
Participants will be requested to complete the DM- SAT 
questionnaire by [CONTACT_1029], independently from the investigator or 
site staff, and without any help from friends or relatives. For validity 
purposes, the questionnaire should be completed by [CONTACT_10132] a 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  [ADDRESS_1008169], at the start of the visit before any other study tests or 
procedures are performed or Soliqua 100/33 is administered. 
Safety 
Assessments:  Safety will be evaluated by [CONTACT_5206], severity, seriousness, and 
duration of any AEs. Hypoglycemi a events, AEs , and SAEs, 
including AESI s, will be recorded at each site visit and phone 
contact [CONTACT_737900]. 
Any abnormal changes in vital signs, standard chemistry, and 
hematology will be assessed  at Visit 1 (ie, screening period), 
Visit 3.1 (ie, before initiation of Soliqua 100/33 treatment), and Visit 7 (ie, end of the treatment period; Section  13.1).  
The safety assessments are as follows:  
• Physical examination . 
• Hypoglycemia events . 
• AEs and SAE s, including AESI s. 
• Vital signs (heart rate, systolic blood pressure [BP], and diastolic BP) . 
• Clinical safety laboratory assessments (eg, clinical chemistry, 
calcitonin [screening only], hematology, urinalysis). 
Physical Examination 
A complete physical examination (including body weight ) will be 
performed , per standard of care, in order to assess the health status 
of the participants at time  points described in the SoE 
(Section  13.1).  Height measurements in conjunction with body 
weight will be utilized to calculate BMI during the screening period.  
Hypoglycemi a Events  
During the study, participants must be instructed to document any 
hypoglycemia events in their eDiary. Hypoglycemia will be reported in the specific hypoglycemia event information form in electronic case report form (eCRF) with onset date and time; symptoms and/or signs; the SMPG value, if available; and the treatment. A 
hypoglycemia event that  fulfills the seriousness criteria will also be 
documented on the SAE form in the eCRF. Participants should be instructed to record their SMP G values  in the eDiary after  the event 
resolves.  
Hypoglycemia will be evaluated in accordance with the consensus 
report of a steering committee on levels of hypoglycemia (Agiostratidou et al 2017 ). These levels are consistent with the ADA 
standard of care 2021 recommendations ( ADA 2021a ). 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  [ADDRESS_1008170]:  
• Overall hypoglycemia. 
• Confirmed hypoglycemia. 
o ADA Level 1 : A measurable glucose concentration of 
<70 mg/dL (3.9 mmol/L) but ≥54 mg/dL (3.0 mmol/L).  
o ADA Level 2 : A measurable glucose concentration of 
<54 mg/dL (3.0 mmol/L) that needs immediate action.  
o ADA Level 3 : A severe event characterized by [CONTACT_737901]/or physical functioning that requires assistance* from 
another person for recovery. 
*Note that “requires assistance” means that the person could not help themselves. Assisting a person out of kindness, when assistance is not required, should not be considered a “requires assistance” incident. 
Clinical symptoms that are related to a hypoglycemia epi[INVESTIGATOR_737868] (but are not necessarily limited to) increased sweating, 
nervousness, asthenia, tremor, dizziness, increased appetite, palpi[INVESTIGATOR_814], headache, sleep disorder, confusion, seizures, unconsciousness, and coma ( Agiostratidou et al 2017). 
Adverse Event s and Serious A dverse Events, including Adverse 
Events of Special Interest  
All AEs (serious or nonserious) will be collected from the signing of the informed consent form (ICF) until the follow-up visit 
(Section  13.1). The definitions of AEs and SAEs are provided in the 
Section  13.5. 
AESI : An AESI is an AE (serious or nonserious) of scientific and 
medical concern specific to the sponsor’s product or program, for which ongoing monitoring and immediate notification by [CONTACT_230013]. Such events may require further investigation in order to characterize and understand them. Adverse events of special interest may be added, modified, or removed during a study by [CONTACT_12548]. 
The f ollowing AEs will be considered AESI s in this study: 
• Pregnancy of a female participant enrolled in the study as well 
as pregnancy occurring in a female partner of a male participant enrolled  in the study with IMP/non- investigational medicinal 
product (NIMP). 
• Symptomatic overdose (serious or nonserious) with IMP/NIMP . 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 28 of 156 o An overdose (accidental or intentional) with the IMP /NIMP  
is an event suspected by [CONTACT_737902], in the investigator’s opi[INVESTIGATOR_737869], is considered significantly greater than the prescribed dose of insulin or is  at least twice the intended 
dose within the intended therapeutic interval ( for example,  
for a participant prescribed 60  units/20 µg Soliqua 100/33 
once a day , administration of  ≥120 units of insulin glargine 
U100 with  ≥40 μg of lixisenatide  once a day  would be 
considered an overdose), adjusted according to the tested drug. 
• Increase in ALT (>3  × ULN ; Section  13.6).  
The investigator is responsible for repor ting all AEs that are 
observed or reported during the study, regardless of their relationship to study drug or their clinical significance. The 
investigator remain s responsible for following up on AEs that are 
serio us, considered related to the study treatment or study 
procedures, or caused the participant to discontinue the Soliqua 100/33 treatment and/or the study. 
Vital Signs  
Vital signs will be recorded at the time points specified in the SoE (Section  13.1).  
Clinical Safety Laboratory A ssessments  
All clinical safety laboratory assessments will be performed by a 
central laboratory. The investigator must review the laboratory 
report  and document this review. The laboratory reports must be 
filed with the source documents. 
Clinically significant abnormal laboratory findings associated with 
the underlying disease or vital signs will not be considered 
clinically signific ant or be reported as AEs unless  one of the 
following criteria is met: 
• Participant is symptomatic (and/or laboratory values or vital 
signs are clinically significant per the investigator’s discretion) . 
• Participant r equires either corrective treatment or co nsultation .  
• Participant requires  Soliqua 100/33 treatment to be discontinued 
or modification of dosing. 
• Event f ulfills  a seriousness criterion . 
• Event meets the  definition of an AESI  (Section  [IP_ADDRESS] ). 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  [ADDRESS_1008171] will be performed at time  points specified in 
the SoE (Section  13.1). Any female participant who becomes 
pregnant while participating in the study will be discontinued from 
study drug treatment.  
Study Visits  The SoE is provided in Section  13.1. 
• The screening period (Visit 1) will encompass up to 2 week s and 
include s obtaining informed consent, eligibility criteria,  
demographic assessment, review of medical/surgical history and curre nt medications, physical examination (BMI calculation) , 
dispensing of glucometer, HbA1c measurement, setting up the eDiary, recording of vital signs, and  clinical chemistry, 
calcitonin , hematology, urinalysis, and pregnancy tests. 
• The run-in period (Visit 2) will encompass 2 weeks , including 
the baseline period, and includes HbA1c measurement and application of blinded CGM device (FreeStyle Libre Pro).  
o Visit 3.1 will be a site visit and include s assessment of 
eligibility criteria, MMTT,  CGM device removal and data 
download (after the MMTT), CGM compliance assessment, evaluation of PPG and biomarkers of β- cell function 
(insulin, C-peptide, plasma glucose) during the MMTT, 
instructions for certain therapi[INVESTIGATOR_014] (eg, DPP-4i, oral daily or weekl y GLP -1 RA, and down-titration of SU by 50% when 
starting Soliqua 100/33), dispensing of Soliqua 100/33 and 
providing instruction for SoloStar™ pen use, HbA1c and 
FPG measurement s, administration of the DM-SAT, 
recording of vital signs  and body weight, and  clinical 
chemistry , hematology, urinalysis, and pregnancy tests. 
o Visit 3.2 ( ie, Day 0) during the baseline period is the first  
day of Soliqua 100/[ADDRESS_1008172] to ALL  participants to ensure that all administration  
procedures were successfully executed and to answer any questions. ( Note: The first day of Soliqua administration 
[ie, Visit 3.2, Day 0] for participants on weekly GLP-1 RA 
will depend on their administration schedule and may not be the day immediately following Visit 3.1. Soliqua 100/33 
administration  for these participants  should be 7 [± 2] days 
after their last weekly GLP -1 RA dose.) 
 A phone c ontact should  also be made ONLY to 
participants on weekly  GLP -1 RA on the day before 
Soliqua 100/33 initiation , to remind  them of the next 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 30 of 156 morning’s injection  and to provide instructions for 
SoloStar pen use. The participants will provide their 
concomitant medication details to the site personnel over the phone. 
• The treatment period will encompass  up to  16 weeks  (Visits  3.2 
through 7), and includes the following: 
o Visit 3.2 (ie, Day  0) is the first day of Soliqua 100/33 
administration and begins the open- label treatment period 
(with different initiation requirements based on weekly or 
daily GLP-1 RA use, as explained above). 
o Titration period (Visits 4.0 to 4.6, 5, and 5.1 to 5.4). 
 For Vi sits 4.0 to 4.6, titration of the Soliqua 100/33 dose 
will occur via phone contacts, but it can occur  at the 
study site or at home for Visit  5. For Visits  5.1 through 
5.4, titration of Soliqua 100/33 dose will again occur via phone contacts. 
 During the tit ration period, participants will continue to 
make entries into their eDiary, administer  Soliqua 
100/33, adjust the Soliqua 100/[ADDRESS_1008173] complaints. 
 Other than an unscheduled visit, dispensing of Soliqua 100/[ADDRESS_1008174] will also be conducted at Visit 5. 
o Visit 6 : Application of blinded CGM device, assessment of 
Soliqua 100/[ADDRESS_1008175] 
complaints.  
o Visit 7 (ie, end of the treatment pe riod): P hysical 
examination  (including body weight), MMTT (only to derive 
PPG measures), removal of CGM device and download of data, assessment of Soliqua 100/33 adherence, HbA1c and FPG measurements, recording of the DM-SAT, vital signs, and clinical chem istry, hematology, urinalysis, and 
pregnancy tests. 
o At the end of the study (ie, Visit 7), participants should discuss with the investigator, in collaboration with the ir 
HCP, whether to remain on the Soliqua 100/33 treatment regimen or transition to an alternate antihyperglycemic therapy . 
• An unscheduled visit can be performed  at any time during the 
treatment  period and may include  dispensing of Soliqua  100/33, 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 31 of 156 adjustment of Soliqua 100/33 dose, review of concomitant 
medications, and recording of hypoglycemia events  and 
AEs/SAEs (including AESIs ). 
• The follow-up safety period (Visit 8) will occur 2 weeks after 
the end of the treatment period. 
• Fasting SMPG values  and those measures required to manage 
hypoglycemia events will occur from the run- in period (Visit 2) 
through the end of the treatment period (Visit 7).  
• Soliqua 100/33 dosing will occur from the end of the baseline 
period (Visit 3.2) through the end of the treatment period (Visit 7).  
• eDiary completion, recording of hypoglycemia events , and  
AEs/SAEs (including AESI s) will occur from the screening 
period (Visit 1) through the follow-up period (Visit 8) , whereas 
review of concomitant medications will occur from the baseline period (Visit 3.1) through the follow-up period (Visit 8). 
Study Drug, Dosage, and Route of Administration:  • Formulation: Soliqua 100/33 will be supplied as a sterile, non-pyrogenic, clear, colorless solution in SoloStar prefilled (disposable) pen for subcutaneous (SC) injection. The SoloStar 
pen is necessary for Soliqua 100/33 administration, and it is considered an integral part of the Soliqua 100/33 therapy . 
o The prefilled  SoloStar disposable pen contains 3 mL of 
sterile solution containing 100 units/mL insulin glargine and 
33 μg/mL lixisenatide in a 3:1 ratio (ie, 3 units of insulin glargine to 1 μg lixisenatide), and it allows for 
administration of both ingredients simultaneously with doses 
ranging from 15 units/5  μg to 60 units/20 μg (insulin 
glargine U100/lixisenatide). 
o Soliqua pen instructions will be given to all participants at Visit 3.1. 
o A phone contact [CONTACT_737903] -1 RA on the day before Soliqua 100/33 initiation, to 
remind them of the next morning’s injection and to provide instructions for SoloStar pen use. 
• Route of administration: SC injection using the SoloStar pen into the abdominal area, thigh, or upper arm. Injecti on sites  
should be rotated within the same region from one injection to 
the next to reduce the risk of lipodystrophy. 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 32 of 156 • Time of administration: Soliqua 100/[ADDRESS_1008176] dose of Soliqua 100/33 will be administered on the 
morning of Day 0 (ie, Visit 3.2). This date should be 7 [± 2] days after the last weekly GLP -[ADDRESS_1008177] dose of DPP-4i, or daily GLP-1 RA (oral or injectable) administration.  
Starting Dose 
• For all participants, the starting dose of Soliqua 100/33 will be 
15 units of insulin glargine (corresponding to 5 μg of 
lixisenatide).  
• The m aximum daily dose of Soliqua 100/33 should not exceed 
60 units of insulin glargine (corresponding to 20 μg of lixisenatide).  
Dose Modifications 
The dose of Soliqua 100/33 will be adjusted  with the aim of 
attaining a target fasting SMPG value of 80 to 100 mg/dL. The dose 
will be adjusted based on the lowest fasting SMPG values in conjunction with measurements from the previous 3 days 
throughout the study period. During the titration period (ie, Weeks 1 through 12) fasting SMPG should be assessed on each of the 3  to 
4 days before each dose adjustment. During the titration period, the dose of Soliqua 100/33 should be adjusted upwards or downwards by 2 to 4 units every week (with additional titration also at the 
discretion of the investigator in accordance with  the participant ’s 
blood glucose monitoring results) with the goal of achieving a fasting SMPG value of 80 to 100 mg/d L, as well as other glycemic 
goals, while minimizing the risk of hypoglycemia and 
hyperglycemia . The duration of the titration period and number of 
phone contacts to safely meet the study goals will also be at the 
discretion of the investigator. 
As stated above, dose titration is at the discretion of the investigator. Study participants should be trained and retrained on an ongoing basis to establish proper understanding of titration procedures 
because very close communication between the participant and the study site is necessary to ensure adequate titration while minimizing 
the associated risks. Investigators may adjust or stop titration or temporarily reduce the dose if they believe further titration would 
result in participants experiencing any AEs (eg, hypoglycemia, 
AESI s). After  the target fasting SMPG value  has been achieved, the 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 33 of 156 dose of Soliqua 100/[ADDRESS_1008178] 8 weeks 
of treatment, the investigator has the option to continue weekly dose titration phone contacts for an additional 4 weeks ( until Week  12) 
for the purpose of achieving glycemic targets. 
Doses will be adjusted at least weekly, but additional titration may be considered at the investigator’ s discretion. Participants are, 
therefore, required to record their fasting SMPG values before breakfast at least 3  to 4 times per week throughout the study period 
to inform each dose adjustment. 
Recommended Dose Adjustment Algorithm for Soliqua 100/33 
Median of Fasting SMPG Values 
(With Lowest Value Considered in 
Conjunction With Previous 
3 Measurements)  Soliqua 100/33 Dosage 
Adjustment (Units/Week)  
>140 mg/dL (>7.8 mmol/L)  +4 units  
>100 to ≤140 mg/dL (> 5.5 to 
≤7.8 mmol/L)  +2 units 
Glycemic target: 80 to 100 mg/dL 
(4.4–5.5 mmol/L), inclusive  No change 
≥60 to <80 mg/dL (≥3.3 to 
<4.4 mmol/L)  –2 units  
<60 mg/dL (<3.3 mmol/L) or 
occurrence of 2 (or more) 
symptomatic hypoglycemi a event s or 
1 severe hypoglycemia event 
(requiring  assistance) documented in 
the preceding week  –2 to – 4 units or at the 
discretion of the investigator or 
any qualified designee 
Notes: Dose changes should also be based on the median SMPG values (with the 
lowest value considered in conjunction with the previous 3 measurements). If 
the lowest value from the previous 3 measurements is from  80 to 100 mg/dL 
and the other 2  values are well above 100 mg/dL, further titration may be 
implemented at the investigator ’s discretion. If the lowest value is <70  mg/dL 
and the other 2 values are near 100 mg/dL, the investigator may stop or 
temporarily reduce the dose if , in their judgment , further titration would be 
hazardous. 
 
 
 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 34 of 156 NIMP  and Concomitant Therapy 
Background OADs (eg, SU, biguanides, thiazolidinediones, 
α-glucosidase inhibitors , sodium -glucose co -transporter-2 [SGLT2] 
inhibitors, bile acid sequestrants, dopamine agonists) are permitted  
during the screening and  treatment period s of the study, initiated and 
at stable doses for a minimum of 3 months before the screening 
period. Meglitinides will be prohibited (eg , repaglinide, 
nateglinide). 
Appropriate Correcti ve Action/ Rescue Therapy 
Titration will be exceedingly important throughout the first 
12 weeks of this study and will require  consistent reviews of fasting 
SMPG  values , the daily insulin dose, and hypoglycemia events to 
identify participants whose Soliqua 100/33 dose is  not being 
appropriately managed. 
If after Week  12 (ie, end of the titration period), the participant’ s 
FPG level is >240  mg/d L with no reasonable explanation for severe 
hyperglycemia, such as intercurrent illnesses or nonadherence to 
instructed titration, the investigator should obtain an HbA1c measurement and decide whether rescue therapy is warranted.  
Devices  
Blood G lucose Meter Kit: Each study participant will be provided 
with a blood glucose meter kit, in order to perform SMPG assessments. The blood glucose meter kit will include a blood glucose meter, lancing  device, test strips, sterile lancets, storage 
box, control solution, and instructions for use.  
CGM Device (FreeStyle Libre Pro Flash Glucose Monitoring 
System) : The  device will be applied to the back of the upper arm of 
each participant , and they will be required to wear it continuously 
for 14  days during CGM data collection both at baseline (during the 
run-in period) and for 2 weeks at the end of the treatment period 
(ie, Weeks  14 to 16). 
Management of 
Clinical Supplies  Study Drug Packaging and Storage 
Packaging will be in accordance with the administration schedule. 
The content of the label ing is in accordance with the local 
regulatory specifications and requirements. The appropriate number of kits (including pen needles as ancillar y supplies ) will be 
dispensed to provide participants with Soliqua 100/[ADDRESS_1008179] with DTP Soliqua 100/33 delivery ( Section  13.1). Storage conditions and use-by- end date 
(ie, expi[INVESTIGATOR_5695]) are part of the Soliqua 100/33 label text. 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 35 of 156 Investigators or other authorized persons (eg, pharmacists, IMP 
managers) are responsible for storing Soliqua 100/[ADDRESS_1008180] in accordance with local regulations, labeling 
specifications, policies, and procedures. Control of Soliqua 100/33 storage conditions, especially control of temperature (eg, refrigerated storage) , and information on in-use stability and 
instructions for handling the Soliqua 100/33 should be managed according to the rules provided by [CONTACT_456]. 
Study Drug Accountability The investigator or other personnel designated by [CONTACT_737904], including dates of receipt. In addition, accurate records will be kept regarding when and how much study drug is dispensed and used by [CONTACT_737905]. The investigator or other personnel designated by [CONTACT_737906] 100/33 and requesting any 
resupply, as needed. 
All Soliqua 100/33 will be dispensed in accordance with the 
investigator’ s oversight. I t is also the investigator’s responsibility to 
ensure that an accurate record ing of S oliqua 100/33 kits issued and 
returned is maintained. 
Any quality issue noticed with the receipt or use of Soliqua 100/33 
pen (deficiency in condition, appearance, documentation, labeling, expi[INVESTIGATOR_320], etc.) must be promptly reported  to the sponsor. 
Under no circumstances will the investigator supply Soliqua 100/[ADDRESS_1008181] party (except for DTP shipment, fo r which a courier 
company has been approved by [CONTACT_456]), allow the Soliqua 100/33 pen to be used other than as directed by [CONTACT_239204], or dispose of the Soliqua 100/33 pen . 
Overdose Management  An overdose (accidental or intentional) with the IMP/NIMP is an event suspected by [CONTACT_737907], in the 
investigator’s opi[INVESTIGATOR_737870], is considered 
significantly grea ter than the prescribed dose of insulin or is at least 
twice the intended dose within the intended therapeutic interval. Any overdose, with or without associated AEs, must be promptly reported in eCRFs by [CONTACT_30107], which will then be notified to the spons or’s representative (ie, [COMPANY_003] Pharmacovigilance). Overdoses 
without signs or symptoms should be recorded as a standard overdose; any AEs associated with the overdose should be reported on the relevant AE/SAE sections in the eCRF.  
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 36 of 156 Treatment of Overdose 
Insulin Glargine 
Excess insulin administration may cause hypoglycemia and 
hypokalemia. Mild epi[INVESTIGATOR_737871]. Adjustments in study drug dose, meal patterns, or exercise may be needed.  
More severe epi[INVESTIGATOR_737872], seizure, or 
neurologic impairment may be treated with intramuscular/subcutaneous glucagon or concentrated intravenous glucose. After apparent clinical recovery from hypoglycemia, continued observation and additional carbohydr ate intake may be 
necessary to avoid recurrence of hypoglycemia. Hypokalemia must be corrected appropriately.  
Lixisenatide  
During clinical studies, doses up to 30 µg of lixisenatide twice daily (3 times the da ily recommended dose) were administered to pati ents 
with T2DM in a 13-week study. I ncreased incidence of GI disorders 
was observed ( Soliqua 2019).  
In case of overdose, appropriate supportive treatment should be initiated according to the participant’ s clinical signs and symptoms, 
and the Soliqua 100/33 dose should be reduced to the prescribed dose. 
Treatment 
Adherence The investigator or their delegate will track treatment 
accountability/ adherence by [CONTACT_737908] ( EDC ) tool with  the 
treatment /accountability log, eDiary information about daily doses, 
and number of treatment kits provided versus number of treatment kits returned (whether empty or unused). 
The monitor in charge of the study will check the data entered on 
the Soliqua 100/33 administration page of the eCRF by [CONTACT_737909] 100/33 study drug that has been returned  and 
the participant ’s treatment log form.  
Sample Size:  Suffici ent participants will be screened from approximately 15 sites 
to include 100 patients, such that approximately 82 evaluable participants complete the study ( anticipating  that approximately 
15% of participants discontinue the study before Week 16). 
Determination of Sample Size  
The sample size is based on the primary objective to demonstrate the significant mean change (ie, increase) in the percentage of  TIR 
(70‑180  mg/dL) from baseline to Week 16 with sufficient power. A 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  [ADDRESS_1008182] 95% power to detect an 
absolute increase in TIR means of 10%, assuming a standard 
deviation ( SD) of 25 for the change in TIR , with a two -sided type I 
error of 0.05. Anticipating  a 15% loss to follow-up rate, 100 patients 
would need to be enrolled. 
Statistical 
Methods:  Analysis Sets  
• Enrolled set: All eligible participants who are dispensed 
Soliqua 100/33 and sign the ICF. 
• Efficacy analysis set: All enrolled participants who receiv e 
≥1 dose of Soliqua 100/[ADDRESS_1008183] evaluable CGM data at 
baseline.  
• Safety set: All enrolled participants who receive ≥1  dose of 
Soliqua 100/33. 
General Statistical Methods  
In general, descriptive statistics of quantitative efficacy and safety parameters (result and change from baseline) by  [CONTACT_737910] (OC; ie, inclusion of only participants having non- missing assessments at a specific visit). The 
baseline value is defined as the last available value before the first injection of Soliqua 100/33. 
All ef ficacy analyses (primary, key secondary, secondary, and other 
efficacy endpoints ) will be performed on the efficacy analysis set. 
Analysis of demographics, baseline characteristics, and prior and 
concomitant medications will be provided in detail in the statistical 
analysis plan ( SAP). 
The extent of study treatment exposure and adherence will be 
assessed and summarized with dose frequency and duration of treatment.  
Continuous data will be summarized using number of observations available, mean, SD, quartile ranges, minimum, median, and maximum. Categorical data will be summarized using count and percentage.  
Primary Analysis  
Mean change in the percentage of TIR (70‑180 mg/dL) from 
baseline to Week 16 and its associated 95% confidence interval (CI). 
A one- sample t -test will be applied to test the significance of 
changes at Week 16 over baseline. A p-value <0.05 will be considered significant. 
 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 38 of 156 Key Secondary Analysis  
Mean changes for continuous outcomes (eg, CV , mean daily blood 
glucose, maximum PPG exposure in the [ADDRESS_1008184] 
meal, TAR >180  mg/dL) will be presented at baseline and at the end 
of the treatment period (Week 16). Mean (SD) and associated 95% CI, as well as minimum, median, and maximum will be provided. 
Analysis of Secondary Endpoints  
• Mean changes for continuous outcomes will be presented at 
baseline and at the end of the treatment period (Week  16). Mean 
(SD) and associated 95% CI, as well as minimum, median, and 
maximum will be provided. 
• Binary outcomes will be summarized with proportions and 95% 
CI using the Clopper Pearson exact method. 
Analysis of Other Efficacy Endpoints 
• Mean changes for continuous outcomes will be presented at 
baseline and at the end of the treatment period (Week  16). Mean 
(SD) and associated 95% CI, as well as minimum, median, and maximum will be provided. 
• The correlation of TIR to PRO, HbA1c, and requirement for 60 units/day of insulin glargine U100 (related to TIR >70%) at Week  16 will be assessed using Pearson correlation coefficient.  
Analysis of PRO Endpoint  
• Change in diabetes medication treatment -related impact and 
satisfaction, as measured by [CONTACT_737911] -SAT, from baseline to 
Week 16 will be analyzed using the efficacy analysis set and described as mean (SD) and associated 95% CI as well as minimum, median, and maximum for overall score and by [CONTACT_737893] . 
Safety Endpoints 
All safety and tolerability endpoints will be described by [CONTACT_6227], proportions, and the associated 95% CI for proportions. Adverse event incidence tables will be presented by [CONTACT_9313] (SOC ; sorted by [CONTACT_56496]), high-level group term 
(HLGT), high- level term (HLT), and preferred term (PT) sorted in 
alphabetical order  with  the number (n) and percentage of 
participants experiencing an AE. Participants with more than 1 AE 
epi[INVESTIGATOR_737873]. The denominator for computation of percentages will be the safety  set. Hypoglycemia 
events will be counted with multi ple epi[INVESTIGATOR_737874], if 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 39 of 156 available, and the event rate per person -years will be reported  
overall and by [INVESTIGATOR_67147]. 
Handling of Missing D ata 
Missing data will be  handl ed differently in accordance with  the 
reason s for the missing  data for both primary and key secondary 
endpoints. If the missing data are due to technical issues with the 
CGM device (ie,  CGM data are not evaluable if at least 10 out of 
14 days [not necessarily consecutive] have <80% of evaluable CGM data per 24 -hour period during the run-in period as well as the end 
of the treatment period  [ie, from Weeks 14 to 16]), the participant  
will be excluded from the analysis ( missing completely at random 
[MCAR ] approach). For other reasons for missing measurements 
(eg, l ost to follo w-up, discontinued treatment), the baseline value 
carried  forward (M CAR, conservative approach) is planned for both 
primary and key secondary analyse s. 
Multiple Comparisons and M ultiplicity  
A hierarchical test ing procedure will be performed. Key secondary 
endpoints will be evaluated with a one-sample t -test to determine  
whether there is any  change at Week  [ADDRESS_1008185] is nonsignificant (p >0.05), then the testing  will be stopped (or consider all further 
tests to be only secondary , and no formal conclusions can be 
drawn ).  
Study Committees:  Scientific steering committee: No  
Adjudication committee: No  
Data monitoring committee: No  
Date of Protocol:  18 Aug 2021  
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  [ADDRESS_1008186]  
BP blood pressure  
CDC  Centers for Disease Control and Prevention 
CFR  Code of Federal Regulations 
CI confidence interval 
CGM  continuous glucose monitoring  
CNIL  Commission Nationale de l’Informatique et des Libertés  
CONSORT  Consolidated Standards of Reporting Trials 
CRA  clinical research associate 
CRF  case report form  
CSR  clinical study report 
CV coefficient of variation  
DM-SAT Diabetes Medication Satisfaction Tool  
DPP-4i dipeptidyl peptidase-[ADDRESS_1008187] -to-patient  
EASD  European Association for the Study of Diabetes  
ECG  electrocardiogram  
eCRF  electronic case report form  
EDC  electronic data collection  
eDiary  electronic diary  
EU European Union  
FDA  Food and Drug Administration  
FPG fasting plasma glucose 
GCP  Good Clinical Practice  
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  [ADDRESS_1008188]  
OAD  oral antidiabetic drug 
OC observed cases  
OTC  over-the-counter 
PPG postprandial glucose 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  [ADDRESS_1008189]  upper limit of normal 
WOCBP  woman of childbearing potential 
WONCBP  woman of non-childbearing potential 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 43 of 156 1. Introduction  
1.1 Background Information  
Diabetes represents a major health burden in the US and had a prevalence of 34.2 million  
people of all ages in 2018, which is expected to increase to  54 million  by 2030. Despi[INVESTIGATOR_737875], 50% of patients still have a glycated hemoglobin 
(HbA1c ) >7% , and 14% of patients have an HbA1c >9%, signifying poor glycemic control 
(Centers for Disease Control and Prevention [ CDC 2020] ; HEDIS Comprehensive D iabetes 
Care 2021). The 2021 American Diabetes Association (ADA)/European Association for the 
Study of Diabetes (EASD) consensus report recommends combination therapy with a basal 
insulin and a glucagon-like peptide-[ADDRESS_1008190] (GLP-1 RA) as one approach to 
glycemic control in patients  with type 2 diabetes ( T2DM ) with HbA1c levels more than 1.5% 
above their target ( Davies et al 2018;  ADA 2021b ). 
In 2017, t he total  US cost of diagnosed diabetes  care was projected  to be $237.3 billion 
(ADA 2018). Approximately 38% of these costs were attributed  to hospi[INVESTIGATOR_307]- related fees  
(eg, outpatient treatment [$12.1 billion] , inpatient care [$69.7 billion] , emergency department 
costs [$8.0 billion], and ambulance charges [$332.0 million]). I ndirect costs associated with 
loss of productivity and  these direct  costs  account for 73.1% of the total cost of diabetes 
(Anderson et al 2020). Patients  with T2D M, who account for 90% of all US diabetes cases , 
are often hospi[INVESTIGATOR_737876]. In particular, those patients  with fluctuations of HbA1c and very low or very 
high mean HbA1c levels  contribute significantly to these costs ( Conn et al 2015; Cannon 
et al 2018; Critchley et al 2019). 
Traditional methods of measuring blood glucose have resulted in substandard glycemic control in many patients with T2DM ( Stone et al 2013; Carls et al 2017 ). Measuring HbA1c 
provides a retrospective 3-month glucose average  with little, if any, information on hypo- or 
hyperglycemia, which can  subsequently lead to microvascular or macrovascular 
complications. Although self -measured plasma glucose (SMPG), when used within a 
structured testing program, has demonstrated improved glycemic control and quality of life in people with diabetes (both insulin- treated and noninsulin- treated) , it cannot predict 
impending hyperglycemia, hypoglycemia, or alert for hypoglycemia, and therefore, 
alternative glucose measurement methods must be considered  (Danne et al 2017 ). 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 44 of 156 Continuous glucose monitoring (CGM) can address many of the limitations of HbA1c testing 
and SMP G monitoring, and  has contributed to rapid gr owth amongst specialists  and patients 
in the US over the past few years. Randomized, controlled , clinical studies evaluating CGM 
use in insulin -requiring individuals have demonstrated improvements in  HbA1c , glycemic 
variability,  and increased time in target glycemic range as well as reductions in hypoglycemi a 
events  (Anderson et al 2020). Based on the benefits and utility of CGM, several national and 
international medical organizations have recommended CGM use for people with diabetes 
who require insulin therapy in type 1 diabetes mellitus ( T1DM) and T2D M and/or those at 
risk for hypoglycemia. Glucose measures captured via CGM are also being considered as a 
required accompanying measure to HbA1c in clinical studies investigating new diabetes 
therapi[INVESTIGATOR_737877] (FDA). 
However , utilization of CGM monitoring in primary care settings  has remained low, in part, 
due to the new skills required to meaningfully and appropriately use the data collected. As 
the pandemic has propelled  primary care into  the virtual healthcare arena,  the pandemic has 
also increased  patient demand for CGM use . Primary care physicians  have developed  the 
skills  required  to improve telemedicine visits. Similarly , primary care will be  forced to 
embrace the utility of continuously collected glucose data to  improve the glycemic 
management and refine the self -care behaviors of their patients  (Johnson and Kayne 2020). 
1.2 Rationale  
Soliqua™ 100/33 is a fixed-ratio combination of insulin glargine U100 (100 units/mL) plus 
lixisenatide (33  μg/mL), a GLP -1 RA ( Soliqua 2019). The combination of a basal insulin and 
a GLP -1 RA addresses both fasting and postprandial hyperglycemia, thus ensuring more 
comprehensive glycemic control than basal insulin alone. The efficacy and safety of Soliqua 100/33 has been clearly established in randomized controlled clinical studies. In the LixiLan -O study, the HbA1c of patients uncontrolled on oral antidiabetic drugs (OADs) who 
were treated with Soliqua 100/33 decreased from 8.1% (baseline) to 6.5% (end of study) with 
the majority (74%) achieving the HbA1c target of <7% ( Rosenstock et al 2016). The efficacy 
of Soliqua 100/33 was  also demonstrated by a 2.9% Hb A1c red uction from baseline, with 
74% of patients achieving an HbA1c of <7%, in a subgroup of patients with T2DM with 
baseline HbA1c ≥9% uncontrolled on OADs from the LixiLan-O study ( Davies et al 2019 ). 
Similarly, patients uncontrolled on basal insulin in the LixiLan -L study demonstrated an 
HbA1c reduction from 8.1% to 6.9%, and most (55%) reached their target HbA1c of <7% (Aroda et al 2016). T hese results were achieved without weight gain and with fewer 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 45 of 156 gastrointestinal (GI) side effects than with  lixisenatide alone, likely due to a more gradual 
titration of the GLP -1 RA dose ( Rosenstock et al 2016; Davies et al 2019 ). 
Continuous glucose monitoring provides a more complete pi[INVESTIGATOR_737878]-monitored blood glucose or HbA1c ( Danne et al 2017 ). In the US , use of 
CGM is becoming mainstream, driven by [CONTACT_737892], convenience, ease of 
use, cost-effectiveness, and increased reimbursement. Continuous glucose monitoring  
facilitates improved glycemic control while reducing hypoglycemia risk ( Danne et al 2017;  
Battelino et al 2019 ) and is rapi[INVESTIGATOR_737879] (HCPs) for management of patients with T1DM  and insulin- treated T2DM . 
Time in range (TIR) is one of the metrics derived from CGM and is increasingly utilized to 
assess glycemic control. It can correlate with HbA1c values as well as the risk of 
diabetes -related complications (both microvascular and macrovascular). The International 
Consensus Report on “clinical targets for CGM interpretation” has identified “TIR” as a 
metric providing more actionable information than  HbA1c and has defined targets for clinical 
use ( Battelino et al 2019 ). For example, in patients with uncomplicated T2DM  whose HbA1c 
targets are <7%, the recommended TIR (for a target range of 70 -180 mg/dL) is >70% of the 
readings. 
Soliqua 100/[ADDRESS_1008191] to diet and exercise to improve glycemic control in 
adults with T2DM ( Soliqua 2019). The 2021 Standards of Medical Care in Diabetes from the 
ADA ( ADA 2021a ; ADA 2021b) reco mmends the use of fixed-ratio combinations when the 
combination of individual components is indicated, such as when a GLP-1 RA is added to 
basal insulin or vice versa. The ADA 2021 Standards also recommend dual combination 
therapy in individuals with HbA1c  values  ≥1.5% from their glycemic target ( ADA 2021b). 
Correlations of HbA1c and TIR indicate that CGM glucose readings of patients with an HbA1c ≥9% are in range 40% of the time or less, compared with  the 7 0% TIR  associated 
with an HbA1c of 7% ( Battelino et al 2019 ). Although there are currently no studies using 
CGM measurements to capture glycemic excursions and variability related to Soliqua 100/33, a post hoc analysis demonstrated improvement in all measures of glycemic variability compared with its individual components (eg, lixisenatide or insulin glargine 
U100), assessed by 7-point blood glucose profiles. These findings were attributable to 
Soliqua 100/33’s complementary mechanisms of action, which demonstrate reductions in 
both fasting and postprandial hyperglycemia ( Aronson et al 2019).  
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 46 of 156 The current study is intended to replicate these results using CGM to measure TIR and 
glycemic variability in a patient population with very uncontrolled T2DM  (HbA1c 
≥9%-13%), wh o are most likely to benefit from a fixed -ratio combination approach, such as 
Soliqua 100/33. 
The primary objective of this study is to demonstrate an improvement in the percentage of 
TIR from  baseline to the end of the study (16  weeks) in insulin -naïve pa tients with very 
uncontrolled ( HbA1c ≥9 %-13%) T2DM on 2+ OADs with or without GLP-1 RA s. 
1.3 Benefit-Risk Assessment  
Soliqua 100/33 has demonstrated superior glycemic efficacy in patients with T2DM uncontrolled on oral therapi[INVESTIGATOR_014], basal insulin, or GLP- 1 RA (including weekly GLP- 1 RA) 
with durable efficacy (52 weeks) compared with its individual components (insulin glargine U100 and  lixisenatide ), and recently premixed insulin analog (BIAsp 30 ) in those 
uncontrolled on basal insulin and oral therapi[INVESTIGATOR_014] ( Rosenstock et al 2021) . Additionally, 
compared with insulin glargine U100 alone, patients on Soliqua 100/33 had weight neutrality 
with no increase in hypoglycemia events ; compared with  lixisenatide  alone, they experienced 
fewer GI adverse events (AEs)  (Aroda et al 2016;  Rosenstock et al 2016;  Blonde et al 2019). 
Soliqua 100/33 has also shown greater HbA1c reduction, less weight gain, and less 
hypoglycemia compared to a premixed insulin analog (BiAsp 70/30) in individuals not 
controlled on basal insulin therapy ( Rosenstock et al 2021).  No new risks have been 
identified for the population to be included in Study LPS16990. In this study, t reatment with 
Soliqua 100/33 will be  consistent with the current US FDA-approved label indications 
(Soliqua 2019). During the titration period, the dose of Soliqua 100/33 will be adjusted 
upwards or downwards by 2 to 4 units every week, or at the investigator’s discretion, based 
on the participant’s blood glucose monitoring results , with the objective of safely attaining  a 
fasting SMPG value of 80 to 100 mg/dL, as well as other glycemic goals , while minimizing 
the risk of hypoglycemia and hyperglycemia. The duration of the titration period and number 
of phone contacts to safely meet the study goals will also be at the discretion of the 
investigator. Theref ore, the risk for patients participating in this study and using daily doses 
of Soliqua 100/33 up to a maximum of 60 units of insulin glargine and 20 μg of lixisenatide 
is considered acceptable. All patients enrolled in this study will benefit from medical care 
and continuous monitoring of their glucose levels. 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 47 of 156 The important identified risks for Soliqua 100/33 are hypoglycemia or hyperglycemia 
associated with alterations in  the insulin dosing regimen, hypersensitivity reactions, overdose 
due to medication errors, injection site reactions, and GI AEs, including nausea, diarrhea, and 
vomiting. This study proposes a titration algorithm with titration targets that will closely 
follow the US label for Soliqua 100/33 ( Soliqua 2019), except in instances of hyper- or 
hypoglycemia, which require specific attention. All study participants will benefit from the 
safety monitoring planned during site visits as well as during the additional titration phone 
contacts.  
Given the expected improvement of glycemic control and the additional measures to improve diabetes management, the benefits are considered to outweigh any potential risks associated with Soliqua 100/33. Therefore, the benefit- risk ratio for patie nts participating in 
Study LPS16990 is considered favorable. 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 48 of 156 
 Study Objectives, Estimands, and Endpoints  
Objectives : 
To determine the effect of Soliqua 100/33 on indices of glycemic control and variability, as 
measured via CGM, from baseline to Week 16, in insulin -naïve patients  with  very 
uncontrolled ( HbA1c  ≥9%-13%) T2DM . 
2.1 Primary Efficacy Objective, Estimands, and Endpoint s 
The primary efficacy objective, estimand , and endpoint are presented in  Table  2-1. 
Table  2-1 Primary Efficacy Objective , Estimand , and Endpoint  
Primary Objective  Primary Estimand 
Description  Primary Endpoint  
• To demonstrate that in 
patients with T2DM failing 
to achieve glycemic control (HbA1c ≥9%-13%) on their current regimen of 2+ OADs with or without GLP -1 RAs, introduction 
of Soliqua 100/33 exhibits superiority in terms of time spent in range (70-180 mg/dL) at Week  16 
compared with baseline, as 
measured by [CONTACT_28047]
  • The primary estimand is the mean change in the percentage of TIR (70-180 mg/dL) from 
baseline to Week  16. 
The primary estimand will be estimated based on the efficacy analysis set using obtained measurements , 
regardless of 
intercurrent events  • Change in the percentage of TIR 
(70-180 mg/dL) from 
baseline to Week  16 
Abbreviations: CGM, continuous glucose m onitoring; GLP -[ADDRESS_1008192]; 
HbA1c, glycated hemoglobin; OAD, oral antidiabetic drug; T2DM, type  2 diabetes mellitus; TIR, time in 
range.  
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 49 of 156 2.2 Key Secondary Efficacy Objectives and Endpoints  
The key secondary efficacy objectives and endpoints are presented in Table  2-2. 
Table  2-2 Key Secondary Efficacy Objectives and Endpoi nts 
Key Secondary Objectives  Key Secondary Endpoints  
• To evaluate the impact of Soliqua 
100/33 on measures of glycemic control and variability in patients with T2D M • Change (%) from baseline to Week 16 in CV 
• Change (mg/dL) from baseline to Week  16 in mean daily blood glucose 
• Change (mg/dL) from baseline to Week  [ADDRESS_1008193] meal  
• Change (%) from baseline to Week 16 in 
TAR (>180 mg/dL) 
Abbreviations: CV , coefficient of variation; PPG, postprandial glucose; T2DM, type 2 diabetes mellitus; 
TAR,  time above range.  
2.3 Secondary , Other Efficacy,  and Safety Objectives and Endpoints  
The secondary, other efficacy,  and safety objectives and endpoints are presented in Table  2-3. 
Table  2-3 Secondary , Other Efficacy , and Safety Objectives and Endpoints  
Objectives  Endpoints  
Secondary   
• To evaluate the impact of Soliqua 
100/33 on other measures of glycemic 
control and variability in patients with T2DM  • Proportion (%) of patients achieving CV <36% 
• Change (%) from baseline to Week 16 in  
TIR (70 -180 mg/dL) for specific time 
blocks (6 am-12 pm, 12 pm -6 pm, 
6 pm-12 am, and 12 am-6 am)  
• Proportion (%) of patients achieving GMI <7% and <9% at Week  16 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 50 of 156 Objectives  Endpoints  
• Change from baseline to Week  [ADDRESS_1008194] meal, including T max 
• Proportion (%) of patients at Week  16 
who spend <15  minutes/day at a glucose 
level <54  mg/dL 
Other Efficacy   
• To evaluate the impact of Soliqua 
100/33 on additional measures of glycemic control and variability in patients with T2DM  • Change (mg/dL) from baseline to Week  16 in MODD of glucose levels 
• Change (%) from baseline to Week 16 in TAR (>250 mg/dL) 
• Change (%) from baseline to Week 16 in TBR (<70  mg/dL) 
• Correlation of change in the percentage of TIR (70 -180 mg/dL) and LS mean 
change in PRO from baseline to Week  16 
• Correlation of percentage of  TIR 
(70-180 mg/dL) and HbA1c percentage 
achieved at Week  16 
• Correlation of patients reaching 
60 units/day insulin glargine U100 and 
TIR >70% 
• Change in HbA1c percentage from baseline to Week  16 
PRO   
• To assess patient -perceived treatment 
impact on HRQoL  and treatment 
satisfaction  • Change from baseline to Week  16 in 
diabetes medication treatment satisfaction scores (total score and by [CONTACT_737893] ), using the DM- SAT 
questionnaire 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 51 of 156 Objectives  Endpoints  
Safety   
• To assess the safety and tolerability of 
Soliqua 100/33 Safety evaluations will include evaluation 
of the following (for 16 weeks):  
• Overall hypoglycemia 
• Confirmed hypoglycemia 
 o ADA Level 1: Measurable glucose concentration <70 mg/dL (3.9 mmol/L) but ≥54 mg/dL (3.0 mmol/L)  
 o ADA Level 2: Measurable glucose concentration <54 mg/dL (3.0 mmol/L) that needs immediate action  
 o ADA Level 3: Severe event characterized by [CONTACT_226405]/or physical functioning that 
requires assistance* from another 
person for recovery  
• AEs, SAEs, and AESIs 
Abbreviations: ADA, American Diabetes Association; AE, adverse event; AESI, adverse events of special 
interest; AUC 0-4h, area under the concentration versus time curve  from time 0 to 4 hours ; CV , coefficient of 
variation; DM -SAT, Diabetes Medication Satisfaction Tool; GMI, Glucose Management Indicator; 
HbA1c,  glycated hemoglobin; HRQoL, health -related quality of life; LS, least square; MODD, mean of 
daily difference; OAD, oral antidiabetic drugs; PPG, postprandial glucose; PRO, pat ient-reported outcome; 
SAE,  serious adverse event; T2DM, type 2 diabetes mellitus; Tmax, time to reach maximum concentration; 
TAR,  time above range; TBR, time below range; TIR, time in range.  
*Note that “requires assistance” means that the person could not  help themselves. Assisting a person out of 
kindness, when assistance is not required, should not be considered a “requires assistance” incident.  
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 52 of 156 
 Investigational Plan  
3.1 Study Design  
This is a 16-week, multicenter, interventional, open-label, single-arm, Phase 4 study using 
blinded CGM (FreeStyle Libre Pro) to demonstrate improvement in the percentage of TIR 
from baseline in patients adding Soliqua 100/33 and treated for 16 weeks. The study will be 
conducted in approximately 100 patients whose T2DM is very uncontrolled on 2+ OADs 
with or without GLP-1 RAs (with stable doses for 3 months), as evident from a screening 
HbA1c of ≥9%-13%. The study will attempt to represent the diversity of the US patient 
population with T2DM  through site recruitment efforts . 
All eligible participants will undergo 14 days of blinded continuous CGM monitoring at 
baseline ( the run-in period) and a mixed -meal tolerance test (MMTT) while on baseline 
medications . Soliqua 100/33 treatment will be initiated on Day 0  (Visit 3.2), after  the MMTT 
(which is scheduled at Visit 3.1; Figure 3–1). Sulfonylurea (SU) doses should be 
down-titrated by 50% when starting Soliqua 100/33, and  the last doses of daily dipeptidyl 
peptidase-4 inhibitor (DPP-4i) and daily GLP -1 RA (oral or injectable)  should be 
administered  on the morning of Day –1, the day before the first dose of Soliqua 100/33.  
At Visit 3.1, participants on OADs or an oral or injectable  GLP -1 RA will be required to take 
their dose after the blood sample for fasting plasma glucose ( FPG) and HbA1c is collected 
and 30 minutes before  administration of the meal during the MMTT  (during which measures 
for both β -cell function and postprandial glucose [PPG] analyses will be captured) . 
Participants on a weekly GLP -[ADDRESS_1008195] their baseline MMTT conducted  within 
7 (± 3) days after their last dose  and administer their last weekly GLP -1 RA  dose 7 (±  2) days 
before  the first dose of Soliqua 100/33. 
The dose of Soliqua 100/33 will be adjusted during the titration period (ie, from Weeks 1 through 12; Visits 4.0 to 5.4), at the investigator’s discretion until the desired fasting SMPG 
value (80 -100 mg/dL) is achieved.  
During the end of the treatment period (from Visit 6 to Visit 7), participants will again be 
required to undergo 14 days of blinded continuous CGM monitoring and  a MMTT (only to  
derive PPG measures). Soliqua 100/33 should be administered 30 minutes before 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 53 of 156 administration of the meal during the MMTT at Visit 7 (during which only measures for PPG 
analyses will be captured).   
All participa nts will be allow ed to continue their backgro und OADs (except DPP-4i and SU, 
as previously described) at sta ble doses and regimens throughout the study period, unless 
they have to be stopped or modified for safety reasons. 
Adverse eve nts, including adv erse events of special interest ( AESI s), will be assessed. 
Physical exa mination  (including body weight), hypoglycemia events, clinical laboratory 
values, and vital signs will be  measured  to evaluate the safety of the study drug treatments 
(Section  13.1).  
The maximum study duration per participant will be [ADDRESS_1008196] (IMP) shipment will need at least 72 hours’ notice from the 
investigator t o arrange a hom e visit and direct- to-patient (DTP) IMP supply, if required. An 
unscheduled site or home visi t can be planned during the treatment period for IMP resupply, 
if required. If  DTP Soliqua 100/[ADDRESS_1008197] 72  hours’ notice to collect Soliqua 100/33 treatment kits from a study site. 
 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)   18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 54 of 156 Figure  3–1 Study Diagram 
 
Abbreviations: CGM, continuous glucose monitoring; DPP- 4i, dipeptidyl peptidase -4 inhibitor;  DTP, direct -to-patient; GLP-[ADDRESS_1008198] ; HCP, healthcare provider; IMP, investigational medicinal product; MMTT, mixed -meal tole rance test; SMPG, self -measured plasma 
glucose ; SU, sulfonylurea . 
Note s: During the run- in period, CGM device reinsertion will be allowed for participants who do not  meet the equivalent of at least 8  days of evaluable CGM 
data (not necessarily consecutive) over a 14- day period as a result of  premature sensor f ailure ( eg, days of CGM device wear × % time CGM device 
active  < 8; Section  6.2.1). 
During the end of the treatment period, CGM device reinsertion will also  be allowed for participants who do not  meet the equivalent of at least 8  days of 
evaluable CGM data (not necessarily consecutive) over a 14- day per iod as a result of  premature sensor failure  (eg, days of CGM device wear  × % time CGM 
device active < 8), if data can be captured during the 14 -day end- of-treatment window  (Section  6.2.1 ). 
a An unscheduled visit can be planned anytime  during the treatment period if IMP resupply is  required. This can be a site visit or via phone contact [CONTACT_737912]. If DTP Soliqua 100/[ADDRESS_1008199] 72 hours’ notice to collect Sol iqua 100/[ADDRESS_1008200] dose 7 (±  2) days before  the first dose of Soliqua 100/33, whereas the last dose of daily DPP -4i 

[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)   18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 55 of 156 and daily GLP -1 RA (oral or injectable) should be administered on the morning of Day –1, the day before the first dose of Soliqua  100/[ADDRESS_1008201] day of Soliqua 100/[ADDRESS_1008202] day of Soliqua 100/33 administration (ie, Visit 3.2, Day 0) for participants on weekly GLP- 1 RA 
will depend on their administration schedule and may not be the day immediately following Visit 3.1. Soliqua 100/33 administration for these participants 
should be 7 (± 2)  days after their last wee kly GLP -[ADDRESS_1008203]  should be made  to participants on weekly GLP -1 RA on the day before  
Soliqua 100/33 initiation , to remind them of the next morning’s injection and to provide instructions for SoloStar pen use.  The participant s will provide  
their concomitant medication details to the site personnel over the phone.  
d Doses of SU should be down -titrated by 50% when Soliqua 100/33 is started on Day 0.  
e Weekly phone contacts for dose adjustments are to continue at the investigator ’s discretion until the desired fasting SMPG value is achieved.  
f If the desired fasting SMPG value is not achieved in the first 8 weeks of treatment; the investigator has the option to continue weekly dose titration phone 
contacts for an additional 4 weeks  (until Week 12 ) for the purpose of achieving glycemic targets . 
g At the end of the study, participants should discuss with the investigator, in collaboration with their HCP, whether to continue on the Soliqua 100/33 treatment 
regimen or transition to an a lternate antihyperglycemic therapy.  
h At baseline, the CGM device will be removed and the data will be downloaded on Day –1 at their next site visit (ie, Visit 3.1), after collection of C-peptide, 
insulin , and plasma glucose  data from the MMTT. Downloaded CGM data will be reviewed by [CONTACT_737896]’ study eligibility.  
NOTE: Participants on weekly GLP- [ADDRESS_1008204] their baseline MMTT conducted within 7 (± 3) days after their last dose. At the end of the treatment 
period, the CGM device will be removed and the data will be downloaded on the fifteenth day after CGM placement  (ie, Visit 7 ; after collection of only 
plasma glucose data from the MMTT). Downloaded CGM data will be verified by [CONTACT_737913]’ study completion.  
 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0) 18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 56 of 156 3.1.1 Rationale of Study Design  
This study is designed to demonstrate improvement in the percentage of TIR with 
Soliqua 100/33 in patients with very uncontrolled T2DM (HbA1c ≥9%- 13%) after 3  months 
of stable treatment with 2+ OADs with or without additional GLP -1 RA therapy. 
Continuous glucose monitoring has significantly improved the ability to monitor glycemic 
variability throughout the day. Data from CGM can be critical in making daily treatment decisions and quantifying TIR, which provides more actionable information than HbA1c 
alone (Battelino et al 2019 ). Continuous glucose monitoring is a much -improved measure of 
TIR compared with SMPG (ie, hundreds of values to analyze versus a single measure in 
time) , to truly understand glycemic variability in people with T2DM. 
In a previous post hoc analysis, treatment with Soliqua 100/33 improved measures of 
glycemic variability (ie, 7 -point blood glucose data) in patients uncontrolled on either oral or 
insulin therapi[INVESTIGATOR_25365] i ts individual components (ie, lixisenatide or insulin glargine 
U100). This finding was attributed to the complementary reductions of both fasting and 
postprandial hyperglycemia ( Aronson et al 2019). Clinicians frequently request CGM 
measures to better understand their patients’ TIR, time above range ( TAR ), and time below 
range ( TBR ). Hence, the current study is intended to replicate and enhance the results from 
the 7 -point blood glucose study, but using CGM . Measures such as TIR, coefficient of 
variation ( CV), TAR,  TBR , and PPG  will be collected in this patient population with very 
high HbA1c. This is the first CGM study performed with  Soliqua 100/33 in patients with 
very uncontrolled T2DM (HbA1c  ≥9%-13%) on oral therapi[INVESTIGATOR_737880] -1 RA s. 
3.1.2 Duration of Study Participation for Each Participant  
The study comprises the following periods (further detailed in the graphical study diagram 
[Figure 3–1] and the schedule of events [SoE ; Section  13.1] ): 
• A screening period of up to 2 week s. 
• A run -in period of 2 weeks, including the baseline period. 
o At Visit 2, the CGM device will be applied to the back of the upper arm of the 
participant and baseline CGM data will be collected continuously for 14 days ; the 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0) 18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 57 of 156 device will be removed at the subsequent site visit during the baseline period 
(ie, Visit 3.1), after the MMTT.  
o During the baseline period , on Day –1 (Visit 3.1), participants will return to the site 
for the MMTT  (for both β-cell function and PPG measures ) and CGM removal and 
data download (after the MMTT) . Dispensing of the Soliqua 100/33 pen and 
instruction on administration of Soliqua 100/[ADDRESS_1008205] during this visit. 
o Visit 3.2 ( ie, Day 0) during the baseline period is the first day of Soliqua 100/[ADDRESS_1008206] to ALL  participants to ensure all 
administration procedures were successfully executed and to answer any questions. 
(Note: The first day of Soliqua 100/33 administration  [ie, Visit 3.2, Day  0] for 
participants on weekly GLP-1 RA will depend on their administration schedule and 
may not be the day immediately following V isit 3.1. Soliqua 100/33 administration  
for these participants  should be 7 [±  2] days after  their last weekly GLP -1RA dose.) 
 A phone contact [CONTACT_737914] -1 
RA on the day before Soliqua 100/33 initiation , to remind them of the next 
morning’s injection and  to provide instructions for SoloStar pen use. The 
participants will provide their concomitant medication details to the site personnel over the phone. 
• A 16 -week open -label treatment period . 
o Visit 3.2 ( ie, Day 0) is the first day of Soliqua 100/33 administration and begins the 
open-label treatment period (with different initiation requirements based on weekly or daily GLP-1 RA use, as explained above). 
o The dose of Soliqua 100/33 will be adjusted during the titration period (ie, from Weeks  1 through 12; Visits 4.0 to 5.4), at the investigator’s discretion, until the 
desired fasting SMPG value (80 -100 mg/dL) is achieved ( Table 5-1).  
o During Visits 4.0 to 4.6, weekly phone contacts for dose adjustments are to continue 
at the investigator ’s discretion until the desired fasting SMPG value is achieved.  
o If the desired fasting  SMPG value is not achieved in the first 8 weeks of treatment, 
the investigator has the option to continue weekly dose titration phone contacts for an 
additional 4 weeks (until Week 12; ie, from Visits 5.1 to 5.4) with the purpose of 
achieving glycemic tar gets. 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0) 18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 58 of 156 o At Visit 6, a blinded CGM device will again  be applied to the back of the upper arm 
of the participant, and CGM data will be collected continuously for 14 days; the 
device will be removed at the subsequent site visit (ie, Visit 7), after the MMTT (on ly 
to derive PPG measures).  
o At the end of the study (ie, Visit 7), participants should discuss with the investigator, in collaboration with the ir HCP , whether to continue on the Soliqua 100/33 treatment 
regimen, or transition to an alternate antihyperglycemic therapy. 
• A 2-week post- treatment safety follow -up period after the last dose of Soliqua 100/33 
(eg, treatment completion ) or after premature/permanent  treatment  discontinuation from 
Soliqua 100/33. 
The total duration of the study will be approximately [ADDRESS_1008207] participant in the study. 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0) 18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 59 of 156 
 Selection of Study Population and Discontinuation/Withdrawal  
One-hundred participants will be enrolled at approximately [ADDRESS_1008208] meet all of the following criteria to be enrolled in this study:  
1. Is capable of understanding the written informed consent, provides signed written 
informed consent, is willing and able to complete the electronic diary (eDiary ), and 
agrees to comply with protocol requirements (confirmed by [CONTACT_737894] ). 
2. Is an adult ≥18 years of age. 
3. Has an HbA1c ≥9%-13% during the run -in period. 
4. Was d iagnosed with T2DM at least 6 months before  the baseline period. 
5. Has been t reated with 2+ OADs with or without GLP-1 RAs with stable doses ( for both) 
for 3  months before the screening period . 
6. Is willing and able to wear the CGM device continuously for 14 days to capture CGM 
measures at baseline (from Visit 2 [ie, the run-in period] until the next site visit at 
Visit 3.1) and again at  the end of the treatment period [ie, from Visit 6 until the next site 
visit at Visit 7; Section  13.1).  
7. Is willing and able to prick fingers a minimum of 2 to 4 times per week , using sterile 
lancets provided with a manual blood gluc ose meter kit.  
8. Is willing to discontinue daily (oral or injectable)  or weekly GLP- 1 RA or DPP -4i before  
administration of Soliqua 100/33. 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0) [ADDRESS_1008209] Soliqua 100/33 and increase dose as needed to achieve 
SMPG target.  
10. If female, is not pregnant or breastfeeding and one of the following conditions applies: 
o Is a woman of non-chi ldbearing potential (WONCBP), as defined in contraceptive 
and ba rrier guidance ( Section 13.7). 
o Is a w oman of childbea ring potential (WOCBP) and agrees to use a contraceptive 
method that is highly e ffective, with a failure rate of <1%, as described in 
contra ceptive and barr ier guidance ( Section  13.7), during the study treatment period 
(to be effective before starting the study drug) and for at least [ADDRESS_1008210] 
administration of study drug. 
 A WOCBP must h ave a negative urine pregnancy test at both screening and 
baseline visits. (Note: If a urine test cannot be confirmed as negative [eg, an 
ambiguous result], a serum pregnancy test is required. In such cases, the 
participant must be excluded from participation if the serum pregnancy result is 
positive.) 
4.2 Exclusion Criteria 
Participants meeting any of the following criteria will be excluded from the study: 
1. Has T1DM  or any other types of diabetes except T2DM. 
2. Is being treated with meglitinides (eg , nateglinide, repaglinide). 
3. Has a b ody mass index (BMI) >40 kg/m² during the screening period.* 
*Body weight and height will be recorded during the screening period for the calculation of 
BMI (metric: BMI = weight (kg)/height [m2]). 
4. Provides less than equivalent of 8 days  of evaluable CGM data (not necessarily 
consecutive) over a 14-day period (eg, days of CGM device wear × % time CGM device 
active < 8; Section  6.2.1). 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0) 18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 61 of 156 5. Has any current or previous skin conditions, including (but not limited to) severe 
psoriasis, burns, eczema, scarring, and excessive tattoos, that would inhibit proper wearing of the CGM device.  
6. Has a h istory of severe nausea and vomiting that resulted in  discontinuation of GLP-1 
RA. 
7. Has a k nown history or presence of clinically significant pancreatitis or gastroparesis. 
8. Has had an epi[INVESTIGATOR_737881] (defined as 
the onset of neuroglycopenia before the appearance of autonomic warning symptoms [for example, blurred vision, difficulty speaking, feeling faint, difficulty thinking, and confusion] or as the failure to sense a significant fall in blood glucose below normal levels) within the 6 months before  the screening period. 
9. Has any clinically significant abnormality identified from the  physical examination, vital 
sign measurements, or laboratory tests (eg, amylase, lipase, alanine aminotransferase 
[ALT] >3 × upper limit of normal [ULN], calcitonin ≥20 pg/mL, severe renal impairment 
[estimated glomerular filtration rate, <30mL/min/1.73m
2], or end stage renal disease) or 
visual impairment at screening that, in the opi[INVESTIGATOR_737882], would make implementation of the protocol or interpretation of the study results difficult or would preclude safe participation in the study. 
10.  Has personal or immediate family history of medullary thyroid cancer (MTC) or a 
genetic condition that predisposes the participant to MTC (eg, multiple endocrine 
neoplasia syndromes). 
11. Has current or known history of alcohol or drug abuse within 6 months before  the 
screening period. 
12. Has s ignificant current (within past 2 months) or expected use of medications known to 
affect glycemia (eg, ≥5  mg/day prednisone). 
13. Uses substances known to interfere with CGM readings, such as aspi[INVESTIGATOR_248] -containing 
products (>650 mg/day of salicylic acid ) or supplements containing vitamin  C 
(>1000 mg/day of ascorbic acid ) taken during the 14-day periods of CGM measure at 
baseline (ie, Visit 2  to Visit 3.1) and the end of the treatment period ( ie, Visit 6  to Visit 7).  
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0) 18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 62 of 156 14. Has undergone previous treatment with any insulin (except for short- term treatment due 
to intercurrent illness, including gestational diabetes, at the discretion of the investigator). 
15. Is enrolled in another clinical study or has taken other investigational drug(s) within 
1 month or 5 half-lives from screening, whichever is longer. 
16. Is cur rently  in an institution because of a regulatory or legal order ( ie, is a prisoner or 
participant who is  legally institutionalized ). 
17. Is an employee or family member of the investigator or study site personnel. 
18. Is not suitable for participation, whatever the reason, as judged by [CONTACT_093], 
including medical or clinical conditions, or potentially  is at risk of noncompliance to 
study procedures. 
19. Is involved in a specific situation during study implementation  or the course of the study 
that may raise ethics considerations.  
20. Has a h ypersensitivity to Soliqua 100/33, either of its active components (insulin glargine 
or lixisenatide), or any of its excipi[INVESTIGATOR_11792], in the opi[INVESTIGATOR_871], 
contraindicates participation in the study. 
21. Has used  weight loss drugs (including over-the- counter [OTC] and herbal medications) 
within 12 weeks before  the screening visit. 
4.3 Screen Failure  
Screen failures are defined as participants who consent to participate in the clinical study but 
are not subsequently enrolled. A minimal set of screen failure information is required to 
ensure transparent reporting to meet Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to respond to queries from regulatory authorities. 
Minimal information includes demography, screen failure reasons, eligibility criteria, and any 
serious adverse event s (SAE s). 
Participants who are screen failed may be rescreened based on a discussion between the 
medical monitor and the investigator. 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0) 18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 63 of 156 4.4 Discontinuation From Study Treatment and/or Withdrawal From the 
Study  
4.4.1 Discontinuation From Study Treatment  
[IP_ADDRESS]  Permanent Discontinuation  
All efforts should be made to keep participants on treatment. 
In rare instances, it may be necessary for a participant to permanently discontinue study 
treatment. Before permanent discontinuation of treatment regardless of the reason or as soon 
as possible after the decision for discontinuation has been made, if poss ible, the participant 
will undergo all procedures planned for the last dosing day with Soliqua 100/33 and the 
follow-up visit ( Section  13.1). 
All cases of permanent treatment discontinuation ( Section  4.4.3) must be recorded by [CONTACT_737915] (eCRF ) when 
confirmed. 
[IP_ADDRESS]  Temporary Discontinuation  
Temporary study drug discontinuation decided by [CONTACT_206375] 
1 dose not administered to the participant. 
Temporary study drug discontinuation may be considered by [CONTACT_737916]. In case of study drug interruption due to an AE, 
reinitiating Soliqua 100/33 treatment at the appropriate dose will be done under close and appropriate  clinical/and or laboratory monitoring if the investigator deems the relationship of 
the event to Soliqua 100/[ADDRESS_1008211] to follow -up if they repeatedly fail to return for 
scheduled visits and are unable to be contact[CONTACT_9298]. 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0) [ADDRESS_1008212] be taken if a pa rticipant fails to return to the clinic for a required 
study visit: 
• The site must attempt to contact [CONTACT_46342]. The participant should be counselled on the importance of maintaining the assigned visit schedule and ask ed whether they wish to and/or should continue in the 
study. 
• Before a participant is deemed lost to follow -up, the investigator or designee must make 
every effort to regain contact [CONTACT_6635]. The methods to contact [CONTACT_737917] 2 phone calls and, if necessary, a certified letter to the participant’s last known 
mailing address or local equivalent methods. These contact [CONTACT_13140]’s medical record. 
If the participant continues to be unreachable, they will be considered to have withdrawn 
from the study. 
4.4.[ADDRESS_1008213] document this in the site study records. 
Participants who discontinue study treatment or active participation in the study will no 
longer receive study drug. When a participant withdraws from the study, the reason(s) for 
withdrawal shall be recorded by [CONTACT_11764]. 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0) 18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 65 of 156 A participant may withdraw from the study or study treatment under the circumstances 
(including, but not limited to) listed below: 
• The participant inten ds to  becom e pregnant. 
• The participant may be withdrawn at the discretion of the investigator due to 
noncompliance or due to a safety concern. 
• The participant will be withdrawn if starting any drugs that interfere with glucose 
metabolism (eg, steroid doses equivalent to prednisone ≥5 mg/day). 
• The participant may be withdrawn if diagnosed with acute pancreatitis (defined as 
meeting 2 of the following 3 rules: typi[INVESTIGATOR_737883]; amylase/lipase >3  × UL N; 
and/or characteristic ultrasound, computed tomography, or magnetic resonance imaging findings). 
• If the fasting or the mean SMPG value during 3 consecutive days is >300 mg/dL, the 
investigator will schedule an unplanned visit as soon as possible to obtain confirmatory 
FPG and investigate the cause. If no apparent or intercurrent cause is detected, the 
participant may be withdrawn. 
• The participant has recurrent severe hypoglycemia or recurrent nocturnal hypoglycemia 
during the treatment period that poses a potential risk to the participant, as judged by [CONTACT_1275]. 
• The participant is u nable to comply with the study protocol, at the investigator’s 
discretion. 
Whenever possible, all participants who discontinue study treatment or withdraw from the 
study prematurely will undergo all end-of-study and follow-up assessments. Participants who fail to return for final assessments will be contact[CONTACT_737918]. 
Participants who withdraw from the study treatment should be explicitly asked about the 
contribution of possible AEs to their decision, and any AE information elicited must be documented on the relevant page of the eCRF. 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0) [ADDRESS_1008214] be made to undertake protocol- specified, safety, and 
follow-up procedures. 
4.4.4 Replacements  
Participants who discontinue the study will not be replaced.  
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0) 18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 67 of 156 
 Study Treatments  
5.1 Study Drug  
• Formulation: So liqua 100/33 will be supplied as a sterile, non-pyrogenic, clear, colorless 
solution in a SoloStar™ prefilled (disposable) pen for subcutaneous (SC) injection. The 
SoloStar pen is necessary for Soliqua 100/33 administration, and it is considered as an 
integral part of Soliqua 100/33 therapy . 
o The prefilled  SoloStar disposable pen contains 3 mL of sterile solution containing 
100 units/mL insulin glargine and 33 μg/mL lixisenatide in a 3:1 ratio (ie, 3 units of insulin glargine to 1 μg lixisenatide). 
o The pen allows  for administration of both ingredients simultaneously with  doses 
ranging from 15 units/5 μg to  60 units/20 μg (insulin glargine U100/lixisenatide). 
o Soliqua pen instructions will be given to all participants at Visit 3.1. 
o A phone contact [CONTACT_737919]- 1 RA on the day 
before Soliqua 100/33 initiation, to remind them of the next morning’s injection and 
to provide instructions for SoloStar pen use. 
• Route of administration: SC injection using the SoloStar pen into the abdominal area, 
thigh, or upper arm. I njection sites should be rotated within the same r egion from 
one injection to the next to  reduce the risk of lipodystrophy. 
5.[ADDRESS_1008215]  
The protocol- mandated background OADs  (Section  5.2.1) are considered non -investigational 
medicinal product (NIMP). 
5.2.1 Background OADs Related to Glycemic Management  
The following oral class es of medication  related to glycemic management  are permitted 
during the screening and  treatment period s of the study, init iated and at stable doses for  a 
minimum of  3 months before  the screening period: 
• SU (which will be down-titrated by 50% when starting Soliqua 100/33 on Day 0). 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0) 18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 68 of 156 • Biguanides. 
• Thiazolidinediones. 
• α-glucosidase inhibitors. 
• Sodium-glucose co -transporter-2 (SGLT2) inhibitors. 
• Bile acid sequestrants . 
• Dopamine agonists. 
5.2.2 Appropriate Corrective Action /Rescue Therapy  
Titration will be exceedingly important throughout the first 12 weeks of this study and will 
requir e consistent reviews of fasting SMPG  values , the daily insulin dose, and hypoglycemia 
events  to identify participants whose Soliqua 100/33 dose is not being appropriately 
managed.  
If after Week  12 (ie, end of the titration period), the participant’ s FPG level is >240  mg/d L 
with no reasonable explanation for severe hyperglycemia, such as intercurrent illnesses or nonadherence to instructed titration, the investigator should obtain an HbA1c measurement and decide whether rescue therapy is warranted.  
5.[ADDRESS_1008216] use, the Soliqua 100/33 pen should be stored in a refrigerator from  36°F to  46°F 
(2°C to 8°C) and protected from light and must  not be frozen. Pens  are to be discarded only 
after accountability and reconciliation is performed by [CONTACT_3642]’s clinical research associate 
(CRA) and after the expi[INVESTIGATOR_199904]. All pens in the same kit should have 
the same expi[INVESTIGATOR_320]; therefore, pens from the same kit should be st ored separately  
(eg, the pen currently being utilized should be stored at room temperature , whereas  the other 
non-utilized pens should be stored in the refrigerator). The site should contact  [CONTACT_737920][INVESTIGATOR_243396] a pen/kit is near (eg, for possible 
re-labeling ; do not automatically discard  any pens/ kits). Expi[INVESTIGATOR_737884] s should not be 
provided to participants . 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0) 18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 69 of 156 The Soliqua 100/33 pen should not be stored in the freezer and should not be fr ozen . The 
Soliqua 100/33 pens should be separated  (from the kit and any other pens) and stored  (either 
at room temperatur e if the pen is in use, or in the refrigerator if not yet used) and should 
not be used  if frozen  or previously frozen. The site should not discard any Soliqua 100/[ADDRESS_1008217] use, the Soliqua 100/33 pen should be store d at room temperature below 77°F 
(25°C). The pen c ap should be replaced after each use to protect  it from light. The participant 
should keep any empty pens in the kit box to be returned to the site during the next site visit. 
Each  pen should be replaced with a new pen [ADDRESS_1008218] use. 
The pen needle should be removed after each injection  and discarded,  and the Soliqua 100/33 
pen should be stored at room temperature  without a needle attached. This  type of storage 
should prevent infection  and/or contamination  or leakage of the Soliqua 100/33 pen and will 
ensure accurate dosing. A new needle should always be us ed for each injection to prevent 
infection and/or contamination. 
5.4 Method of Assigning Participants to Treatment Groups  
Not applicable. This is an open- label, single-arm study. 
5.5 Treatments Administered  
• Time of administration:  
o Soliqua 100/[ADDRESS_1008219] dose of Soliqua 100/33 will be administered on the morning of Day 0 (ie, Visit 3.2). This date should be 7 [± 2] days after the last weekly GLP-[ADDRESS_1008220] dose of DPP-4i or daily GLP-1 RA (oral or 
injectable) admi nistration.  
Starting dose 
• For all participants, the starting dose of Soliqua 100/33 will be 15 units of insulin 
glargine (corresponding to 5 μg of lixisenatide).  
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0) 18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 70 of 156 • The m aximum daily dose of Soliqua 100/33 should not exceed 60 units of insulin 
glargine (corresponding to 20 μg of lixisenatide).  
5.5.1 Dose Modifications  
The dose of Soliqua 100/33 will be adjusted with the aim of attaining a target fasting SMPG 
value of 80 to 100 mg/dL ( Table  5-1). The dose will be adjusted based on the lowest fasting 
SMPG values in conjunction with measurements from the  previous 3 days throughout the 
study period. During the titration period (ie, Weeks 1 through 12), fasting SMPG should be 
assessed  on each of the 3 to 4 days before each dose adjustment. During the titration period, 
the dose of Soliqua 100/33 should be adjusted upwards or downwards by 2 to 4 units every 
week (with additional titration  also at the discretion of the investigator in accordance with the 
participant ’s blood glucose monitoring result), with the objective of safely attaining  a fasting 
SMPG level of 80 to 100 mg/dL, as well as other glycemic targets , while minimizing the risk 
of hypoglycemia and hyperglycemia), at the investigator’ s discretion . The duration of the 
titration period and number of phone contacts to meet the study goals will also  be at the 
discretion of the investigator. 
As state d above, dose titration will be at the investigator ’s discretio n and  guided by [CONTACT_737921] a fasting 
SMPG value of 80 to 100 mg/d L (Table  5-1). Study participants should be trained and 
retrained on an ongoing basis to e stablish  proper understanding of titration procedures 
because very close communication between the participant and the study site is necessary  to 
ensure adequate titration while minimizing the  associated risks. Investigators may adjust or 
stop titration or temporarily reduce the dose if they believe further titration would result in 
participants experie ncing any A Es (eg, hypoglycemia, AESIs ). After the target fasting SMPG 
value has been achieved, the dose of Soliqua 100/[ADDRESS_1008221] 8  weeks of treatment, the investigator has the option to continue weekly dose 
titration phone contacts for an additional 4 weeks ( until Week  12) for the purpose of 
achiev ing glycemic targets . 
Doses will be adjusted at least weekly, but additional titration may be considered at the 
investigator’s discretion. Participants are, therefore, required to record their fasting SMPG 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0) [ADDRESS_1008222] 3 to 4 times per week throughout the study period to inform 
each dose adjustment . 
Table  5-1 Recommended Dose Adjustment Algorithm for Soliqua 100/33 
Median of Fasting SMPG Values ( With 
Lowest Value  Considered  in Conjunction 
With Previous 3 Measurements)  Soliqua 100/33 Dosage Adjustment 
(Units/Week)  
>140 mg/dL (>7.8  mmol/L)  +4 units  
>100 to ≤140 mg/dL (> 5.5 to ≤7.8  mmol/L)  +2 units  
Glycemic target: 80 to 100  mg/dL 
(4.4-5.5 mmol/L), inclusive  No change 
≥60 to <80 mg/dL (≥3.3 to <4.4 mmol/L)  –2 units  
<60 mg/dL (<3.3  mmol/L) or occurrence of 
2 (or more) symptomatic hypoglycemia events  
or 1 severe hypoglycemia event (requiring 
assistance) documented in the preceding week  –2 to –4 units or at the discretion of the 
investigator or any qualified designee 
Abbreviation: SMPG, self -measured plasma glucose.  
Notes: Dose changes should also be based on the median SMPG values (with the lowest value  considered in 
conjunction with  the previous 3 measurements). If the lowest value from the  previous  3 measurements is 
from  80 to 100 mg/dL and the other 2 values are well above 100 mg/dL, further titration may be 
implemented at the investigator ’s discretion. If the lowest value is <70 mg/dL and the other 2 values are 
near 100 mg/dL, the investigator may stop or temporarily reduce  the dose if , in their judgment , further 
titration would be hazardous.  
5.[ADDRESS_1008223]  
Soliqua 100/33 (insulin glargine/lixise natide) is a sterile, non -pyrogenic, clear, colorless 
solution in a SoloStar prefilled (disposable) pen for SC injection. 
[COMPANY_011] will provide adequate supplies of Soliqua 100/33 pen to the s ites directly.  
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0) 18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 72 of 156 The following drug supplies will be used in the study: 
Product  Supplied as:  
Soliqua 100/33 SoloStar pens (containing a 3 mL of sterile 
solution of insulin glargine 100 units/mL 
and lixisenatide 33 μ g/mL)  
5.7 Management of Clinical Supplies  
5.7.1 Study Drug Packaging and Storage  
Soliqua 100/33 is an injection supplied as a sterile, clear, colorless solution in a 3 mL , 
prefilled, disposable, single- patient -use pen injector and is shipped by [CONTACT_13225]. Soliqua 100/[ADDRESS_1008224] ied as open -label treatment kits. Packaging will be in accordance 
with the a dministration schedule. The content of the labeling will be in accordance with the 
local regulatory specifications and requirements. The appropriate number of kits (including 
pen needl es as ancillary supplies ) will be dispensed to provide participants with 
Soliqua 100/[ADDRESS_1008225] with DTP Soliqua 100/33 
delivery ( Section  13.1). Storage conditions and use-by-end date (ie, expi[INVESTIGATOR_5695]) are part of 
the Soliqua 100/33 label text. 
Investigat ors or other authorized persons (eg, pharmacists, IMP managers) are responsible for 
storing Soliqua 100/[ADDRESS_1008226] in accordance with local regulations, 
labeling s pecifications, policies, and procedures. Control of Soliqua 100/33 storage 
conditions , especially control of temperature (eg, refrigerated storage), and information on 
in-use stability a nd instructions for handling Soliqua 100/[ADDRESS_1008227] be reported 
and resolved before use of the study drug. 
5.7.2 Study Drug Accountability  
The investigator or other personnel designated by [CONTACT_737922], including dates of receipt. In addition, accurate records will be kept regarding when and how much study drug is dispensed and used by [CONTACT_737923]™ 100/33  
Protocol: LPS16990 (Original, Version 1.0) 18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 73 of 156 in the study. The investigator or other personnel designated by [CONTACT_737924] s tocks of Soliqua 100/[ADDRESS_1008228] also be recorded. 
At the completion of the study, to satisfy regulatory requirements regarding drug 
accountability, all study drug will be reconciled and retained or destroyed according to applicable regulations. 
All Soliqua 100/33 will be dispensed in accordance with the investigator’s oversight. It is 
also the investigator’s responsibility to ensure that an accurate recording of Soliqua 100/33 
kits issued and returned is maintained. 
Any quality issue noticed with the receipt or use of Soliqua 100/33 pen (deficiency in 
condition, appearance, documentation, labeling, expi[INVESTIGATOR_320], etc.) must be promptly 
reported to the sponsor. Some deficiencies may be recorded through a complaint procedure 
(Section  6.3.7).  
A potential defect in the quality of the Soliqua 100/[ADDRESS_1008229] made by [CONTACT_456], in order to recall the Soliqua 100/33 pens and 
eliminate potential hazards.  
Under no circumstances will the investigator supply Soliqua 100/[ADDRESS_1008230] party, 
(except for DTP shipment, for which a courier company has been approved by [CONTACT_456]), 
allow the Soliqua 100/33 pen to be used other than as directed by [CONTACT_239204], 
or dispose of the Soliqua 100/33 pen. 
5.7.3 Other Supplies  
[IP_ADDRESS]  Blood Glucose Meter Kit  
Each study participant will be provided with a blood glucose meter kit, in order to perform SMPG assessments. The blood glucose meter kit will include a blood glucose meter, lancing  
device, test strips, sterile lancets, storage box, control solution, and instructions for use.  
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0) 18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 74 of 156 [IP_ADDRESS]  CGM Device (FreeStyle Lib re Pro Flash Glucose Monitoring 
System)  
The FreeStyle Libre Pro Flash Glucose Monitoring System (Abbott Laboratories) is a 
professional CGM device indicated for detecting trends and tracking patterns in people with 
diabetes (aged ≥18 years). The system automatically captures the glucose concentration in the interstitial fluid every minute. It also automatically records the glucose concentration 
every 15 minutes, storing that data in a rolling 8-hour log. The system has 3 main parts: a 
disposable sensor, a handheld reader, and FreeStyle Libre Pro software. Participants will not have access to the reader or software (these will remain with the investigator) and therefore will remain  blinded to the data. 
The device will be applied to the back of the upper arm of each participant , and they will be 
required to wear it continuously for 14 days during CGM data collection at baseline (during the run-in period) and for 2 weeks at the end of the treatment period (ie, Weeks  14 to 16). 
The device does not require user calibration with blood glucose values. 
Clinical sites and participants will be provided with device adhesion guidance, including 
proper skin preparation and products to increase adhesion (TORBOT SKIN TAC™, a 
latex -free “tacky” skin barrier, and MASTISOL  LIQUID ADHESIVE
®, a clear, non- irritating 
liquid adhesive that secures dressings). Clinical sites will be thoroughly trained on the device 
adhesion guidance as well as the checks that must be performed to ensure that the devices  are 
fully functioning before a participant leaves the site.  
5.8 Overdose Management  
An overdose (accidental or intentional) with the IMP/NIMP is an event suspected by [CONTACT_737925], in the in vestigator’s opi[INVESTIGATOR_737870], is considered 
significantly greater than the prescribed dose of insulin or is at least twice the intended dose 
within the intended therapeutic interval. Any overdose, with or without associated AEs, must 
be promptly reported in eCRFs by [CONTACT_30107], which will then be notified to the sponsor’s 
representative (ie, [COMPANY_003] Pharmacovigilance). Overdoses without signs or symptoms should be 
recorded as a standard overdose ; any A Es associated with the overdose should be reported on 
the relevant AE/SAE sections in the eCRF.  
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0) 18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 75 of 156 5.8.1 Treatment of Overdose  
Insulin Glargine  
Excess insulin administration may cause hypoglycemia and hypokalemia. Mild epi[INVESTIGATOR_737885]. Adjustments in study drug 
dose, meal patterns, or exercise may be needed.  
More severe epi[INVESTIGATOR_737886], seizure, or neurologic impairment may be 
treated with intramuscular/subcutaneous glucagon or concentrated intravenous glucose. After 
apparent clinical recovery from hypoglycemia, continued observation and additional 
carbohydrate intake may be necessary to avoid recurrence of hypoglycemia. Hypokalemia must be corrected appropriately.  
Lixisenatide  
During clinical studies, doses up to 30 µg  of lixisenatide twice daily ( 3 times the daily 
recommended dose) were administered to patients with T2DM in a 13-week study. I ncreased 
incidence of GI disorders was observed ( Soliqua 2019). 
In case of overdose, appropriate supportive treatment should be initiated according to the participant ’s clinical signs and symptoms, and the Soliqua 100/33 dose should be reduced to 
the prescribed dose.  
5.9 Blinding  
Not applicable. This is an open- label , single- arm study. 
5.10 Treatment Accountability and Adherence  
Measures taken to ensure and document treatment adherence and IMP accountability include 
the following: 
• The treatment kit number  should be properly recorded as required on the appropriate 
eCRF page, for accounting purposes. 
• All medication treatment kits (whether empty or unused) are to be returned by [CONTACT_737926]. 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0) 18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 76 of 156 • Participants will record their daily dose details in an eDiary ( Section  13.3).  
• The investigator or their delegate will track t reatment accoun tability/adherence by 
[CONTACT_737927] ( EDC ) tool 
with the treatment/accountability log, eDia ry information about daily doses, and number 
of treatment kits provided versus number of treatment kits ret urned (whether empty or 
unused). 
• The monitor in charge of the study will check the data entered on the Soliqua 100/33 
administration page of the eCRF and compare them with the Soliqua  100/33 study drug 
that has been ret urned and the participant ’s treatment log form.  
5.11 Concomitant Therapy  
Use of all concomitant medications will be recorded in the participant’s eCRF. The minimum 
requirement is that drug name [CONTACT_160531]. This 
includes all prescription drugs, herbal products, vitamins, minerals, and OTC medications. 
Any changes in concomitant medications will also be recorded in the participant’s eCRF.  
The participants should be reminded that vitamin C alone, supplements containing vitamin  C 
with >1000 mg of ascorbic acid , aspi[INVESTIGATOR_264086], or aspi[INVESTIGATOR_248] -containing products with >650 mg 
of salicylic acid will interfere with CGM readings and should not be taken during the 14-day periods of CGM measure  (ie, at baseline [from Visit 2 to Visit 3.1 ] and the end of the 
treatment period  [from Visit 6 to Visit 7] ). Additionally , medications known to affect 
glycemia , such as ≥5 mg/day of prednisone should be prohibited during this 16- week study 
period. Participants  on meglitinides (eg, nateglinide , repaglinide) or weight loss drugs should 
also be prohibited from  inclusion into the study. 
Any concomitant medication deemed necessary for the welfare of the participant during the study may be given at the discretion of the investigator. However, the investigator is 
responsible for ensuring that details  regarding the medication are recorded in full in the 
eCRF.  The Soliqua 100/33 label should be consulted for any additional information regarding 
concomitant medication administration.  
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0) 18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 77 of 156 
 Study Assessments and Procedures  
Before performing any study procedures , all potential participants will sign an informed 
consent form (ICF). Participants will have the opportunity to have any questions answered 
before signing the ICF. The investigator must address all questions raised by [CONTACT_2299]. 
The investigator will also sign the ICF. 
6.1 Study Visits  
The SoE is detailed in Section  13.1. 
• The screening period (Visit 1) will encompass up to 2 week s and includes the following: 
o Obtaining informed consent. 
o Eligibility criteria.  
o Demographic assessment.  
o Review of medical/surgical history and current medications.  
o Physical examination  (BMI calculation) , dispensing of glucometer, HbA1c 
measurement, and setting up the eDiary.  
o Recording of vital signs, and  clinical chemistry, calcitonin , hematology, urinalysis, 
and pregnancy tests. 
• The run- in period (Visit 2) will encompass  2 weeks, including the baseline period, and 
includes HbA1c measurement and application of blinded CGM device (FreeStyle Libre Pro).  
o Visit 3.1 will be a site visit and include s assessment of eligibility criteria, M MTT, 
CGM device removal and data download (after the MMTT), CGM compliance assessment, evaluation of PPG and biomarkers of β-cell function (insulin, C-peptide, plasma glucose) during the MMTT, instructions for certain therapi[INVESTIGATOR_014] (eg, DPP-4i, oral 
daily  or weekly GLP -1 RA, and down-titration of SU by 50% when s tarting  
Soliqua 100/33), dispensing of Soliqua 100/33 and providing instructions for SoloStar 
pen use HbA1c and FPG measurement s, administration  of the Diabetes Medication 
Satisfaction Tool (DM-SAT ), recording of vital signs and body weight, and  clinical 
chemistry,  hematology, urinalysis, and pregnancy tests. 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0) 18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 78 of 156 o Visit 3.2 ( ie, Day 0) during the baseline period is the first  day of Soliqua 100/[ADDRESS_1008231] to ALL  participants to ensure that all 
administration procedures were successfully executed  and to answer any questions. 
(Note: The first day of Soliqua 100/33 administration  [ie, Visit 3.2, Day 0] for 
participants on weekly GLP-1 RA will depend on their administration schedule and 
may not be the day immediately following Visit 3.1. Soliqua 100/33 administration  
for these participants should be 7 [±  2] days after  their last weekly GLP -1 RA dose.) 
 A phone contact [CONTACT_737928] -1 
RA on the day before Soliqua 100/33 initiation , to remind them of the next 
morning’s injection and  to provide instructions for SoloStar pen use. The 
participants will provide their concomitant medication details to the site personnel 
over the phone. 
• The treatment period will encompass up to 16 weeks (Visits 3.2 through 7) and includes 
the following: 
o Visit 3.2 (ie, Day  0) is the first day of Soliqua 100/33 administration  and begins the 
open- label treatment period (with different initiation requirements based on weekly or 
daily GLP-1 RA use, as explained above). 
o Titration period (Visits 4.0 to 4.6, 5, and 5.1 to 5.4). 
 For Visits 4.0 to 4.6, titration of the Soliqua 100/33 dose will occur via phone 
contacts, but it can occur at the study site or at home for Visit  5. For Visits  5.1 
through 5.4, titration of Soliqua 100/33 dose will again occur via phone contacts. 
 During the titration period, participants will continue to make entries into their 
eDiary, administer Soliqua 100/33, adjust the Soliqua 100/[ADDRESS_1008232] complaints. 
 Other than an unscheduled visit, dispensing of Soliqua 100/[ADDRESS_1008233] will be conducted at Visit 5. 
o Visit 6:  
 Application of blinded CGM device and assessment of Soliqua 100/33 adherence. 
 Capturing of any product complaints.  
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0) 18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 79 of 156 oVisit 7 (ie, end of the treatment period):
Physical exam ination  (including body weight), MMTT (only to derive PPG
measures), removal of CGM device and download of data, and assessment of
Soliqua 100/33 adherence.
HbA1c and FPG measurements and recording of the DM- SAT.
Vital signs  and clinical chemistry , hematology, urinalysis, and pregnancy tests.
oAt the end of the study (ie, Visit 7), participants should discuss with the investigator,
in collaboration with the ir HCP , whether to continue on the Soliqua 100/33 treatment
regimen or tran sition to an alternate antihyperglycemic therap y.
•An unscheduled visit can be performed  at any time during the treatment period and may
include the following:
oDispensing and adjustment of Soliqua 100/33 dose.
oReview of concomitant medications .
oRecording of hypoglycemia events  and AEs/SAEs (including AESIs).
•The follow-up safety  period (Visit 8) will occur 2 weeks after the end of the treatment
period.
•Fasting SMPG values and  those measures  required to manage hypoglycemia events will
occur from the run-in period (Visit 2) through the end of the treatment period (Visit 7).
•Soliqua 100/33 dosing will occur from the end of the baseline period (Visit 3.2) throughthe end of the treatment period (Visit 7).
•eDiary completion, recording of hypoglycemia events , and AE s/SAEs (including AESI s)
will occur from the screening period (Visit 1) through the follow-up period (Visit 8),whereas review of concomitant medications will occur  from  the baseline period
(Visit 3.1) through the follow-up period (Visit 8).
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0) 18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 80 of 156 6.2 Efficacy Assessments  
6.2.1 CGM Measures 
Blinded CGM will be performed for 14 continuous days during baseline (ie, from Visit  2 to 
Visit 3.1) and again for 14 days at the end of the treatment period (ie, from Visit 6 to Visit 7; 
Section  13.1 ). The baseline CGM measure will be captured before discontinuing the daily 
(oral or injectable) or weekly GLP -1 RA , DPP -4i, or down- titration of  SU by 50%, and 
before  initiation of Soliqua 100/33 treatment . The blinded CGM device (FreeStyle Libre Pro) 
will be applied to the back of the upper arm of the participant and activated at Visit 2 (ie, the 
run-in period). Participants will be required to wear the device continuously for 14 days for 
baseline CGM data collection, with device removal and data download on Day –1 at their 
next site visit during the baseline period (ie, Visit 3.1), after collection of  C-peptide, insulin, 
and plasma glucose data from the MMTT. Downloaded CGM data will be reviewed by [CONTACT_737929]’ study eligibility. (Note: During the run-in period, 
CGM device reinsertion will be allowed for participants who do not meet the equivalent of at 
least 8 days of evaluable CGM data [not necessarily consecutive] over a 14 -day period as a 
result of premature sensor failure [eg, days of CGM device wear × % time CGM device active < 8] .) Similarly, participants will be required to continuously wear the device for 
14 days at the end of the treatment period from Weeks 14 to 16 (ie, Visit 6 to Visit 7) to 
collect CGM data, with device removal and data download on the fifteenth day after CGM 
placement  (ie, Visit 7), after collection of only plasma glucose data from the MMTT. 
Downloaded CGM data will be verified by [CONTACT_737930]’ study completion. During the end of the treatment period, CGM d evice 
reinsertion will also be allowed for participants who do not meet the equivalent of at least 
8 days of evaluable CGM data (not necessarily consecutive) over a 14-day period as a result 
of premature sensor failure (eg, days of CG M device wear × % time CGM device active < 8), 
if data can be captured during the 14-day end of treatment window. (Note: The minimum 
requirement for evaluable CGM data is if at least 10  out of 14 days [not necessarily 
consecutive] have at least  ≥80% of evaluable CGM data per 24 -hour period  during the run-in 
period as well as  the end of the treatment period  [ie, from Weeks  14 to 16] ; Battelino et al 
2020.) Criteria for CGM  device reinsertion are provided in Table  6-1 and Figure 6–1. Any 
combination of number of days of CGM device worn and % time CGM devic e is active 
(Table  6-1) that results in fewer than 8  equivalent days (defined as ineligibility) of evaluable 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0) 18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 81 of 156 CGM data will require device reinsertion . Eligibility and analysis criteria for CGM measures 
are provided in Section 13.9. 
Table  6-1 Criteria for CGM Device Reinsertion  
No. of Days CGM Device 
Worna  Time CGM Device 
Active (%)a  Equivalent Days  
8 100 8.00 
9 89 8.01 
10 80 8.00 
11 73 8.01 
12 67 8.04 
13 62 8.01 
14 57 7.98 
Abbreviations : AGP, Ambulatory Glucose Profile; CGM , continuous glucose monitoring. 
a AGP report.  
Figure  6–1 Criteria for CGM Device Reinsertion  
 
Abbreviation: CGM , continuous glucose monitoring. 
Participants with less than equivalent of 8 days of evaluable CGM data (not necessarily 
consecutive) of a 14-day period ( eg, days of CGM device wear × % time CGM device 
active < 8) during the run -in period will be considered as screen failures . For partici pants 

[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0) [ADDRESS_1008234] the CGM data  before  they permanent ly discontinue the treatment . 
6.2.2 MMTT -Derived β-Cell Function and PPG Measures 
Participants will undergo the MMTT (while wearing the CGM device) to assess maximum 
PPG exposure in the 4-hour period after the breakfast meal (tested at a central laboratory) 
with biomarkers of β-cell function ( plasma glucose,  insulin , and C-peptide) meas ured at 
Visit 3.1 (ie, site visit during the baseline period). The baseline MMTT will be conducted 
before discontinuing the daily (oral or injectable) or weekly GLP -1 RA , DPP-4i, or 
down- titration of SU  by 50%. At Visit 3.1, participants on OADs or an oral or injectable 
GLP -[ADDRESS_1008235] their baseline MMTT conducted within 7 (±  3) days after  
their last dose. During baseline (Visit 3.1), blood samples will be collected at the following 
time points: premeal (30  min)  and just before administration of OADs or GLP -1 RA (oral or 
injectable) (baseline) ; time 0 (just before meal administration),  10 min , 20 min; and 0.5, 1.0, 
1.5, 2.0, 2.5, 3.0, and 4.[ADDRESS_1008236]- meal  for plasma glucose,  C-peptide, and insulin levels.  
At the end of the treatment period (Visit 7), participants will again undergo the MMTT (while wearing the CGM device; only to derive PPG measures). Soliqua 100/33 should be 
administered 30 minutes before administration of the meal during the MMTT at Visit 7. At 
the end of the treatment period  (Visit 7) , blood samples will be collected for plasma glucose 
levels , as follows: premeal  (30 min)  and just before administration of Soliqua 100/33; and  
time 0 (just before meal administration),  0.5, 1.0, 1.5, 2.0, 2.5, 3.0, and 4.[ADDRESS_1008237] meal following Soliqua 
100/33 adm inistration at Week  16 compared with baseline. During both baseline and 
end-of-treatment assessments, removal of the CGM device and download of data will be 
done after completion of the MMTT ( Section 13.1 ). 
The MMTT includes a standardized meal (ie, Boost Very High Calorie ) that contains 
approximately 530 kcal and is composed of 19% carbohydrates, 44% protein, and 33% fat. The composition and the quantity of the standardized meal must be identical throughout the 
study period. 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0) 18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 83 of 156 During the baseline period (ie, Visit 3.1), on the day of the MMTT, the participants must not 
eat any food or drink, except water, for at least [ADDRESS_1008238] (to be completed in the mo rning). At the end of the treatment period ( ie, Visit 7 ), the MMTT will  
also be performed in a fasted state (eg, no consumption of any food or drink for at least 
[ADDRESS_1008239] ), and participants will receive their 
Soliqua 100/[ADDRESS_1008240] ( ie, consumption 
of the meal  and just after the first blood draw). 
For participants who discontinue study treatment prematurely, the visit window can be extended by [ADDRESS_1008241] the CGM data, followed by [CONTACT_737898], before they 
permanently discontinue the treatment. 
6.2.3 Fasting SMPG  
Participants will be supplied with a glucometer kit and an eDiary at the screening visit. Appropriate training will be provided to the participants related to proper use of the glucometer and eDiary completion. Fasting SMPG values (lowest values in conjunction with 
measurements from the previous 3 days) will be used to titrate and adjust Soliqua 100/[ADDRESS_1008242] 3 measurements is between 
80 to  100 mg/dL but the 2 other values are  above 100 mg/dL and further titration is required 
to manage hyperglycemia. The participants are required to measure fasting SMPG values 
before breakfast at least 3 to 4 times per week throughout the study period (to inform each 
dose adjustment) and record the results in the eDiary. During the titration period, fasting 
SMPG should be performed on each of the 3 to 4 days before each dose adjustment. 
(Note:  Additional titration is  at the discretion of the investigator with the goal of achieving 
glycemic targets while minimizing  the risk of hypoglycemia and hyperglycemia.) 
[IP_ADDRESS]  SMPG During Symptomatic Hypoglycemia  
Whenever participants experience hypoglycemia symptoms, they (or others, if applicable) 
should measure plasma glucose, if possible. Participants should be instructed to measure 
plasma glucose levels before  carbohydrate intake/administration of glucose whenever 
symptomatic hypoglycemia is suspected, unless safety considerations necessitate immediate 
carbohydrate/glucose rescue before  confirmation with the SMPG  values . Participants must 
contact [CONTACT_737931]™ 100/33  
Protocol: LPS16990 (Original, Version 1.0) 18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 84 of 156 that a  decision regarding  any necessary actions can be made. Participants should be 
instructed to measure plasma glucose levels again aft er the event resolves.  
6.2.4 FPG Measurements 
Blood samples will be collected to determine FPG at the time points specified in the SoE 
(Section  13.1) and will be measured at a central laboratory. For the scheduled site visits, 
participants are required to arrive fasting without administering the  Soliqua 100/33 injection. 
Fasting is defined as no food intake in the 8 hours before blood sampling, except water. 
6.2.5 HbA1c Measurements 
Blood samples will be collected to measure HbA1c during the screening  and run-in periods 
and at  Visit 3.1 (before administration of the meal)  at the central laborator y, to determine 
study eligibility and at the end of the 16- week treatment period (Visit 7), to determine change 
in glycemic control. 
6.2.[ADDRESS_1008243] on participants’ health -related quality of life 
(HRQoL) and their satisfaction with diabetes therapy will be assessed using the DM- SAT 
questionnaire ( Anderson et al 2009) at  the baseline visit b efore  stoppi[INVESTIGATOR_737887]- titration  of 
baseline therap ies and at the end of the tr eatment period ( Section  13.1). The DM -SAT 
questionnaire ( Section  13.2) is a 16 -item measure with 4  subscales assessing wellbeing 
(3 items), medical control (3 items), lifes tyle (5 items), an d convenience (5  items).  
Participants will be requested to complete the DM -SAT questionnaire by [CONTACT_1029], 
independently f rom the investigator or si te staff, and without any help from friends or 
relatives. For validity purposes, the quest ionnaire should be completed by [CONTACT_737932] a 
quiet place, at t he start of the visit before  any other study tests or procedures are performed or 
Soliqua 100/33 is administered . 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0) 18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 85 of 156 6.3 Safety Assessments  
6.3.1 Physical Examination  
A complete physical examination (including body weight) will be performed , per standard of 
care, in order to assess the health status of the participants at time  points described in the SoE 
(Section  13.1).  Height measurements in conjunction with body weight will be utilized to 
calculate BMI during the screening  period . 
Body weight will be measured to allow the estimation of change from baseline to Week  16. 
While measuring body weight the participant should be wearing only undergarments or very 
light clothing and no shoes and have an empty bladder. 
The same weight scale should be used throughout the study and calibrated on a regular basis 
as recommended by [CONTACT_3455]. Calibration should be documented in source 
documents by [CONTACT_779]. 
The use of balance scales is recommended; if digital scales are used, testing with standard 
weights is of particular importance. The floor surface on which the scale rests must be hard 
and should not be carpeted or covered with other soft material. The scale should be balanced 
with both weights at zero and the balance bar aligned. The participant should stand in the center of the platform as standing off- center m ay affect  the measurement. The weights are 
moved until the beam balances (the arrows are aligned). The weight should be read and 
recorded in the eCRF and source documents. 
Self-reported weights are not acceptable on physical examination; participants must not read 
the scales themselves.  
6.3.[ADDRESS_1008244] be instructed to document any hypoglycemia events in 
their eDiary. Hypoglycemia will be reported in the specific hypoglycemia event information form in the eCRF with onset date and time ; symptoms and/or signs; the SMPG value, if 
available; and the treatment. A hypoglycemia event that  fulfills the seriousness criteria will 
also be documented on the SAE form in the eCRF. 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0) 18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 86 of 156 Hypoglycemia will be evaluated in accordance with the consensus report of a steering 
committee on levels of hypoglycemia ( Agiostratidou et al 2017). These levels are consistent 
with ADA standard of care 2021 recommendations ( ADA 2021a ). 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0) [ADDRESS_1008245]:  
• Overall hypoglycemia. 
• Confirmed hypoglyc emia.  
o ADA Level 1: A measurable glucose concentration of <70 mg/dL (3.9 mmol/L) but 
≥54 mg/dL (3.0 mmol/L) that can alert a person to take action. Blood glucose 
concentration of 70 mg/dL (3.9 mmol/L) has been recognized as a marker of physiological hypoglycemia in humans. Recurrent epi[INVESTIGATOR_737888], Therefore, glucose levels <70 mg/dL 
(3.9 mmol/L) are clinically important, independent of the severity of acute symptoms. 
o ADA Level 2: A measurable glucose concentration of <54 mg/dL (3.0 mmol/L) that 
needs immediate action. At approximately 54 mg/dL (3.0 mmol/L), neurogenic and 
neuroglycopenic hypoglycemia symptoms begin to occur, ultimately leading to brain 
dysfunction at levels <50 mg/dL (2.8 mmol/L). Neuroglycopenic symptoms, 
including behavioral changes, visual changes, seizure, and loss of consciousness, are the result of central nervous system neuronal glucose deprivation. 
o ADA Level 3: A severe event characterized by [CONTACT_226405]/or physical 
functioning that requires assistance* from another person for recovery. Severe 
hypoglycemia captures events during which the symptoms associated with hypoglycemia affect  a patient such that the patient requires assistance from others.  
*Note that “requires assistance” means that the person could not help themselves . Assisting  a 
person out of kindness, when assistance is not required, should not be considered a “requires 
assistance” incident.  
Clinical symptoms that are related to  a hypoglycemia epi[INVESTIGATOR_277098] (but are not 
necessarily limited to) increased sweating, nervousness, asthenia, tremor, dizziness, increased appetite, palpi[INVESTIGATOR_814], headache, sleep disorder, confusion, seizures, unconsciousness, and coma ( Agiostratidou et al 2017). 
6.3.[ADDRESS_1008246] 
of clinical laboratory tests to be performed is provided in Section 13.4. The timing and 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0) 18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 88 of 156 frequency of sample collection s are provided in the SoE (Section  13.1). Additional tests may 
be performed at a local or central laboratory at any time during the study as determined 
necessary by [CONTACT_11006]. If they are used to evaluate an 
AE (diagnostic, follow-up, outcome), the results must be entered into the eCRF 
(Section  13.4). 
• The investigator must review the laboratory report, document this review, and record any clinically relevant changes occurring during the study in the AE section of the eCRF. 
• The laboratory reports must be filed with the source documents. Clinically significant abnormal laboratory findings associated with the underlying disease or vital signs will 
not be considered clinically significant or be reported as AEs unless  one of the following 
criteria is met: 
o Participant is  symptomatic (and/or laboratory values are or vital signs are clinically 
significant per the investigator’s discretion). 
o Participant r equires either corrective treatment or consultation . 
o Participant requires Soliqua 100/33 treatment to be discontinued or modification of 
dosing. 
o Event f ulfills  a serious ness criterion . 
o Event meets the definition of  an AESI ( Section  [IP_ADDRESS]). 
• All laboratory tests with va lues considered clinically significantly abnormal during 
participation in the study s hould be repeated until the values return to normal/baseline or 
are no longer considered cl inically significa nt by [CONTACT_093]. 
o If clinically significant values do not return to normal/baseline within a period of time 
judged reasonable by t he investigator, the etiology should be identified and t he 
sponsor notified. 
• All protocol-required laboratory assessments, as defined in Section 13.4, m ust be 
conducted in accordance with the laboratory manual and the SoE ( Section  13.1).  
• The r ecommended decision tree for the managem ent of ALT increa se is provided in 
Appendix 13.6. 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0) 18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 89 of 156 6.3.4 Vital Signs  
Vital signs (heart  rate, systolic blood pressure [BP], and diastolic BP) will be recorded at the 
time points specified in the SoE ( Section  13.1).  
• Blood pressure will be assesse d in a seated position using the same device (automated BP 
monitor or a manual sphygmomanometer) for each participant. 
• Seated BP should be measured in both arms after at least a 5-minute rest, and then again 
after [ADDRESS_1008247] value will be recorded in the eCRF. 
• At subsequent visits, BP should be measured using the participant ’s designated  arm, to be 
preceded by [CONTACT_2669] [ADDRESS_1008248] in a quiet setting without distractions 
(eg, television, cell phones). 
• Heart rate will be measured concurrently with the measurement of seated BP.  
• Vital sign abnormalities are to be recorded as AEs only if  at least one of the following 
criteria is met: 
o Participant is  symptomatic  (and/or vital signs are clinically significant per the 
investigator’s discretion). 
o Participant r equires either corrective treatment or consultation . 
o Participant r equires Soliqua 100/33 treatment to be discontinued  or the dose to be 
modified .  
o Event fulfills  a seriousness criterion . 
o Event meets the defin ition of  an AESI  (Section  [IP_ADDRESS]). 
6.3.5 Adverse Events  
The investigator is responsible for reporting all AEs that are observed or reported during the 
study, regardless of their relationship to study drug or their clinical significance. The 
investigator remain s responsible for following up on all AEs  that are serious , considered 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0) 18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 90 of 156 related to the study treatment or study procedures, or caused the participant to discontinue 
Soliqua 100/33 treatment  and/or the study. 
All AEs (serious  or nonserious) will be collected from the signing of the ICF until the 
follow-up vis it (Section  13.1).  
The definitions of AEs and SAEs are provided in Section  13.5. The definition of an AESI is 
provided in Section  [IP_ADDRESS]. 
All SAEs and AE SIs will be recorded and reported to the sponsor or designee immediately 
and under no cir cumstances should this be longer than 24 hours of awareness , as indicated in 
Section  [IP_ADDRESS]. T he investigator will submit any updated SAE data to the sponsor or 
designee within 24 hours of receipt of the information . 
After the initial AE s/AESI s/SAE s report, the investigator is required to proactively  follow-up 
with each participant at subsequent visits/contacts. At the prespecified study end date, all 
SAEs and AESI s (as defined in Section [IP_ADDRESS]), will be followed until resolution, 
stabilization, the event is otherwise explained, or the participant is lost to follow -up (as 
defined in Section  4.4.2). Further information on follow-up procedures is provided in 
Section  13.5.3. 
Investigators are not obligated to actively seek information on AEs or SAEs after the conclusion of study participation. However, if the investigator learns of any SAE, including a 
death, at any time after a participant has been discharged from the study, and they consider 
the event to be reasonably related to study treatment or study participation, the investigator must promptly notify the sponsor. 
[IP_ADDRESS]  Suspected Unexpected Adverse Events  
A suspected unexpected serious adverse reaction (S[LOCATION_003]R ) is defined as an adverse reaction, 
the nature or severity of which is not consistent with the applicable product information/labeling (eg, investigator’s brochure for an unapproved IMP). 
A “Dear Investigator” letter must be prepared for S[LOCATION_003]Rs according to local regulatory 
requirements and sponsor policy and forwarded to investigators as necessary. 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0) 18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 91 of 156 An investigator who receives an investigator safety report describing an SAE, S[LOCATION_003]R, or 
any other specific safety information (eg, summary or listing of SAEs) from the sponsor wi ll 
review and then file it along with the package insert  and will notify the institutional review 
board ( IRB), if appropriate according to local requirements. It is the responsibility of the 
sponsor to assess whether an event meets the criteria for a S[LOCATION_003]R and thus is expedited to 
regulatory authorities. 
[IP_ADDRESS]  Adverse Events of Special Interest  
An AESI is an AE (serious or nonserious) of scientific and medical concern specific to the sponsor’s product or program, for which ongoing monitoring and immediate notification by [CONTACT_230013]. Such events may require further investigation in 
order to characterize and understand them. Adverse event s of special interest may be added, 
modified, or removed during a study by [CONTACT_12548]. 
The following AEs will be considered as AESIs in this study: 
• Pregnancy of a female participant enrolled in the study as well as pregnancy occurring in 
a fem ale partner of a male participant en rolled in the study with IMP /NIMP . 
o Pregnancy will qualify as an SAE only if it fulfills one of the seriousness criteria 
(Section  13.5.2).  
o If it is a  pregnancy in a female participant, IMP should be discontinued. 
o Follow-up of the pregnancy of a female participant or a female partner of a male 
participant is mandatory until the outcome has been determined. 
• Symptomatic overdose (serious or nonserious) with IMP /NIMP . 
o An overdose (accidental or intentional) with the IMP /NIMP  is an event suspected by 
[CONTACT_737933] , in the investigator’s opi[INVESTIGATOR_737870], is 
considered significantly greater than the prescribed dose of insulin or is at least twice 
the intended dose within the intended therapeutic interval ( for example, for a 
participant prescribed 60 units/20 μg of Soliqua 100/33 once a day, administration of 
≥120 units of insulin glargine and ≥40 μg of lixisenatide once a day would be 
considered an overdose), adjusted according to the tested drug. 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0) [ADDRESS_1008249] overdose . The circumstances 
(ie, accidental or intentional) should be clearly specified in the verbatim, and 
symptoms, if any, must be entered on separate AE /SAE  forms.  
• Increase in ALT (>3 × ULN ; Sectio n 13.6).  
[IP_ADDRESS]  Pregnancy  
A urine pregnancy test will be performed at time  points specified in the SoE ( Section 13.1). 
To ensure participant safety, each pregnancy must be reported to [COMPANY_011] within [ADDRESS_1008250] be followed up to determine th e outcome 
(including spontaneous miscarriage, elective t ermination, normal birth, or congenital 
abnormality) and the status of mother and chil d, even if the participant was dis continued 
from the study. Pregnancy complications and elective terminations for medica l reasons must 
be reported as an AE or SAE. Spontaneous mi scarriages must be reported as a n SAE. 
Any SAE occurring in association with a pregnancy that is brought to the inve stigator’s 
attention after the participant has completed the study and is considered by [CONTACT_737934]. 
Any female participant who becomes pregnant while participating in the study will be 
discontinued from study drug treatment. 
[IP_ADDRESS]  Eliciting and Documenting AEs 
Adverse events will be assessed from the time the participant signs the ICF until exit from 
the study. 
Serious AEs that occur more than [ADDRESS_1008251] been 
hospi[INVESTIGATOR_057], had any accidents, used any new medications, or changed concomi tant 
medication regimens (both prescription and OTC medications). 
In addition to participant ’s observations, AEs identified from any study data (eg, laboratory 
values, physical examination findings) or identified from review of other documents 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0) 18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 93 of 156 (eg, participant’s eDiary) that are relevant to participant’s safety will be documented on the 
AE page in the eCRF.  
[IP_ADDRESS]  Reporting AEs 
All AEs reported or observed during the study will be recorded on the AE page in the eCRF. 
Information to be collected includes drug treatment, dose, event term, time of onset, investigator-specified assessment of severity and relationship to study drug, time of resolution of the event, seriousness, any required treatment or evaluations, and outcome. 
Adverse events resulting from concurrent illnesses, reactions to concurrent illnesses, 
reactions to concurrent medications, or progression of disease states must also be reported. All AEs will be followed to adequate resolution. The Medical Dictionary for Regulatory 
Activities ( MedDRA ) will be us ed to code all AEs.  
Any medical condition that is present at the time that the participant is screened but does not 
deteriorate shoul d not be re ported as an AE. However, if it deteriorates at any time during the 
study, it should be recorded as an AE. 
Any A E that me ets criteria of an SAE ( Section  13.5.2) or an AESI (Section  [IP_ADDRESS]) must be 
reported to [COMPANY_003]  Pharmacovigilance  immediately (ie, wi thin 24 hours) after site personnel 
first learn about t he event ( Section  13.5.4).  
[IP_ADDRESS]  Assessment of Severity  
The severity or i ntensity of  an AE refers to the extent to which an A E affects the participant’s 
daily activities. The intensity of the AE s will be rated as mild, mode rate, or severe as 
described in  Section  13.5.3. 
Changes in the severity of an AE should be documented to allow an assessment of the 
duration of the event at each level of intensity to be performed. Adverse events characterized 
as intermittent do not require documentation of the onset and duration of each epi[INVESTIGATOR_1865]. 
[IP_ADDRESS]  Assessment of Causality  
The investigator’s assessment of an AE’s relationship to study drug is part of the documentation process (Section  13.5.3), but it is not a factor in determining what is or is not 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0) 18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 94 of 156 reported in the study. If there is any doubt as to whether a clinical observation is an AE, the 
event should be reported. 
The relationship or association of the study drug in causing or contributing to the AE will be 
characterized using the following classification and criteria:  
Related : If the cause of the AE is related to IMP/NIMP and cannot be reasona bly 
explained by [CONTACT_1604], such as the participant’ s clinical state, 
concomitant therapy, and/or other interventions OR  if the cause of the AE 
is unknown after a thorough review of the other factors. 
Not Related : When there is a clear alternative cause for the event other than the 
IMP/NIMP . 
[IP_ADDRESS]  Follow -up of Participants Reporting AEs 
All AEs must be reported in detail on the appropri ate page in the eCRF and followed to 
satisfactory resolution, until the investigator deem s the event  to be chronic or not clinically 
significant or until the participant is c onsidered to be stable ( Section  13.5.3). 
6.3.[ADDRESS_1008252] complaint form within the required timelines.  
Appropriate information (eg, samples, labels, or documents like pi[INVESTIGATOR_12989]) related to product identification and to the potential deficiencies may need to be gathered. 
The investigator will assess whether the quality issue has to be reported with an AE or SAE. 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0) [ADDRESS_1008253] on participants’ HRQoL  and their satisfaction 
with diabetes therapy will be assessed using the DM-SAT questionnaire, as described in 
Section  6.2.6. 
6.[ADDRESS_1008254] blood samples at the visits specified in the SoE ( Section  13.1). 
These samples will be processed at the site and shipped the same day to a central laboratory, 
as specified in the laboratory manual. The central laboratory will analyze blood samples for PPG measures, HbA1c, and FPG, clinical chemistry, hematology, and biomarkers of β- cell 
function (during the MMTT). Results will be returned to the site within [ADDRESS_1008255] participant response to treatment. Therefore, data and biological 
samples will be stored and used for future research when consented to by [CONTACT_4317] 
(Section  9.3) unless prohibited by [CONTACT_21475] (in such case, consent for future use of 
sample will not be included in the local ICF).  
For participants who consent to the storage and use of their data and remaining and/or extra 
clinical samples, data and samples may be used after the study ends for future research 
related to the drug, the mechanism of action, the disease, or its associated conditions. Such research may  include, but is not limited to, performing assessments on DNA, RNA, proteins, 
or metabolites. If future research on genetic material is performed, this will also be limited to 
the purpose of addressing research questions related to the drug, the mechanism of action, the 
disease, or its associated conditions. 
In the event future research is conducted for other purposes, study participants will be 
informed of those purposes and will be given the means to object to those research projects.  
Data and samples will be used in compliance with the information provided to participants in 
the ICF Part  2 (future research).  
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0) 18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 96 of 156 All study participant data and samples will be coded such that no participant ’s directed  
identifiers will  be linked to them. Coded data and samples may be transferred to a sponsor 
site (or a subco ntracto r site) that may be located outside of the country where the study is 
conducted. The  sponsor adopts safeguards for protecting participant confidentiality and 
personal data ( Section  10.2).  
The samples w ill be stored for a maximum of [ADDRESS_1008256] notify the  sponsor in writing. In such cases, samples will be destroyed, and related 
coded data wil l be anonymized unless otherwise required by [CONTACT_5751]. 
Study parti cipant s’ coded data will be stored for future research for up to 25 years after the 
end of the study. If the data are still considered of important scientific value after this period, 
coded data already available will be anonymized unless otherwise required by [CONTACT_21476] (the same will apply to the data of a study participant who has requested the destruction 
of their samples).  
Participant s’ coded data sets provided to researchers for a specific research project will be 
available to the researchers for  a maximum of [ADDRESS_1008257] 
(end of project is defined by [CONTACT_211289]).  
6.6.1 Assessment of β-Cell Function Indices  
β-cell function biomarkers ( plasma glucose, C- peptide,  and insulin) will be collected from all 
eligible participants at baseline during the MMTT for assessment of β- cell responsivity , 
insulin and glucose sensitivity , and  any relationships to glycemic control . After database 
lock, data will be trans ferred to an academic partner who will utilize modelling techniques to 
derive these measures. These results will be reported separately.  
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0) 18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 97 of 156 
 Study -Specific Committees  
No scientific  steering committee, data safety monitoring committee, or clinical endpoint 
committee will be used in this study.  
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0) 18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 98 of 156 
 Statistical Considerations  
8.1 Estimands and Intercurrent Events  
The estimand frame work  is provided in Table  8-1. 
Table  8-1 Estimand Framework  
Estimand Definition  Variable (or Endpoint)  Strategy for Addressing 
Intercurrent Event  Population -Level 
Summary  
Estimand [Primary]     
The primary estimand is 
the mean change in the percentage of TIR 
(70‑180 mg/dL) from 
baseline to Week  16. 
The primary estimand 
will be estimated based 
on the efficacy analysis set using obtained 
measurements , 
regardless of intercurrent  events.  Mean change in percentage 
of TIR at Week  16 from 
baseline  Treatment policy strategy  Mean and 95% CI of change in p ercentage 
of TIR at Week  16 
from baseline  
Estimand [ Key 
Secondary]      
Mean  percent  changes 
of CV at Week  16 from 
baseline among the 
efficacy analysis set , 
regardless of 
intercurrent events  Mean  percent  changes of 
CV at Week  16 from 
baseline  Treatment policy approach  Mean and 95% CI  
Mean mg/d L change of 
mean daily blood glucose at Week  16 
from baseline among the efficacy analysis set , 
regardless of intercurrent events   Mean  mg/d L change of 
mean daily blood glucose at Week  16 from baseline  Treatment policy approach  Mean and 95% CI  
Mean  mg/d L change in 
the maximum PPG exposure in the [ADDRESS_1008258] meal at 
Week  16 from baseline 
among the efficacy 
analysis set , regardless 
of intercurrent events   Mean  mg/d L change in 
maximum PPG exposure in the 4-hour period after the 
breakfast meal  at Week  16 
from baseline  Treatment policy approach  Mean and 95% CI  
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0) 18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 99 of 156 Estimand Definition  Variable (or Endpoint)  Strategy for Addressing 
Intercurrent Event  Population -Level 
Summary  
Mean  percent  change in 
TAR >180 mg/dL at 
Week  16 from baseline 
among the efficacy 
analysis set , regardless 
of intercurrent events   Mean  percent  change  in 
TAR >180 mg/dL at 
Week  16 from baseline  Treatment policy approach  Mean and 95% CI  
Abbreviations: CI, confidence interval; CV , coefficient of variation; PPG, postprandial glucose; TAR, time 
above range; TIR, time in range.  
The following intercurrent events for the primary estimand will be handled by [CONTACT_737935]: initiation of rescue medication other than the study IMP, discontinuation of IMP, withdrawal from the study, and recording of <80% of evaluable CGM data per 24-hour 
period over 10 days  of a 14-day period, during the run -in period as well as the end of the 
treatment period (ie, from Weeks 14 to 16; Section  13.9). This estimand aims to reflect the 
estimated treatment effect under the intention- to-treat (ITT) . 
8.2 Statistical Hypothesis  
The null hypothesis (H0) for the primary endpoint is that the efficacy analysis set will have no improvement in TIR at Week [ADDRESS_1008259] an increased TIR at Week  16 compared 
with baseline at the significan ce level of 0.05. 
8.3 Sample Size Determination  
A total of 100 participants will be enrolled in the study. Sufficient participants will be screened from approximately 15 sites to include 100 patients, such that app roximately 
82 evaluable participants complete the study ( anticipating  that approximately 15% of 
participants discontinue the study before Week 16). 
The sample size is based on the primary objective to demonstrate the significant mean 
change (ie, increase) in the percentage of TIR (70‑180  mg/dL) from baseline to Week [ADDRESS_1008260] 95% power to detect an absolute 
increase in TIR means of 10%, assuming a standard deviation (SD) of 25 for the change in TIR, with a two -sided type I error of 0.05. Anticipating a 15% loss to follow-up rate, 
100 participants would need to be enrolled. 
[COMPANY_011]  SOLIQUA™ 10 0/33 
Protocol: LPS16990 (Original, Version 1.0) 18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 100 of 156 Assumptions for Sample Size Determinations  
• Patients with an HbA1c ≥9% are in range 40% of the ti me or less ( Batellino et al 2019 ). 
• Per Vigersky and McMahon, every 10% increase in TIR corresponds to 0.8% HbA1 c 
reduction ( Vigersky and McMahon 2019).  
• Post hoc analyses from the LixiLan -O study in patients with an HbA1c of ≥9% produced 
an HbA1c reduction of 2.9% at 30 weeks ( Davies et al 2019 ). Therefore, 0.8% HbA1c 
reduction (conside red equal to 1 6% improvement in TIR) at Week 16 seems reasonable. 
• Assumption for SD is 25. In the AWARD -4 study in patients with T2DM, the increase in 
TIR at Week  26 was 20% to 30%, and the SE was approximately 3.0 (corresponding to 
an SD of approximately 20) ( Jendle et al 2016).  
8.4 Analysis Sets 
The following analysis sets will be used in the statistical analyses : 
• Enrolled set: All eligible participants who are dispensed Soliqua 100/33 and sign the ICF. 
• Efficacy  analysis set: All enrolled participants who receiv e ≥1 dose of Soliqua 100/[ADDRESS_1008261] evaluable CGM data at baseline.  
• Safety set: All enrolled participants who receive ≥1 dose of Soliqua 100/33.  
8.5 Description of Subgroups to Be An alyzed  
The following subgroups are planned for the primary analyses, if the number of participants 
in each subgroup is sufficient: participants with OAD only or OAD plus GLP -1 RA at 
baseline.  The number of patients deemed sufficient for a subgroup analysis will be 
determined in the statistical analysis plan ( SAP). 
8.6 Accountability, Demographics, and Baseline Characteristics  
Treatment adherence, demographics, and baseline characteristics will be summa rized in 
descriptive tables. Continuous data will be summarized using number of observations 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0) 18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 101 of 156 available, mean, SD, quartile ranges, minimum, median, and maximum. Categorical data will 
be summarized using count and percentage. 
8.6.1 Adherence  
Overall  treatment adherence is defined as the actual number of days with IMP injection 
compared with the planned number of days with IMP injection during the treatment period, 
up to treatment  discontinuation. It is calculated according to the following formula: 
 
A given administration will be considered noncompliant if the participant  did not take the 
planned dose of treatment as required by [CONTACT_760]. No imputation will be made for partic ipants with  missing or incomplete data.  
Treatment adherence will be summarized using mean, SD, median, and range for the safety 
set. In addition, the percentage of participants  who have <60%, ≥60% to <80%, ≥80% to 
≤100%, and >100% adherence will be summarized.  
The duration of IMP exposure will be calculated as  date of the last IMP injection  – date of 
the first IMP injection  + 1. 
8.7 Statistical Analysis Methodology  
Statistical analysis will be performed using SAS Enterprise software Version 7.1 or higher. In 
general, descriptive statistics of quantitative efficacy and safety parameters (result and change from baseline) by [CONTACT_400340] (OC; 
ie, inclusion of only participants having non- missing assessments at a specific visit). The 
baseline value is defined as the last available value before the first injection of Soliqua 
100/33. All efficacy analyses (primary, key secondary, secon dary, and other eff icacy 
endpoints) will be performed on the efficacy analysis set. Analysis of demographics, baseline 
characteristics, and prior and concomitant medications will be provided in detail in the SAP. 
The extent of study treatment exposure and adherence will be assessed and summarized with 
dose frequency and duration of treatment. 

[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0) 18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 102 of 156 Continuous data will be summarized using number of observations available, mean, SD, 
minimum, median, and maximum. Categorical data will be summarized using count and percentage.  
Details of the statistical analyses, methods, and data conventions are described in the SAP. 
All statistical tests will be 2 -sided and performed using a 0.05 significance level, leading to 
95% (2 -sided) confidence intervals (CIs). 
Laboratory values below the lower limit of quantification  (LLOQ) will be set to ½LLOQ.  
 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 103 of 156 8.7.1 Overview of Statistical Methods: Estimation of Estimands and Sensitivity Analyses  
A summary of statistical methods, including sensitivity analyses , is provided in Table  8-2. 
Table  8-2 Summary of Statistical Methods, Including Sensitivity Analyses 
   Main Estimation   
Estimand 
Label  Estimand Description  Analysis Set  Imputation/Data/  
Censoring Rules  Analysis Model/Method  Sensitivity Analysis  
Estimand 1a 
(Primary)  Mean change in the percentage of TIR 
(70‑180 mg/dL) from baseline 
to Week  16 among the entire 
study population. The primary 
estimand will be estimated based on the efficacy analysis 
set using obtained 
measurements. T he value for 
the mean change in the 
percentage of TIR will be  
used regardless of intercurrent 
events at Week  16. Efficacy 
analysis set  Missing endpoint at 
Week  16 due to 
technical issues with the 
CGM device will be excluded from the analysis. Missing 
endpoint at Week 16 due 
to other reasons than 
technical issue s will be 
imputed by [CONTACT_737936].  Mean and its associated 95% CI will be calculated on an overall efficacy 
analysis set . A one -sample 
t-test will be applied to 
test the significance of changes at Week  16 over 
baseline. The sensitivity analysis for the primary outcome will be conducted with all missing data imputed using BOCF approach . In case there is 
substantial missing CGM data , a 
second sensitivity analysis may be 
conducted on participants with evaluable data to estimate the  
primary endpoint at Week 16. 
Mean and its associated 95% CI will be reported.   
Abbreviations: BOCF , baseline observation carry forward ; CI, confidence interval; CGM, continuous glucose monitoring; TIR, time in range . 
 
[COMPANY_011]  SOLIQUA™ 1 00/33 
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 104 of 156 8.7.2 Analysis of Primary Endpoint  
[IP_ADDRESS]  Main Estimation of Primary Estimand  
The primary endpoint is to demonstrate the improvement from baseline in the percentage 
of TIR of 70 to 180 mg/dL during the last 2 weeks of treatment (Weeks  15 and 16) for the  
entire study population. The percentage of time spent in the glycemic target ran ge will be 
calculated as 100 times the number of recorded measurements in  the glycemic target range, 
(70-180 mg/dL) inclusive, divided by [CONTACT_737937]. 
As described in Table  8-2, the mean and its associated 95% CI will be used to describe the 
changes in TIR (70 -180 mg/dL) at Week [ADDRESS_1008262] the significance of changes. A p-value <0.05 will be considered significant. 
As part of the definition for the efficacy analysis set, evaluable data (ie, not missing) is 
defined as the availability of at least 10 out of 14 days (not necessarily consecutive) with at 
least ≥80% of eva luable CGM data per 24 -hour period during the run- in period as well as 
the end of the treatment period (ie, from Weeks 14 to 16; Section 13.9), otherwise it will be 
considered as missing. 
The primary estimand will be estimated based on the efficacy analysis set using obtained 
measurements , regardless of intercurrent events . Table  8-[ADDRESS_1008263] (BOCF). 
Missing data due to technical issues of CGM devices will not be imputed. D etails of 
handling missing data are provided in S ection  [IP_ADDRESS]. 
[IP_ADDRESS]  Sensitivity Analysis of Primary Endpoint  
Sensitivity analysis for the primary outcome will be conducted by [CONTACT_737938] (regardless of reasons) with BOCF .  
If there is substantial missing CGM data from for the primary outcome, an additional sensitivity analysis will be conducted on participants with evaluable data to estimate the 
[COMPANY_011]  SOLIQUA™ 1 00/33 
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 105 of 156 primary endpoint at Week 16 ( data from participants who discontinue their treatment 
before Week  [ADDRESS_1008264] evaluable CGM data). Mean and 
its associated 95% CI will be reported.  
[IP_ADDRESS]  Supplementary Analysis of Primary Endpoint  
Analysis of the primary endpoint will be summarized by [CONTACT_737939] (ie, OAD only 
or OAD plus GLP -1 RA) . 
8.7.3 Analysis of Key Secondary Efficacy Endpoints  
[IP_ADDRESS]  Main Estimation of Key Secondary Estimand  
Change in G lycemic Control and Variability  
Mean changes for continuous outcomes (eg, CV , mean daily blood glucose, maximum PPG 
exposure in the [ADDRESS_1008265] meal , TAR >180 mg/dL) will be presented at 
baseline and at the end of the treatment period (Week 16). Mean (SD) and associated 95% 
CI, as well as minimum, median, and maximum will be provided. 
The key secondary estimand will be estimated based on the efficacy analysis set using 
measurements obtained during the study, regardless of intercurrent events. Missing data 
related to  the key secondary estimand will be imputed with their BOCF.  Similarly to 
analysis of primary estimand, missing data due to technical issues of CGM devices will not be imputed. 
[IP_ADDRESS]  Sensitivity Analysis of Key Secondary Endpoints  
No sensitivity analysis is planned for key secondary endpoints. 
[IP_ADDRESS]  Handling of Missing Data  
Missing data will be handled differently in accordance with the reason s for the missing 
data for both primary and key secondary endpoints. If the missing data are due to technical 
issue s with the CGM device (ie, CGM  data are not evaluable if at least 10  out of 14 days 
[not necessarily consecutive] have <80% of evaluable CGM data per 24-hou r period 
during the run- in period as well as  the end  of the treatment period  [ie, from Weeks  14 
[COMPANY_011]  SOLIQUA™ 1 00/33 
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 106 of 156 to 16]), the participant will be excluded from the analysis (missing completely at random 
[MCAR ] approach). For other reasons for missing measurements (eg, lost to follow-up, 
discontinued treatment), the W eek [ADDRESS_1008266] (missing not at random [ MNAR ], conservative approach). The assumption 
that data are MCAR will be evaluated using  an association test (eg,  Chi- square test for 
categorical covariates and Pearson correlation coefficient or two -sample t -test for 
continuous covariates) between baseline covariates and missing data status 
(ie., participants who have missing data for primary endpoint versus those who have 
complete data). The reasons for missing the primary endpoint at Week 16 (eg, lost to 
follow-up, discontinued treatment) will also be presented.  
Multiple Comparisons and M ultiplicity  
A hierarchical test ing procedure will be performed. Key s econdary endpoints will be 
evaluated with  a one- sample t -test to determine whether there is any change at Week  [ADDRESS_1008267] is nonsignificant (p >0.05), then the testing will be stopped  (or consider all further tests to be only secondary , and no formal 
conclusions can be drawn ). 
8.7.4 Analyses of Secondary Endpoints  
Mean changes for continuous outcomes (eg, other measures of glycemic control and 
variability: TIR [70 -180 mg/dL] for four 6-hour time segments,  Glucose Management 
Indicator [ GMI ] <7% and <9%, 4-hour PPG area under the concentration versus time 
curve from 0 to 4 hours ( AUC 0-4h) after start of the breakfast  meal , and time to maximal 
PPG concentration) will be presented at baseline and at the end of the treatment period 
(Week  16). Mean (SD) and associated 95% CI, as well as minimum, median, and 
maximum will be provided. 
Binary outcomes (eg, change in the proportion of patients achieving CV <36% at Week  16, 
the proportion of patients at Week 16 who spend <15 minutes/day at a glucose level 
<54 mg/dL ) will be summarized with proportions and 95% CI using the Clopper Pearson 
exact method.  
[COMPANY_011]  SOLIQUA™ 1 00/33 
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 107 of 156 8.7.5 Analyses of Other Efficacy Endpoints  
Mean changes for continuous outcomes (eg, additional measures of glycemic control and 
variability: mean of daily difference [MODD ] of glucose levels, TAR >250 mg/dL, TBR 
<70 mg/dL, and HbA1c %) will be presented at baseline and at the end of the treatment 
period (Week  16). Mean (SD) and associated 95% CI, as well as minimum, median, and 
maximum will be provided. 
The correlation of TIR to patient-reported outcome (PRO), HbA1c, and relationship of 
patients requiring 60 units/day of insulin glargine (related to TIR >70%) at Week  [ADDRESS_1008268] ion biomarkers ( plasma glucose, C-peptide, and insulin) collected at baseline 
will be analyzed utilizing minimal modelling by [CONTACT_737940] β-cell responsivity , insulin  and glucose sensitivity , and 
any relationships to glycemic control. The β-cell function indices will be included as a post 
hoc analyses and reported separately . 
8.7.[ADDRESS_1008269] and satisfaction, as measured by 
[CONTACT_737911] -SAT, from baseline to Week 16 will be analyzed using the efficacy analysis set and 
described as mean (SD) and associated 95% CI, as well as minimum, median, and 
maximum for overall score and by [CONTACT_737893]. 
8.7.8 Safety Analyses  
All safety and tolerability endpoints will be described by [CONTACT_6227], proportion, and the associated 95% CI for proportions. Adverse event incidence tables will be presented by [CONTACT_9313] ( SOC ; sorted by [CONTACT_56496]), high-level group term 
(HLGT), high- level term (HLT), and preferred term (PT ) sorted in alphabetical order with 
the number (n) and percentage of participants experiencing an AE. Participants with more than 1 AE will be counted only once. The denominator for computation of percentages will 
be the safety  set. 
[COMPANY_011]  SOLIQUA™ 1 00/33 
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 108 of 156 [IP_ADDRESS]  Adverse Events  
A treatment -emergent AE is an event that has  onset date (or increase in severity) during the 
on-treatment observation period.  
The most frequent AEs will be defined as PTs that are experienced by [CONTACT_2669] 5% of the 
participants in any of the treatment arms.  
All AEs will be coded using the most recent version of the MedDRA in-use by [CONTACT_737941] . 
[IP_ADDRESS]  Hypoglycemia Events  
Hypoglycemia events will be summarized similarly to the treatment- emergent AEs for 
on-treatment observation periods based on the safety set. In addition, hypoglycemia events 
will be counted with multiple epi[INVESTIGATOR_737874], if available, and the event rate per 
person-years will be reported overall and by [INVESTIGATOR_67147]. 
8.8 Data Quality Assurance  
• All participant data relating to the study will be recorded on printed case report form s 
(CRFs ) or eCRF s unless transmitted to the sponsor or designee electronically 
(eg, laboratory data). The investigator is responsible for verifying that data entries are 
accurate and correct by [CONTACT_1189]. 
• Guidance on completion of CRFs will be provided in a set of CRF Completion 
Guidelines. 
• The investigator must permit study -related monitoring, audits, IRB review, and 
regulatory agency inspections and provide direct access to source data documents. 
• Monitoring details describing strategy (eg, risk-based initiatives in operations and quality, such as Risk Management and Mitigation Strategies and Analytical Risk -Based 
Monitoring), methods, r esponsibilities , and requirements, including handling of 
noncompliance issues and monitoring techniques (central, remote, or on- site 
monitoring), are provided in separate study documents. 
[COMPANY_011]  SOLIQUA™ 1 00/33 
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 109 of 156 • The sponsor or designee is responsible for the data management of this study, including 
quality checking of the data. 
• The sponsor assumes accountability for actions delegated to other individuals (eg, contract research organizations).  
• Records and documents, including signed ICFs, pertaining to the conduct of this study must be retained by [CONTACT_1732] 25 years after signing of the final study report 
unless local regulations or institutional policies require a longer retention period. No records may be destroyed during the retention period without the written approva l of 
the sponsor. No records may be transferred to another location or party without written 
notification to the sponsor. 
8.8.1 Data Management  
As part of the responsibilities assumed by [CONTACT_6231], the investigator agrees to maintain adequate case histories for the participants treated as part of the research under 
this protocol. The investigator  agrees to maintain accurate eCRFs and source 
documentation as part of the c ase histori es. These source documents may include a 
participant’s eDiary , laboratory reports (Section  13.8).  
[COMPANY_003] will supply access to the eCRF , which will be limited to personnel directly 
participating in the study, and all eCRFs should be completed in English. 
All eCRF information must  be completed . If an item is not available or is not applicable, 
this fact should be indicated per the guidelines for completion. Blank spaces should not be 
present unless otherwise directed.  
Investigative site personnel will enter participant data into Medidata Rave . The analysis 
data sets will be a combination of these data and data from other sources (eg, laboratory 
data, CGM device, PRO).  
Clinical data management will be performed in accordance with applicable [COMPANY_003] standards and data cleaning procedures to ensure the integrity of the data (eg, removing errors and inconsistencies in the data). Adverse events and concomitant medication terms will be coded using MedDRA and WHODrug, respectively. After database lock, each study site 
will receive their site -specific eCRF  data as entered into Medidata Rave for the study, 
[COMPANY_011]  SOLIQUA™ 1 00/33 
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 110 of 156 including full discrepancy and audit history. Additionally, a copy of all data from the study 
will be created and sent to the sponsor for storage. In all cases, participant initials will not be collected o r transmitted to the sponsor. 
[COMPANY_011]  SOLIQUA™ 1 00/33 
Protocol: LPS16990 (Original, Version 1.0)  [ADDRESS_1008270]  
Federal regulations and International Council for Harmonisation (ICH) guidelines require 
IRB approval before the involvement of human participants  in research studies. Before 
study onset, any information related to this study or provided to the participant (eg, the 
protocol, informed consent, advertisements for recruitment of study participants, and any 
other written information) must be approved by [CONTACT_1201]. Documentation of all IRB 
approvals and IRB compliance with ICH harmonised tripartite guideline E6(R1): Good Clinical Practice (GCP) will be maintained by [CONTACT_135780]. 
All IRB approvals should be signed by [CONTACT_737942], with 
the approval date, if a favorable opi[INVESTIGATOR_11744]. 
The investigator is responsible for providing written summaries of the progress and status 
of the study at intervals not exceeding [ADDRESS_1008271] their origin in the Declaration of Helsinki, ICH GCP, and all applicable regulations. 
9.3 Participant Information and Consent  
A written informed consent in compliance with US Title 21 Code of Federal Regulations (CFR) Part 50 shall be obtained from each participant before entering the study or performing any unusual or nonroutine procedure that involves risk to the participant. An 
informed consent template may be provided by [CONTACT_160527]. If any institution -specific modifications  to study-related procedures are proposed or made by [CONTACT_39722], the consent should be reviewed by [CONTACT_737943]™ 1 00/33 
Protocol: LPS16990 (Original, Version 1.0)  [ADDRESS_1008272] sign the revised form. 
Before recruitment and enrollment, each prospective participant will be given a full 
explanation of the study and be allowed to read the approved ICF. Once the investigator is assured that the participant understands the implications of enrolling in the study, the participant will be asked to give consent to participate in the study by [CONTACT_12568]. 
The investigator shall retain the signed original ICF(s) and give a copy of the signed 
original form to the participant. 
[COMPANY_011]  SOLIQUA™ 1 00/33 
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 113 of 156 
 Investigator’s Obligations  
The following administrative items are meant to guide the investigator in the conduct of 
the study but may be subject  to change based on industry and government standard 
operating procedures, working practice documents, or guidelines. Changes will be reported to the IRB but will not result in protocol amendments. 
10.[ADDRESS_1008273] be obtained before  
the disclosure of any said confidential informa tion to other parties.  
10.2 Data Protection  
All personal data collected and/or processed in relation to this study will be handled in compliance with all applicable Privacy & Data Protection laws and regulations, including 
the GDPR (General Data Protection Regu lation). The study sponsor is the [COMPANY_011] company 
responsible for ensuring compliance with this matter, when processing data from any individual who may be included in the [COMPANY_011] databases, including investigators, nurses, 
experts, service providers, Ethics Committee members, etc.  
When archiving or processing personal data pertaining to the investigator and/or to the 
participants, the sponsor takes all appropriate measures to safeguard and prevent access to 
these data by [CONTACT_13159]. 
[COMPANY_011]  SOLIQUA™ 1 00/33 
Protocol: LPS16990 (Original, Version 1.0)  [ADDRESS_1008274] be properly justified and in line with 
the study objective. 
This CGM study will attempt to represent  a diverse set of US people with T2DM as 
advised by [CONTACT_1622]. These people represent a growing proportion of the US population, 
are historically under-represented in clinical studies, and are disproportionately affected by 
T2DM. For example, non- Hispanic Black, Hispanic, and American Indian/Alaska native 
adults are twice as likely to have diagnosed diabetes as non -Hispanic W hite adults. 
• Participants will be assigned a unique identifier by [CONTACT_456]. Any participant records or datasets that are transferred to the sponsor or its service providers will be identifi able 
only by [CONTACT_13160]; participant names or any information that  would make 
the participant identifiable will not be transferred to the sponsor. 
• The participant must be informed that their personal study- related data will be used by 
[CONTACT_737944]. The level of disclosure 
must also be explained to the participant as described in the informed consent. 
• The participant must be informed that their medical records may be examined by 
[CONTACT_737945], by [CONTACT_42506], and by [CONTACT_6668]. 
• Participants must be informed that their study -related data will be used for the 
following steps necessary for the development of the investigational product, including to support negotiations with payers and the publication of results. 
Protection of Data Related to Professionals I nvolved in the Study  
• Personal data (eg, contact [CONTACT_8972], affiliation details, job title and related professional information, role in the study, professional resume, training records) are necessary to allow [COMPANY_011] to manage involvement in the study and/or the related contractual or 
pre-contractual relationship. They may be communicated to any member  of the [COMPANY_011] 
group (“[COMPANY_011]”) or to [COMPANY_011] service providers, where needed. 
[COMPANY_011]  SOLIQUA™ 1 00/33 
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 115 of 156 • Personal data can be processed for other studies and projects. Objection to processing 
can be made at any time  by [CONTACT_13164] (link 
available at [COMPANY_011].com).  
• In cases of refusal to pro cess personal data by [CONTACT_13165], it will be 
impossible to involve the professionals in any future  [COMPANY_011] study. In case the 
professionals have already been involved in a [COMPANY_011] study; they w ill not be able to 
object to the processing of their personal data as long as they are required to be 
processed by [CONTACT_5279]. The same rule applies if the professionals are 
listed on a regulatory agency disqualification list.  
• Personal data can be communicated to the following recipi[INVESTIGATOR_840]: 
o Personnel within [COMPANY_011] or partners or service providers involved in the study. 
o Judicial, administrative,  and regulatory authorities, in order to comply with legal or 
regulatory requirements and/or to respond to specific requests or orders in the framework of judicial or administrative procedures. Contact [CONTACT_737946].  
• Personal data may be transferred to entit ies located outside the Economic European 
Area, in countries where the legislation does not necessarily offer the same level of data protection or in countries not recognized by [CONTACT_125487]. Those transfers are safeguarded by [CONTACT_737947] , including the following: 
o The standard contractual clauses of the European Commission for transfers to our partners and service providers. 
o [COMPANY_011]’s Binding Corporate Rules for intra -group transfers.  
• Professionals are able to lodge a complaint with [COMPANY_011] leading Supervisory Authority, 
the “Commission Nationale de l’Informatique et des Libertés” (CNIL) , or any 
competent local regulatory authority. 
• Personal data of  professionals will be retained by [CONTACT_21489] 30 years, unless 
further retention is required by [CONTACT_5279]. 
[COMPANY_011]  SOLIQUA™ 1 00/33 
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 116 of 156 • In order to facilitate the maintenance of investigators’ personal data, especially if they 
contribute to studies sponsored by [CONTACT_13170], [COMPANY_011] 
participates in the Shared Investigator Platform (SIP) and in the Transcelerate Investigator Registry (IR) project 
(https://transceleratebiopharmainc.com/initiatives/investigator -registry/ ). Therefore, 
personal data will be securely shared by [CONTACT_737948]. This sharing allows investigators to keep their 
data up -to-date once, for access by [CONTACT_737949], with the right to object to the transfer of the data to the Transcelerate project. 
• Professionals have the right to request access to and rectification of their personal data, as well as their erasure (where applicable) by [CONTACT_225405]: [COMPANY_011] DPO - 54 rue La Boétie - [ZIP_CODE] PARIS - [LOCATION_009] (to contact [CONTACT_13173], visit https://www.sanofi.com/en/our-responsibility/sanofi-global- privacy -
policy/contact ). 
10.[ADDRESS_1008275] provide to the 
sponsor a commitment to promptly update this information if any relevant changes occur 
during the course of the investigation and for 1 year following completion of the study. 
Neither the sponsor nor [COMPANY_003] is financially responsible for further testing or treatment of 
any medical condition that may be detected during the screening process. In addition, in the absence of specific arrangements, neither the sponsor nor [COMPANY_003] is financially 
responsible for furth er treatment of the participant’s disease.  
10.4 Investigator Documentation  
Before  beginning the study, the investigator will be asked to comply with ICH E6(R2) 
Section  8.2 and Title 21 of the CFR by [CONTACT_322452], including but not 
limited to the following: 
[COMPANY_011]  SOLIQUA™ 1 00/33 
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 117 of 156 • IRB approval. 
• Original investigator -signed agreement page of the protocol. 
• Curriculum vitae for the investigator and each sub-investigator. 
• Financial disclosure information to allow the sponsor to submit complete and accurate 
certification or disclosure statements required under [ADDRESS_1008276] provide to the sponsor a commitment to promptly update this 
information if any relevant changes occur during the course of the investigation and for 
1 year aft er the completion of the study. 
• IRB-approved informed consent, samples of site advertisements for recruitment for this 
study, and any other written information regarding this study that is to be provided to 
the participant . 
• Signed Clinical Study Agreement.  
10.[ADDRESS_1008277]  
The investigator agrees that the study will be conducted according to the principles of ICH 
E6(R2) and all applicable guidelines and regulations. The investigator will conduct all 
aspects of this study in accordance with all national, state,  and local laws or regulations. 
Study information from this protocol will be posted on publicly available clinical study 
registers before enrollment of participants begins. 
10.6 Adverse Events and Study Report Requirements  
The investigator agrees to submit reports of SAEs to the sponsor and/or the IRB according to the timeline and method outlined in the protocol. In addition, the investigator agrees to submit annual reports to the study site IRB as appropriate. 
10.7 Investigator’s Final Report  
Upon completion of the study, the investigator, where applicable, should inform the institution; the investigator/institution should provide the IRB with a summary of the study’s outcome and the sponsor and regulatory authority(ies) with any reports required. 
[COMPANY_011]  SOLIQUA™ 1 00/33 
Protocol: LPS16990 (Original, Version 1.0)  [ADDRESS_1008278] of the study with the 
investigator and personnel. 
The medical monitor and sponsor will hold monthly meetings to review AEs noted during 
the month, unless an SAE is noted and reported as described in Section [IP_ADDRESS]. 
All aspects of the study will be carefully monitored, by [CONTACT_3552], for 
compliance with applicable government regulation with respect to current GCP and current 
standard operating procedures. 
11.1.[ADDRESS_1008279] copi[INVESTIGATOR_119257]. 
[COMPANY_011]  SOLIQUA™ 1 00/33 
Protocol: LPS16990 (Original, Version 1.0)  [ADDRESS_1008280] be submitted in writing to the investigator’s IRB for approval before participants can be enrolled into an amended protocol. 
11.2.[ADDRESS_1008281] document and explain in the participant’s source documentation any deviation from the approved protocol. The investigator may implement a deviation from, or a change of, the protocol to el iminate an immediate hazard to study 
participants without prior IRB approval. As soon as possible after such an occurrence, the implemented deviation or change, the reasons for it, and any proposed protocol amendments should be submitted to the IRB for review and approval, to the sponsor for agreement, and to the regulatory authorities, if required. 
A deviation from the protocol is an unintended or unanticipated departure from the 
procedures or processes approved by [CONTACT_737950]. A significant deviation occurs when there is nonadherence to the protocol by 
[CONTACT_737951] a significant additional risk to the participant. 
Significant deviations can include nonadherence to inclusion or exclusion criteria, 
enrollment of the participant without prior sponsor approval, or nonadherence to FDA regulations or ICH GCP guidelines and will lead to the participant being withdrawn from the study ( Section 4.4).  
Protocol deviations will be documented by [CONTACT_135786]. Principal investigators will be notified in writing by [CONTACT_11783]. The IRB should be notified of all protocol deviations in a timely manner. 
11.3 Study Termination  
Although [COMPANY_011] has every intention of completing the study, [COMPANY_011] reserves the right to discontinue the study at any time for clinical or administrative reasons.  
[COMPANY_011]  SOLIQUA™ 1 00/33 
Protocol: LPS16990 (Original, Version 1.0)  [ADDRESS_1008282] participant in the 
study. 
11.4 Final Report  
Whether the study is completed or prematurely terminated, the sponsor will ensure that the clinical study report ( CSR) is  prepared and provided to the regul atory agencies as required 
by [CONTACT_1214]. The sponsor will also ensure that the CSRs in marketing applications meet the standards of the ICH harmonis ed tripartite guideline 
E3: Structure and content of clinical study reports. 
Where required by [CONTACT_25435], an investigator signatory will be 
identified for approval of the CSR. The investigator will be provided reasonable access to 
statistical tables, figures, and relevant reports and will have the opportunity to review the 
complete study results. 
Upon completion of the CSR, the sponsor will provide the investigator with the full 
summary of the study results. The investigator is encouraged to share the summary results 
with the study participants, as appropriate. The study results will be posted on publicly 
available clinical study registers.  
11.[ADDRESS_1008283]. These documents should be retained for a longer period; however, if required by [CONTACT_107245]. The sponsor is responsible for 
inform ing the investigator/institution as to when these documents no longer need to be 
retained.  
[COMPANY_011]  SOLIQUA™ 1 00/33 
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 121 of 156 11.6 Publication Policy, Disclosure, and Clinic al Study Registration  
11.6.1  Publication Policy and Disclosure  
• The results of this study may be published or presented at scientific meetings. If this is 
foreseen, the investigator agrees to submit all manuscripts or abstracts to the sponsor 
before submission. This allows the sponsor to protect proprietary information and to provide comments. 
• The sponsor will comply with the requirements for publication of study results. In 
accordance with standard editorial and ethical practice, the sponsor will generally support publication of multicenter studies only in their entirety and not as individual 
site data. In this case, a coordinating investigator [INVESTIGATOR_12992].  
• Authorship will be determined by [CONTACT_737952]. 
11.6.2  Clinical Study Registration  
In order to ensure that information regarding clinical studies reaches the public in a timely 
manner and to comply with applicable laws, regulations, and guidance, the sponsor (or its 
representative) will register interventional clinical studies it sponsors globally on 
ClinicalTrials.gov or other publicly accessible registers before the start of the study.  
11.6.3  Clinical Study Results Disclosure  
Study Participants  
[COMPANY_011] shares information about clinical studies and results on publicly accessible websites, based on company commitments, international and local legal and regulatory 
requirements, and other clinical study disclosure commitments established by 
[CONTACT_13174]. These websites include clinicaltrials.gov, European Union (EU) clinicaltrialregister (eu.ctr), and sanofi.com, as we ll as some national 
registries.  
[COMPANY_011]  SOLIQUA™ 1 00/33 
Protocol: LPS16990 (Original, Version 1.0)  [ADDRESS_1008284] 
the privacy of participants in our clinical studies. Details on data sharing criteria and the 
process for requesting access can be found at this web address: clinicalstudydatarequest.com. 
Professionals I nvolved in the Study or in the Drug Development Program  
[COMPANY_011] may publicly disclose, and communicate to relevant authorities/institutions, the funding, including payments and transfers of value, direct or indirec t, made to healthcare 
organizations and professionals and/or any direct or indirect advantages and/or any related 
information or document if required by [CONTACT_1289], by [CONTACT_5151], or by a code of 
conduct, such as the “EFPIA Code on Disclosure of Transf ers of Value from 
Pharmaceutical Companies to Healthcare Professionals and Healthcare Organisations.” 
[COMPANY_011]  SOLIQUA™ 1 00/33 
Protocol: LPS16990 (Original, Version 1.0)  [ADDRESS_1008285]  
ADA. Economic costs of diabetes in the U.S. in 2017. Diabetes Care. 2018;41(5):917-28. 
ADA. 6. Glycemic targets: standards of medical care in diabetes –2021. Diabetes Care. 
2021a;44(Suppl. 1):S73-S84. ADA. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in 
diabetes –2021. Diabetes Care. 2021b;44(Suppl. 1):S111-S124. 
Agiostratidou A, Anhalt H, Ball D, et al. Standardizing clinically meaningful outcome 
measures beyond HbA 1c for type 1 diabetes: a consensus report of the American 
Association of Clinical Endocrinologists, the American Association of Diabetes Educators, the American Diabetes Association, the Endocrine Society, JDRF International, The Leona 
M. and Harry B. Helmsley Charitable Trust, the Pediatric Endocrine Society, and the T1D 
Exchange. Diabetes Care. 2017;40(12):1622-30. 
Anderson RT, Girman CJ, Pawaskar MD, et al. Diabetes Medication Satisfaction Tool: a 
focus on treatment regimens. Diabetes Care. 2009;32(1):51-53. 
Anderson JE, Gavin JR, Kruger DF. Current eligibility requirements for CGM coverage 
are harmful, costly, and unjustified. Diabetes Technol Ther. 2020;22(3):169-73. 
Aroda VR, Rosenst ock J, Wysham C, et al. Efficacy and safety of LixiLan, a titratable 
fixed -ratio combination of insulin glargine plus lixisenatide in type 2 diabetes inadequately 
controlled on basal insulin and metformin: the LixiLan- L randomized trial. Diabetes Care. 
2016; dc161495. Aronson R, Umpi[INVESTIGATOR_124012] G, Stager W, Kovatchev B. Insulin glargine/lixisenatide fixed- ratio 
combination improves glycaemic variability and control without increasing 
hypoglycaemia. Diabetes Obes Metab. 2019;21(3):726-31. 
Battelino T, Danne T, Ber genstal RM, et al. Clinical targets for continuous glucose 
monitoring data interpretation: recommendations from the International Consensus on 
Time in Range. Diabetes Care. 2019; 42(8):1593-1603. 
[COMPANY_011]  SOLIQUA™ 1 00/33 
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 124 of 156 Battelino T, Bosnyak Z, Danne T, et al. InRange: Comparison of the second -generation 
basal insulin analogues glargine 300 U/mL and degludec 100 U/mL in persons with type 1 
diabetes using continuous glucose monitoring-study design. Diabetes Ther. 
2020;11(4):1017-27. 
Blonde L, Rosenstock J, Del Prato Stefano, et al. Switching to iGlarLixi versus continuing 
daily or weekly GLP-1 RA in type 2 diabetes inadequately controlled by [CONTACT_34046]-1 RA and oral antihyperglycemic therapy: the LixiLan -G randomized clinical trial. Diabetes  Care. 
2019;42(11):2108-16. 
Blonde L, Rosenstock J, Frias J, et al. Durable effects of iGlarLixi up to 52 weeks in type 2 
diabetes: the LixiLan -G extension study. Diabetes Care. 2021;44(3):774-80. 
Cannon A, Handelsman Y , Heile M, Shannon M. Burden of illness in type 2 diabetes 
mellitus. J Manag Care Spec Pharm. 2018;24(9- a Suppl):S5-S13. 
Carls G, Huynh J, Tuttle E, et al. Achievement of glycated hemoglobin goals in the US 
remains unchanged through 2014. Diabetes Ther. 2017;8(4):863-73. 
CDC . National Diabetes Statistics Report 2020. Estimates of diabetes and its burden in the 
[LOCATION_002] ; 2020 [cited 2021 May  03] [32 screens]. Available from: 
https://www.cdc.gov/diabetes/pdfs/data/statistics/national- diabetes -statistics -report.pdf. 
Conn VS, Ruppar TM, Chan KC, et al. Packaging interventions to increase medication 
adherence: systematic review and meta -analysis . Curr Med Res Opin. 2015;31(1):145-60. 
Critchley JA, Carey IM, Harris T, et al. Variability in glycated hemoglobin and risk of poor 
outcomes among people with type 2 diabetes in a large primary care cohort study. Diabetes 
Care. 2019;42(12):2237-46. 
Danne T, Nimri R, Battelino T, et al. International consensus on use of continuous glucose 
monitoring. Diabetes Care. 2017; 40(12):1631-40. 
Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 
diabet es, 2018. A consensus report by [CONTACT_11026] (ADA) and the 
European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669-2701. 
[COMPANY_011]  SOLIQUA™ 1 00/33 
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 125 of 156 Davies MJ, Russell -Jones D, Barber TM, et al. Glycaemic benefit of iGlarLixi in 
insulin-naïve type 2 diabetes patients with high HbA1c or those with inadequate glycaemic 
control on two oral antihyperglycaemic drugs in the LixiLan- O randomized trial. Diabetes 
Obes Metab. 2019;21(8):1967-72. 
HEDIS Comprehensive D iabetes Care; 2021 [cited 2021 May 03] [ 11 screens]. Available 
from:  https://www.ncqa.org/hedis/measures/comprehensive- diabetes -care/ . 
Jendle J, Testa MA, Martin M, et al. Continuous glucose monitoring in patients with type [ADDRESS_1008286] dulaglutide in combination 
with prandial insulin lispro: an AWARD -4 substudy. Diabetes Obes Metab. 
2016;18(10):999-1005. 
Johnson EL, Kayne DM. Implementation of diabetes technologies in primary care: 
challenges and rewards. Clin Diabetes. 2020;38(5):495-500. 
Rosenstock J, Aronson R, Grunberger G, et al. Benefits of LixiLan, a titratable fixed- ratio 
combination of insulin glargine plus lixisenatide, versus insulin glargine and lixisenatide monocomponents in type 2 diabetes inadequately controlled on oral agents: the LixiLan- O 
randomized trial. Diabetes Care. 2016; 39(11):2026-35. 
Rosenstock J, Emral R, Sauque- Reyna L, et al. Advancing therapy in suboptimally 
controlled basal insulin- treated type 2 diabetes: clinical outcomes with iGlarLixi versus 
premix BIAsp 30 in the SoliMix randomized controlled trial. D iabetes Care. 2021; 
dc210393. SOLIQUA™ 100/33 (insulin glargine and lixisenatide injection) [package insert]. 
[COMPANY_011]-aventis U.S. LLC. A SANOFI COMPANY . Bridgewater (NJ); 2019 [c ited 
2021 Feb  12] [41 screens]. Available from: 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208673s007lbl.pdf. 
Stone MA, Charpentier G, Doggen K, et al. Quality of care of people with type 2 diabetes 
in eight European countries: findings from the Guideline Adherence to Enhance Care 
(GUIDANCE) study. Diabetes Care. 2013;36(9):2628-38. 
Vigersky RA, McMahon C. The relationship of hemoglobin A1c to time- in-range in 
patients with diabetes. Diabetes Technol Ther. 2019;21(2):81-85. 
[COMPANY_011]  SOLIQUA™ 1 00/33 
Protocol: LPS16990 (Original, Version 1.0)  [ADDRESS_1008287] 72 hours’ notice from the investigator to arrange a home visit and DTP IMP supply, if 
required.  
d Participants  on weekly GLP -[ADDRESS_1008288] dose 7 (± 2) days before the first dose  of Soliqua 100/[ADDRESS_1008289] dose of daily DPP -4i and 
daily GLP -1 RA (oral or injectable) should be administered on the morning of Day –1, the day before  the first dose of Soliqua 100/33. 
e It is the first day of Soliqua 100/[ADDRESS_1008290] day of  Soliqua 100/33 administration (ie, Visit 3.2, Day 0) for participants on weekly GLP -1 RA will depend on 
their administration schedule and may not be the day immediately following Visit 3.1. Soliqua 100/33 administration for these participants should be 7 (± 2) days 
after their last weekly GLP -[ADDRESS_1008291] should be made to participants on weekly GLP -1 RA on the day before Soliqua 100/33 initiation,  to 
remind  them of the next morning’s injection and  to provide instructions for SoloStar pen use. The participants will provide their concomitant medication details to 
the site personnel over the phone . 
f Dose s of SU should be down-titrated by 50% when Soliqua 100/33 is started  on Day  0. 
g Weekly phone contacts for dose adjustments will be continued at the investigator ’s discretion until the desired fasting SMPG value is achieved.  
h If the desired fasting SMPG value is not achieved in the first 8 weeks of treatment; the investigator has the option to continue weekly dose titration phone co ntacts for 
an additional  4 weeks (until Week 12) for the purpose of achieving glycemic targets . 
i At the end of the study, participants should discuss with the investigator, in collaboration with the ir HCP, whether to continue on the Soliqua  100/[ADDRESS_1008292] with DTP IMP 
delivery. If DTP Soliqua 100/[ADDRESS_1008293] 72 hours’ notice to collect Soliqua 100/33 treatment 
kits from a study site . 
k Visit 2 will be performed at Day –[ADDRESS_1008294] dose 7 (±  2) days before the first dose 
of Soliqua 100/33; those taking daily SU (dose will be down-titrated by 50% on the morning of  Soliqua 100/33 initiation ); and those taking daily DPP -4i, and 
daily GLP -1 RA  (oral or injectable; their last dose will be administered  on the morning of Day –1, the day before  the first dose of Soliqua 100/33).  
l Body weight and height will be recorded during the screening period for the calculation of BMI (metric: BMI = weight (kg)/height [m2]) and only body weight will be 
recorded during the baseline and at the end of the treatment period . 
m Participants are required to measure fasting SMPG values before breakfast at least 3 to 4 times per week throughout the study period (to inform each dose 
adjustment) and record the results in the eDiary. During the titration period, fasting SMPG should be performed on each of the 3 to 4 days before each dose 
adjustment.  
n HbA1c will be m easured during the screening  and run-in periods , and at Visit 3.1 ( before  administration of the meal ) at the central laboratory , to determine study 
eligibility , and at the end of the 16-week treatment period (Visit 7), to determine change in glycemic control . 
o Blinded CGM will be perform ed for 14 continuous days. The b aseline CGM measure will be captured before discontinuing  the daily (oral or injectable) or weekly 
GLP -1 RA , DPP-4i, or down-titration of SU by 50% , and before  initiation of Soliqua  100/[ADDRESS_1008295] 8 days of evaluable CGM data (not necessarily consecutive) over a 14- day period as a result of 
premature sensor failure  (eg, days of CGM device wear × % time CGM device active < 8 ; Section  6.2.1 ). During the end of the treatment period, CGM device 
reinsertion wi ll also be allowed for participant s who do not  meet the equivalent of at least 8 days of evaluable CGM data (not necessarily consecutive) over a 
14-day period as a result of  premature sensor failure (eg, days of CGM device wear × % time CGM device active < 8), if data can be captured during the 14- day 
end-of-treatm ent window  (Section  6.2.1 ). 
[COMPANY_011]  SOLIQUA™ 1 00/33 
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 131 of 156 p The MMTT includes a standardized meal  (ie, Boost  Very High Calorie ) that contains approximately 530 kcal and is composed of 19% carbohydrates, 44% protein, 
and 33% fat. The composition and the quantity of the standardized meal must be identical throughout the study period. Baseline MMTT  is to be performed before 
discontinuation of daily (oral or injectable) or weekly GLP -[ADDRESS_1008296] 
their baseline MMTT conducted within 7  (± 3) days after their last dose. During the baseline (Visit  3.1), blood samples will be collected at the following time  
points: premeal  (30 min)  and just before administration of OADs or GLP -1 RA (oral or injectable)  (baseline); time 0 (just before meal administration);  10 min; 
20 min; and 0.5, 1.0, 1.5, 2.0,  2.5, 3.0, and 4.[ADDRESS_1008297] -meal  for plasma glucose, C-peptide , and insulin levels . At Visit 3.1, participants on OADs or an oral or 
injectable GLP -1 RA will be required to take their dose after blood sample for FPG and HbA1c is collected and 30 minutes before administration of the meal  
during the MMTT  (during which measures for both β -cell function and  PPG analyses will be captured) . Soliqua  100/33 should be administered 30 minutes before  
administration of the meal  during the MMTT at Visit 7 (during which only measures for PPG analyses will be captured) . At the end of the treatment period (Visit 
7), blood samples will be collected for plasma glucose levels, as follows: premeal (30 min) and just before administration of  Soliqua 100/33; and  time 0 (just 
before meal administration);  0.5, 1.0, 1.5, 2.0, 2.5, 3.0, and 4.[ADDRESS_1008298] meal after Sol iqua 100/33 administration at Week 16 compared with baseline.   
q At baseline, the CGM device will be removed  and the data will be downloaded on Day –1 at their next site visit (ie, Visit 3.1), after collection of C-peptide, insulin, 
and plasma glucose  data from the MMTT. Downloaded CGM data will be reviewed by [CONTACT_737896]’ study eligibility. At the end of  
the treatment period, the CGM device will be removed  and the data will be  downloaded on the fifteenth day after CGM placement (ie,  Visit 7 ; after collection of 
only plasma glucose data from the MMTT) . Downloaded CGM data will be verified by [CONTACT_737953]’ study completion . 
r Participants with less than equivalent of 8 days of evaluable CGM data (not necessarily consecutive) of a 14-day period  (eg, days of CGM device wear × % time 
CGM device active < 8) during the run-in period will be considered as screen failures . 
s Participants will undergo  the MMTT to assess maximum PPG exposure in the [ADDRESS_1008299] meal  with biomarkers o f β-cell function  (plasma 
glucose, insulin , and C -peptide)  measured  at Visit 3.1 (ie, site visit during the baseline period) , whereas  only plasma glucose will be  assessed at Visit  7 (ie,  end of 
the treatment period).  
t Participants should discontinue GLP -[ADDRESS_1008300] been completed. SU doses should be 
down- titrated by 50% when starting Soliqua 100/33, whereas  the last dose of daily DPP -4i and daily GLP -1 RA (oral or injectable) should be  administered  on the 
morning of Day –1, the day before  the first dose of Soliqua 100/33. Participants on weekly GLP -[ADDRESS_1008301] dose 7 ( ± 2) days  before the 
first dose  of Soliqua 100/33.  
u Soliqua pen instructions will be given to all participants at Visit 3.[ADDRESS_1008302] should be  made to  participants on weekly GLP -1 RA on the day before 
Soliqua 100/33 initiation , to remind them of the next morning’s injection and to provide instructions for SoloStar pen use . 
v For the scheduled site visits, participants are required  to arrive fasting without administering the  Soliqua 100/33 injection. Fasting is defined as no food intake in the 
8 hours before blood sampling, except water.  
w Baseline DM -SAT should be completed before discontinuatio n or down-titration  of baseline therapi[INVESTIGATOR_014].  The questionnaire should be completed at the start of the visit 
before any other study tests or procedures are performed or Soliqua 100/[ADDRESS_1008303] will be presented: overall hypoglycemia and confirmed hypoglycemia ( ADA Level s 1, 2, and 3;  Section  6.3.2).  
y Urinalysis: pH, glucose, ketones, leukocytes, blood/Hb, protein. 
z Only for women of childbearing potential; urine pregnancy test.  
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 132 of 156 13.2 Appendix: Diabetes Medication Satisfaction Tool  
(For information only) 

[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 133 of 156 

[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 134 of 156 

[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 135 of 156 

[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 136 of 156 13.3 Appendix: Participant eDiary Information  
Participants will be provided with an eDiary to use during the study. Participants will be 
instructed on how to complete the eD iary. 
eDiary completion will occur from the screening  period (Visit 1) through the follow-up 
period (Visit 8).  The participant is expected to return for site visits with the eDiary 
completed. The eDiary will be reviewed by [CONTACT_737954]. 
The following information is to be recorded in the eDiary: 
• Each dose taken (date/time and actual dose). The participant will document any 
temporary treatment discontinuations. 
• Fasting SMPG values before breakfast at least 3  to 4 times per week throughout the study 
period (to inform each dose adjustment). 
• Symptoms of hypoglycemia: Participants will be trained on the hypoglycemia eDiary completion requirements and the need to contact [CONTACT_737955] a significant hypoglycemia occurrence, so that appropriate actions can be taken  
(eg, intolerance to the study drug injection). 
• If assistance to resolve the hypoglycemia event was required out of necessity or 
convenience. 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 137 of 156 13.4 Appendix: Clinical Laboratory Tests  
• The tests detailed in Table  13-[ADDRESS_1008304] kits that are 
provided by [CONTACT_456]. 
• Protocol- specific requirements for inclusion or exclusion of participants are detailed in 
Section  4 of the protocol. 
• Additional tests may be performed at a local or central laboratory at any time during the 
study as determined necessary by [CONTACT_11006]. If they 
are used to evaluate an AE (diagnostic, follow-up, outcome), the results must be entered 
into the eCRF. 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  [ADDRESS_1008305]  
ALT 
Alkaline phosphatase, total bilirubin (if >ULN, 
then the direct and indirect subfractions must be measured)  
Amylase  
Lipase  
Creatinine  
Uric acid  
Sodium 
Potassium 
Urinalysis  pH 
Glucose 
Ketones  
Leukocytes 
Blood/ Hb 
Protein  
Calcitonin  Calcitonin  
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase;  eCRF, electronic case report 
form; Hb, hemoglobin; ULN, upper limit of normal.  
a All study -required laboratory assessments will be performed by a central laboratory except urine pregnancy 
tests, wh ich will be performed locally; the results of each test must be entered into the eCRF.  
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 139 of 156 13.5 Appendix: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting  
13.5.1  Definition of AEs 
• An AE is any untoward medical occurrence in a patient or clinical study participant, 
whether or not considered related to the study drug . 
• NOTE: An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease (new or exacerbated). 
Events Meeting  the AE Definition  
• Any abnormal laboratory test results (eg, hematology, clinical chemistry, urinalysis) or other safety assessments (eg, electrocardiogram [ECG], radiological scans, vital signs 
measurements), including those that worsen from baseline, considered clinically significant in the medical and scientific judgment of the investigator (ie, not related to 
progression of underlying disease), eg, that meet the following criteria : 
o Are s ymptomatic .  
o Require either corrective treatment or consultat ion. 
o Lead to IMP discontinuation or modification of dosing. 
o Fulfill a seriousness criterion . 
o Meet the definition of an AESI . 
• Exacerbation of a chronic or intermittent pre-existing condition, including either an increase in frequency and/or intensity of the condition. 
• New conditions detected or diagnosed after study drug administration even though it may have been present before the start of the study. 
• Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction. 
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either study drug or a concomitant medication.  
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 140 of 156 • “Lack  of efficacy” or “failure of expected pharmacological action” per se will not be 
reported as an AE or SAE. Such instances will be captured in the efficacy assessments. 
However, the signs, symptoms, and/or clinical sequelae resulting from lack of efficacy will be reported as AE s or SAE s if they fulfill the definition of an AE or SAE.  
Events NOT  Meeting the AE Definition  
• Any clinically sign ificant abnormal laboratory findings or other abnormal safety 
assessments that are associated with the underlying disease, unless judged by [CONTACT_11009]’s condition. 
• The disease/disorder being studied or expected progression, signs, or symptoms of the 
disease/disorder being studied, unless more severe than expected for the participant’s 
condition. 
• Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that leads to 
the procedure is the AE.  
• Situations in which an untoward medical occurrence did not occur (social and/or convenience admission to a hospi[INVESTIGATOR_307]). 
• Anticipated day -to-day fluctuations of pre-existing disease(s) or condition(s) present or 
detected at the start of the study that do not worsen. 
13.5.2  Definition of SAEs 
An SAE is defined as any AE that, at any dose, meets one of the following criteria: 
• Results in death 
• Is life -threatening  
o The term “life -threatening” in the definition of “serious” refers to an event in which 
the participan t was at risk of death at the time of the event. It does not refer to an 
event  that hypothetically might have caused death if it were more severe.  
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 141 of 156 • Requires inpatient hospi[INVESTIGATOR_1081] 
o In general, hospi[INVESTIGATOR_12994] (usually 
involving at least an overnight stay) to  the hospi[INVESTIGATOR_1083]/or treatment that would not have been appropriate in the physician’s 
office or outpatient setting. Complications that occur during hospi[INVESTIGATOR_1084]. 
If a complication prolongs hospi[INVESTIGATOR_9236], the event is serious. When in doubt as to whether hospi[INVESTIGATOR_14275], the AE should be considered serious.  
o Hospi[INVESTIGATOR_5187] a pre -existing condition that did not worsen 
from baseline is not considered an AE. 
• Results in persistent or significant disability/incapacity  
o The term disability means a substantial disruption of a p erson’s ability to conduct 
normal life functions. 
o This definition is not intended to include experiences of relatively minor medical 
significance, such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma (eg, sprained an kle), that  may interfere with or prevent 
everyday life functions but do not constitute a substantial disruption.  
• Is a congenital anomaly/birth defect 
• Other situations:  
o Medical or scientific judgment should be exercised by [CONTACT_737956], such as significant medical 
events that may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition. These events sh ould usually be considered serious.  
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 142 of 156 13.5.3  Recording and Follow-up of AEs and/or SAEs  
AE and SAE Recording  
• When an AE/SAE occurs, the investigator is responsible for reviewing all  documentation 
(eg, hospi[INVESTIGATOR_1088], laboratory reports, and diagnostics reports) related to the 
event.  
• The investigator will then record all relevant AE/SAE information.  
• It is not acceptable for the investigator to proactively send photocopi[INVESTIGATOR_227211]’s medical records, except an autopsy report in the event of death,  to the 
sponsor’s representative in lieu of completion of the required form. 
• There may be instances when copi[INVESTIGATOR_737889]’s representative. In this case, all participant identifiers, with the exception of 
the participant number, will be redacted on the copi[INVESTIGATOR_340722]’s representative. 
• The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE.  
Assessment of Intensity  
The investigator will make an assessment of intensity for each AE and SAE reported during 
the study and assign it to one of the following categories: 
• Mild: An event that is easily tolerated by [CONTACT_2299], causes  minimal discomfort, and 
does not interfere with everyday activities.  
• Moderate: An event that causes sufficient discomfort to interf ere with normal everyday 
activities.  
• Severe: An event that prevents normal everyday activities. An AE that is assessed as severe should not be confused with an SAE. “Severe” is a category used for rating the 
intensity of an event; both AEs and SAEs can be assessed as severe.  
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 143 of 156 An event is defined as “serious” when it meets at least 1 of the predefined outcomes 
described in the definition of an SAE, NOT when it is rated as severe. 
Assessment of Causality  
• The investigator is obligated to assess the relationship between study drug and each 
occurrence of an  AE/SAE/AESI . 
• A “reasonable possibility” of a relationship conveys that there are facts, evidence, and/or arguments to suggest a causal relationship, rather than that a relationship cannot be ruled 
out. 
• The inve stigator will use clinical judgment to determine the relationship.  
• Alternative causes, such as underlying disease(s), concomitant therapy, and other risk 
factors, as well as the temporal relationship of the event to study drug administration will 
be considered and investigated. 
• The investigator will also consult the prescribing information, for marketed products, in 
their assessment.  
• For each AE/SAE /AESI , the investigator must document in the medical notes that they 
have reviewed the AE s/SAE s/AESI s and have provided an assessment of causality.  
• There may be situations in which an SAE has occurred and the investigator has minimal 
information to include in the initial report to th e sponsor. However, it is very important 
that the investigator make s an assessment of causality for every event before initial 
transmission of the SAE data to the sponsor. 
• The investigator may change their opi[INVESTIGATOR_9242]-up information and send an SAE follow-up report with the updated causality assessment. 
• The causality assessment is one of the criteria used when determining regulatory reporting requirements. 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 144 of 156 Follow- up of AEs and SAEs  
• The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by [CONTACT_456]’s 
representative to elucidate the nature and/or causality of the AE s/SAE s/AESI s as fully as 
possible. This may include additional laboratory tests or investigations, histopathological examinations, or consultation with other health care professionals. 
• If a participant dies during participation in the study or during a recognized follow-up 
period, the investigator will provide the sponsor with a copy of any post- mortem 
findings, including histopathology. 
• New or updated information will be recorded in the originally submitted documents. 
• The investigator will submit any updated SAE data to the sponsor or designee within 
24 hours of receipt of the information. 
13.5.4  Reporting of SAEs  
SAE Reporting to the Sponsor via an EDC Tool 
• The primary mechanism for reporting an SAE to the sponsor’s representative (ie, [COMPANY_003] Pharmacovigilance) will be the EDC  tool.  
• If the electronic system is unavailable, then the site will use the paper SAE data 
collection tool ( see the following  section) to report the event within 24 hours. 
• The site will enter the SAE data into the electronic system as soon as it becomes available.  
• After the study is complete d at a given site, the EDC  tool will be taken off-line to prevent 
the entry of new data or changes to existing data. 
• If a site receives a report of a new SAE from a study participant or receives updated data on a previously reported SAE after the EDC  tool has been taken off -line, then the site can 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 145 of 156 report this information on a paper SAE form ( see the following section) or to the 
sponsor’s representative by [CONTACT_648]. 
• Contacts for SAE reporting can be found in the Investigator’s Study File. 
SAE Reporting to the Sponsor via Paper Data Collection Tool 
• Facsimile transmission of the SAE paper data collection tool is the preferred method to 
transmit this information to the sponsor’s representative. 
• In the unlikely event of EDC downtime, the paper forms must be used for reporting of events that require expedited reporting (SAEs/AESIs). Paper forms should be faxed  to 
[COMPANY_003] Pharmacovigilance at [PHONE_343]. 
• Initial notification via fax does not replace the need for the investigator to complete and 
sign the SAE data collection tool within the designated reporting time frames.  
• Contacts for SAE reporting can be found in the Investigator’s Study File.
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 146 of 156 13.6 Appendix: Liver Safety  
 
Abbrevia tions: AST, aspartate aminotransferase; ALT, alanine aminotransferase; CMV , cytomegalovirus; 
CPK,  creatine phosphokinase; CRF, case report form; DNA, deoxyribonucleic acid; EBV , Epstein -Barr 
virus; H AV,  hepatitis A virus; HBc, hepatitis B core; HBV , hepatitis B virus; HCV , hepatitis C virus; 

[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 147 of 156 H E V,  hepatitis E virus; IgM, immunoglobulin M; IMP, investigational medicinal product; 
INR,  international normalized ratio; LFT, liver function test; LKM, liver -kidney microsome; 
PT, prothrombin time; RNA, ribonucleic acid; ULN, upper limit of normal . 
*If unable to retest in 72 hours, use original laboratory  results to decide on further 
reporting/monitoring/discontinuation.  
Note s: 
“Baseline” refers to ALT value  at the baseline visit or , if the baseline value is unavailable, to the last ALT value  
before the baseline visit. The algorithm does not apply to instances of an increase in ALT during screening.  
Section  13.5 provides  guidance on safety reporting.  
Normalization is defined as ≤ULN or baseline value, if the baseline value is >ULN.
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 148 of 156 13.7 Appendix: Contraceptive and Barrier Guidance  
DEFINITIONS  
Woman of Childbearing Potential 
• A woman is considered WOCBP (fertile) from the time of menarche until becoming 
postmenopausal ( as follows) unless permanently sterile ( as follows ). 
• A postmenopausal state is defined as the period of time after a woman has experienced no menses for 12 consecutive months without an alternative medical cause. 
o A high follicle -stimulating hormone (FSH) level in the postmenopausal range may be 
used to confirm a postmenopausal state in women not using hormonal contraception 
or hormonal replacement therapy (HRT). 
o Females on HRT and whose menopausal status is in doubt will be required to use one of the non-estrogen hormonal highly effective contraception methods if they wish to 
continue their HRT during the study. Otherwise, they must discontinue HRT to allow 
confirmation of postmenopausal status before study enrollment. 
Permanent sterilization methods include  the following: 
• Documented hysterectomy.  
• Documented bilateral salpi[INVESTIGATOR_1656].  
• Documented bi lateral oophorectomy.  
• For individuals with permanent infertility due to a medical cause other than these 
procedures (eg, Mullerian agenesis, androgen insensitivity, gonadal dysgenesis), 
investigator discretion should be applied in  determining study eligibi lity. 
Note:  Documentation can come from the site personnel’s review of the participant’s medical 
records, medical examination, or medical history interview. 
If fertility is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cycle cannot 
be confirmed before first administration  of study drug, additional evaluation should be 
considered. 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 149 of 156 Woman of Non-c hildbearing Potential  
Women in the following categories are considered WONCBP: 
1. Any female with permanent infertility due to one of the following: 
o Documented hysterectomy. 
o Documented bilateral salpi[INVESTIGATOR_1656]. 
o Documented bilateral oophorectomy. 
o For individuals with permanent infertility due to a medical cause other than these 
procedures (eg, Mullerian agenesis, androgen insensitivity, gonadal dysgene sis), 
investigator discretion should be applied in  determining study eligibility . 
2. Postmenopausal female. 
A postmenopausal state is defined as the period of time after a woman has experienced no menses for 12 consecutive months without an alternative medica l cause.  
• A high FSH level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or HRT. 
• Females on HRT and whose menopausal status is in doubt must discontinue HRT to allow confirmation of postmenopausal status before study enrollment. 
Note : Documentation can come from the site personnel’s review of the participant’s medical 
records, medical examination, or medical history interview. 
Contraception Guidance  
CONTRACEPTIVESa ALLOWED DURING THE STUDY INCLUDE  THE 
FOLLOWING:  
Highly effective methodsb that have low user dependency  
Failure rate of <1% per year when used consistently and correctly.  
• Implantable progestogen -only hormone contraception associated with inhibition of 
ovulationc 
• Intrauterine device (IUD)  
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 150 of 156 CONTRACEPTIVESa ALLOWED DURING THE STUDY INCLUDE  THE 
FOLLOWING:  
• Intrauterine hormone -releasing system (IUS)c 
• Bilateral tubal occlusion  
• Azoospermic partner (vasectomized or due to a medical cause)  
Azoospermia is a highly effective contraceptive method provided that the partner is the 
sole sexual partner of the WOCBP and the absence of sperm has been confirmed. If not, 
an additional highly effective method of contraception should be used. 
Note: Documentation of azoospermia for a male participant can come from the site 
personnel’s review of the participant’s medical records, medical examination, or 
medical history interview.  
Highly effective methodsb that are user dependent  
Failure rate of <1% per year when used consistently and correctly.  
Combined (estrogen - and progestogen -containing) hormonal contraception associated with 
inhibition of ovulationc 
• Oral 
• Intravaginal 
• Transdermal  
• Injectable  
Progestogen -only hormone contraception associated with inhibition of ovulationc 
• Oral 
• Injectable  
Sexual Abstinence  
Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study drug. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant.  
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 151 of 156 CONTRACEPTIVESa ALLOWED DURING THE STUDY INCLUDE  THE 
FOLLOWING:  
a Contraceptive use by [CONTACT_737957]. 
b Failure rate of <1% per year when used consistently and correctly. Typi[INVESTIGATOR_737890]. 
c Male condoms must be used in addition to hormonal contraception. 
Note: Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal 
(coitus interruptus), spermicides only, and the lactational amenorrhea method (LAM) are 
not acceptable methods of contraception for this study. Male condom and female condom should not be used toge ther (due to risk of failure from friction).  
Collection of Pregnancy Information 
Male Participants With Partners Who B ecome Pregnant  
• The investigator will attempt to collect pregnancy information on any male participant’s 
female partner who becomes pregnant while the male participant is in this study. This 
applies only to male participants who receive Soliqua 100/33. 
• After obtaining the necessary signed informed consent from the pregnant female partner directly, the investigator will record pregnancy information on the appropriate form and 
submit it to the sponsor or designee within 24 hours of learning of the partner’ s 
pregnancy. The female partner will also be followed up to determine the outcome of the 
pregnancy. Information on the status of the mother and child will be forwarded to the sponsor. Generally, the follow-up will be no longer than 6 to 8 weeks after  the estimated 
delivery date. Any termination of the pregnancy will be reported regardless of fetal status (presence or absence of anomalies) or indication for the procedure. 
Female Participants Who B ecome Pregnant  
• The investigator will collect pregnancy information on any female participant who 
becomes pregnant while participating in this study. The initial information will be 
recorded on the appropriate form and submitted to the sponsor or designee within 24 hours of learning of a participant’ s pregnancy.  
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 152 of 156 • The p articipant will be followed up to determine the outcome of the pregnancy. The 
investigator will collect follow -up information on the participant and the neonate and the 
information will be forwarded to the sponsor. Generally, follow-up will not be required 
for longer than 6 to 8 weeks beyond the estimated delivery date. Any termination of 
pregnancy will be reported, regardless of fetal status (presence or absence of anomalies) 
or indication for the procedure. 
• Although pregnancy itself is not considered to be an AE or SAE, any pregnancy 
complication or elective termination of a pregnancy for medical reasons will be reported as an AE or SAE.  
• A spontaneous abortion (occurring at <22 weeks gestational age) or still birth (occurring at >22  weeks gestational age) is always considered to be an SAE and will be reported as 
such. 
• Any poststudy pregnancy- related SAE considered reasonably related to the 
investigational product by [CONTACT_79982]  [IP_ADDRESS]. Although the investigator is not obligated to actively seek this 
information for former study participants, they may learn of an SAE through spontaneous reporting. 
• Any female parti cipant who becomes pregnant while participating in the study will be 
discontinued from study drug treatment.
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 153 of 156 13.8 Appendix: Source Documents  
Source documents provide evidence for the existence of the participant and substantiate the 
integrity of the data collected. Source documents are filed at the investigator’s site.  
Data entered in the eCRF that are transcribed from source documents must be consistent with the source documents or the discrepancies must be explained. The investigator may need to request previous medical records or transfer records, depending on the study. In addition, current medical records must be available.  
DEFINITION OF SOURCE DATA  
Source Data to Be  Found i n the Part icipant’s File  
Evaluations that are reporte d in the eC RF must be supported by [CONTACT_737958], related, 
and identified source docum entation that may include, but is not limited to , the following: 
• Agreement and signatur e of ICFs ( Section  9.3) with the study identification and any 
privacy forms. 
• Study identification (na me). 
• Treatment kit number, d ates of administration , and doses of Soliqua 100/33 administered . 
• Medical, surgical, and diabetes history, including information on the following: 
o Demography, inclusion, and exclusion criteria. 
o History of alcohol consumption and smoking. 
o Comorbidities.  
o Last participation in a clinical study.  
o Contraception method for WOCBP. 
o Previous and conc omitant medications, including treatment for diabetes mellitus.  
o Dates and times of visits and assessments, including examination results. 
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 154 of 156 o Vital signs, height, body weight, and clinical laboratory reports. 
o AEs and follow-up. 
• In case of an SAE, the site should file in the source documents , at least, copi[INVESTIGATOR_737891]-up of 
the SAE.  
• Date of premature study discontinuation (if any) and reason. 
Source documentation may be found in the following: 
• Participant’s identity (identification card or other verification document of participant 
identity).  
• Medical history.  
• Nursing notes. 
• Physician’s notes. 
• Participant’s eDiar y. 
• Glucometer.  
Source Data Verification Requirements for Screen Failures  
For screen failure participants, the following source data must be verified: participant’s identification details, the informed consent signed by [CONTACT_2299], the study identification 
(name), dates of study visits, and the main reasons for screen fa ilure.  
The investigator must maintain accurate documentation (source data) that supports the information entered in the eCRF. 
Study monitors will perform ongoing source data verification to confirm that data entered 
into the eCRF by [CONTACT_113640] s ite personnel are accurate, complete, and verifiable from source 
documents; that the safety and rights of participants are being protected; and that the study is being conducted in accordance with the currently approved protocol and any other study 
agreements, ICH GCP, and all applicable regulatory requirements.
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 155 of 156 13.9 Appendix: Eligibility and Analysis Criteria for C GM Measurements  
Eligibility Criteria  
• Participants with less than equivalent of 8 days of evaluable CGM data (not necessarily 
consecutive) of a 14-day period ( eg, days of CGM device wear × % time CGM device 
active < 8) during the run -in period will be considered as scree n failures  (Section  6.2.1). 
• During the run-in period, CGM device reinsertion will be allow ed for participants who do 
not meet the equivalent of at least 8 days of evaluable CGM data (not nec essarily 
consecutive) over a 14-day period as a result of premature sens or failure ( eg, days of 
CGM device wear × % time CGM device active < 8; Table  13-3 and Figure 13–1). 
• During the end of the treatment period , CGM device reinsertion will also be allowed for 
participants who do not meet the equivalent of at least 8 days of evaluable CGM data (not 
necessarily consecutive) over a 14 -day period as a result of premature sensor failure 
(eg, days of CGM device wear × % time CGM device active < 8), if data can be captured 
during the 14-day end-of- treatment window  (Table  13-3 and Figure 13–1 ). 
• For participants who discontinue study treatment prematurely, the visi t window can be 
extended by [ADDRESS_1008306] the CGM data before they permanent ly discontinue the 
treatment .  
[COMPANY_011]  SOLIQUA™ 100/33  
Protocol: LPS16990 (Original, Version 1.0)  18 Aug 2021  
Property of the [COMPANY_011] Group - strictly confidential  Page 156 of 156 Table  13-3 Criteria for CGM Device Reinsertion  
No. of Days CGM Device 
Worna Time CGM Device Active (%)
a Equivalent Days 
8 100 8.00 
9 89 8.01 
10 80 8.00 
11 73 8.01 
12 67 8.04 
13 62 8.01 
14 57 7.98 
Abbreviations : AGP, Ambulatory Glucose Profile; CGM, continuous glucose monitoring.  
Note: Any combination of number of days of CGM device worn and % time CGM device is active that results 
in fewer than 8 equivalent days (defined as ineligibility) of evaluable CGM data will require device reinsertion.  
a AGP report. 
Figure  13–1 Criteria for CGM Device Reinsertion  
 
Abbreviation: CGM , continuous glucose monitoring. 
Analysis Criteria  
• Endpoint data will be included in the analysis if at least 10 out of 14 days (not necessarily 
consecutive) have at least ≥80% of evaluable CGM data per 24-hour period during the 
run-in period as well as the end of the treatment period (ie, from Weeks 14 to 16). 
